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Halogenated heterocyclic compounds are one of the most important synthetic 
intermediates for synthetic chemist as they form the fundamental units of many 
pharmaceuticals and biologically relevant molecules.   Significant effort has been 
devoted to the development of efficient enantioselective halocyclization processes 
to synthesize such compounds. While, asymmetric halolactonization reactions 
have already been thoroughly researched, there are significantly less reports on 
asymmetric haloetherification and haloamination reactions, primarily attributed to 
the difficulty of developing an efficient synthetic method.  
To explore the scope of haloamination reactions, a catalytic enantioselective 
bromocyclization of olefinic amides using amino-thiocarbamates as the catalysts 
has been developed. The resulting enantioenriched 2-substituted 3-
bromopiperidines can readily be transformed to 3-substituted piperidines through 
a silver salt-mediated rearrangement. This process has been applied to the 
synthesis of a dopaminergic drug, Preclamol. 
Next, catalytic enantioselective synthesis of hetero spirocycles through a 
double-halocyclization strategy is reported. The first of the double cyclization 
involves a desymmetrization-asymmetric bromoetherification process which gives 
rise to two quaternary stereogenic carbons in the cyclic ether products. 










yield a series of chiral hetero spiro systems. This protocol enabled access to a 
class of chiral novel spirocycles that is distinctly absent in the literature.  
 In a separate study, the intramolecular chloroamidation of olefinic substrates 
using diphenyl selenide as the catalyst is developed—the first example reported 
using a Lewis base promoter. The reaction conditions were found to be mild and 
suitable for a wide range of substrates including those which are acid labile. The 
methodology is also complementary to existing strategies that utilize Lewis acid 
catalysts. 
 Lastly, preliminary results for the development of a new class of catalyst for 
halocyclization reactions are reported. Novel proline-based amino-
selenocarbamate catalysts were prepared for but it was found that this class of 
catalyst was unstable and decomposed to form the diselenide products. The 
diselenide was derivatized to form different amino-selenium compounds and their 
catalytic ability for halocyclization reactions was investigated. The amino-
selenoether catalyst produced excellent yields and encouraging enantioselectivty. 
These results are an excellent starting point for further investigations which is 
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The addition of electrophilic reagents to olefins is perhaps one of the most 
fundamental transformations for the rapid construction of complex organic 
molecules. In fact, electrophilic functionalization of olefins was already a classic 
textbook transformation in the early 1930s.1 Amongst all these examples, halogen 
electrophiles are most commonly utilized in these addition reactions. Typically, 
these reactions proceed via the formation of cyclic halonium (haliranium, see 
later) ions 1-2 which is followed by an SN2 ring-opening by a nucleophile, 
yielding anti products 1-3 (Scheme 1.1).   
 
Scheme 1.1 Electrophilic halogen addition to alkenes. 
The incorporation of a halogen atom in a molecule can alter both the physical 
and biological activity of the molecule. This is typically due to the effected 
changes in steric and electronic properties.2 For example, halogenated amino acids 
analogues and active pharmaceuticals have demonstrated to have enhanced 
cytotoxicity when they are evaluated against their non-halogenated counterparts.3  
Currently, over 4500 halogen-containing natural products have been documented, 
of which, most of the carbon-halogen bonds are constructed enzymatically.2a, 4 










versatility that comes with it as alkyl halides can function as precursors or 
modification points for the construction of carbon–carbon bonds, amines, ethers, 
sulfides and epoxides.5 Chiral carbons that have a halogen attached to it may also 
undergo stereospecific SN2 reactions with the inversion of chirality. 
Even though halogenation of olefins is a reaction that has been known for 
some time, enantioselective versions of this class of reaction have only been 
recently developed. This is especially so for halocyclization reactions, a sub-class 
of halofunctionalization reactions, whereby heterocyclic rings are the resultant 
products. For example, lactones can be synthesized through the halocyclization of 
olefinic acids; cyclic lactams can be synthesized through the halocyclization of 
olefinic amides; and cyclic ethers can be synthesized via the halocyclization of 
olefinic alcohols. These reactions typically occur through the intramolecular 
addition of a heteronucleophile to a carbon–carbon double bond in the presence of 
an electrophilic halogen source (Scheme 1.2). 
 
Scheme 1.2 Halocyclization of olefinic substrates. 
Despite being regarded as an important breakthrough in organic chemistry, 
these reports only flagged the beginning of an emerging topic in this field. This 










enantioselective halocyclization reactions and highlight the critical challenges 
faced in developing useful methodologies for this class of reactions. 
 
1.2 Nomenclature of Halogen Cations 
To begin, the nomenclature of halogen cations needs to be first introduced. 
By correlating the terms drawn up for electron-deficient species in Group V and 
VI on the periodic table where hypercoordinate species are called ammonium and 
oxonium ion respectively, the corresponding Group VII cation is termed as a 
halonium ion (Figure 1.1). In unique cases whereby the cation occurs within a 
cyclic structure, it is termed differently, depending on the ring size.  
 
Figure 1.1 Nomenclature of halogen cations. 
For example, iranium is used for the 3-membered ring, etidium and olidinium 










context, electrophilic addition reactions precede by the formation of a 3-
membered cyclic intermediate termed either as “haliranium” or as the commonly 
known “cyclic halonium”. Both terms would be used interchangeably throughout 
this thesis.  
 
1.3 General Strategies for Catalysis of Halocyclization 
After an extensive survey for enantioselective halocyclization reactions that 
were reported in the past decade, it is observed that a trend can be drawn out for 
the general strategies that were employed. Generally, halocyclization reactions 
can be catalyzed by Lewis acids, Brønsted acids, Lewis bases and phase transfer 
catalysts (Figure1.2). 
Lewis acids and Brønsted acids increase the electrophilicity and hence the 
reactivity of halogen sources by binding to the halogenating reagent 
intermolecularly, reducing electron density, and thus increasing electrophilicity. 
Brønsted acids, in addition, can generate the reactive electrophile by protonating 
the N-halosuccinimide. This can result in the transfer of the halogen to the 
conjugate base of the Brønsted acid.7  
Lewis bases can activate halogen reagents by donating its lone pair of 
electrons to the electrophilic halogen. Likewise, this will generate a more reactive 










Lewis base activation of Lewis acids.8 This strategy requires the halogenating 
reagent to be adequately unreactive such that the substrate will not undergo 
uncatalyzed, consequently unselective halofunctionalization. 
Phase transfer catalysts work differently from the above catalysts and usually 
do not depend on the reactivity of the halogen sources. This is because the 
substrates and halogen sources are separated into different phases such that they 




































1.4 Engineering Enantioselectivity in Halocyclization 
One of the key difficulties encountered in asymmetric halocyclization is the 
engineering of enantioselectivity, which is a far more challenging issue when 
compared to catalyzing the racemic reaction.  In devising a successful strategy, it 
is important to note that the chiral catalyst and the cyclic halonium intermediate 
must maintained association throughout, until nucleophilic capture is completed 
(Figure 1.3). Failure to do so will ultimately result in the racemization of the 
haliranium ion. This is observed to be especially so for bromo- and 
iodocyclization reactions.9  
 
Figure 1.3 Chiral catalyst maintains association with haliranium ion. 
The tactics used to engineer enantioselecivity for fluoro- and 
chlorocyclization is similar to those that are used for bromo- and 
iodofunctionalization in that the initial delivery of the halonium ion employs the 
same type of strategies compared to the bromo- and iodo counterparts. However, 
it is observed that the fluoro- and chlorocyclization do not suffer from significant 
racemization compared to the bromo- and iodocyclization due to olefin–olefin 











In recent years, many catalysts for enantioselective halocyclization have been 
developed. Although it seems like each utilizes different means for engineering 
enantioselectivity, the strategies used can be generally classified into four main 
categories (Figure 1.4). The differentiation into these categories can be attributed 
to the type of catalyst used and, more importantly, the strategy applied to maintain 
the association between the catalyst and the cyclic halonium ion. Generally, the 
main types of strategies are as follow: 
 Type A: Chiral Lewis base 
 Type B: Chiral counterion and anion binding 
 Type C: Hydrogen bonding 
 Type D: Chiral Lewis acid 
 
Figure 1.4 Strategies for catalyzed halocyclization.9 
One of the most important tactics used in creating the chiral environment for 
asymmetric halofunctionalization is via the use of a chiral Lewis base (Type A). 










maintain association before nucleophilic capture is completed to ensure that the 
chirality can be effectively transferred. The Lewis base complex tactic is also 
known to be most effective when employed with the other control strategies. 
Brønsted acids can also form comparable interaction with the haliranium ion 
with the exception that the coordination between the Brønsted acid and the 
haliranium ion is ionic instead of being dative (Type B). The advantage of this 
chiral counterion strategy lies in the intensity of the coordination that can be 
derived from such ionic interactions such that the association between the catalyst 
and haliranium ion can be maintained till nucleophilic capture. This is especially 
so in non-polar organic media when both the cations and anions are being forced 
to be in close proximity. The formation of chiral ion pairs is by far the most 
prominent strategies for enantioselective halocyclizations.  
A large fraction of the reported enantioselective halocyclization requires the 
use of hydrogen bonding interactions to maintain close proximity of the catalyst to 
the substrate (Type C). Unlike the first two strategies discussed above, the 
hydrogen bonding strategy is different due to the site where the chiral catalyst 
transfers the chirality. In this case, the catalyst is associated to a secondary site on 
the substrate instead of being directly associated to the haliranium ion. This 
strategy is most useful when the catalyst contains hydrogen bond donors such as 
hydroxy groups, carboxylic acids, sulfonamides, ureas, and thiocarbamates, or 











The last type of asymmetric induction for halocyclization involves the use of 
Lewis acids which can activate either the electrophile or the nucleophile (Type 
D). The Lewis acid–nucleophile activation type of asymmetric induction has been 
performed predominantly with the use of titanium complexes and this method has 
been very well-established over the years.10 The chiral information is imparted 
from the chiral ligands used to form these titanium complexes.11 The Lewis acid–
electrophile (halogen) activation type of enantioselective halocyclization has been 
mainly performed using cobalt (II)/Salen or chromium (III) chloride/salen 
complexes.12  
Although these four strategies have been identified and differentiated, it must 
be noted that the methods commonly employed in the successful examples so far, 
are a combination of these tactics. In many of the cases described in the later part 
of the chapter, the available data suggests the action of multiple mechanisms per 
transformation. Despite this fact, this classification still serves as an important and 
valuable framework for analyzing what has is known so far, as well as what is 
rapidly emerging in this field. The following sections in this chapter will continue 
to showcase how these tactics are employed in various types of asymmetric 











1.5 Halolactonization Reactions 
Halolactonization is one the most common and well-studied type of 
electrophilic halocyclization. The first example of such a reaction is a 
bromolactonization reaction discovered by Fittig and Stobbe in the late 19th 
century.13 This was soon followed by the discovery of the iodine variant, which 
quickly became a useful reaction owing to the enhanced reactivity of the carbon–
iodine bond that allows easy functionalization.14 The chlorine variant was 
however only discovered 20 years after and (just like the other halocyclization 
reactions) was the least preferred choice and therefore infrequently utilized.15 
Fluorolactonization is, in principle, missing in the field of electrophilic 
halocyclization and thus will have no mention here. This section begins with the 
discussion of some examples of racemic halolactonization, the catalysts used and 
new methods used to carry out these reactions.  This will be followed by a detailed 
discussion on the developments in enantioselective halolactonization, particularly 
in the last 5 years.  
 
1.5.1 Racemic Halolactonizations 
 Although iodolactonization was discovered in the early 20th century, the 
mechanism of the reaction was not fully understood and investigated until 










before nucleophilic attack by the carboxylate nucleophile.16 This was widely 
regarded as the mechanism until van Tamelen and Shamma proposed the 
formation of the cyclic iodonium ion as the intermediate in an attempt to reason 
the difference in rates of 5-exo and 6-endo cyclization.17 Klein further refined 
their explanation by suggesting that the lactone formed had the iodine atom and 
carboxylate nucleophile in an anti-configuration.18  
Iodolactonization was later carried out widely by using Bougault conditions14, 
using iodine and potassium iodide in aqueous sodium bicarbonate, until it was 
observed that ICN in chloroform can also perform such a reaction.19 However, the 
reaction inevitably produced one equivalent of HCN as the by-product and its 
toxicity prompted the need for further improvements to be made to the reagents. 
Shortly after, Cook and co-workers utilized N-iodosuccinimide as a highly 
effective electrophilic iodine reagent for iodolactonization.20 Rousseau also 
showed the feasibility of using bis(collidine)-iodonium hexafluorophosphate 












Scheme 1.3 Macro-iodolactonization using bis(collidine)-iodonium 
hexafluorophosphate. 
Fujimoto followed by reporting an unconventional reaction system using a 
combination of Pb(OAc)4 and NaI (Scheme 1.4). 22  Although this methodology 
generally gives poor exo and endo selectivity, it is worth a mention due to its 
unique iodine source. The iodide salt is believed to undergo an in situ oxidation to 
form the iodonium electrophile for the iodolactonization.  
 
Scheme 1.4 Iodolactonization using Pb(OAc)4 and NaI system. 
 Soon after, a diastereoselective iodolactonization for substrates with a 
hydroxyl (OH) or sulfonamide (NHTs) moiety on the α-carbon of the carboxylic 
acid was reported by Taguchi and co-workers (Scheme 1.5).23 In this case, a 
Lewis acid, Ti(Oi-Pr)4 was used in stoichmetric quantities while the iodine source 










prior to cyclization such that a high cis to trans ratio of products was obtained 
after NIS was added.  
 
Scheme 1.5 Diastereoselective iodocyclization using stoichmetric Lewis acidic 
catalyst. 
 More recently, Denmark and co-workers carried out an extensive 
investigations on the catalytic ability of Lewis base catalysts in an attempt to 
improve selectivity and yields of bromo- and iodolactonization (Scheme 1.6).24 A 
good range of Lewis base catalysts were surveyed for this purpose and NIS was 
used as the electrophilic iodine source.  
 
Scheme 1.6 Triphenylphosphine sulfide catalyzed bromo- and iodolactonization. 
Denmark used the concept of Lewis base activation of Lewis acid and 










resulting in the formation of the more reactive iodonium ion. As expected, the 
selectivity and reactivity can be tuned by varying the steric and electronic 
properties of the catalysts.  
First and foremost, the most obvious trend that can be observed is that the 
rates of catalyzed iodolactonization are affected most significantly by the Lewis 
base donor (Table 1.1). Catalyst containings sulfur (R2C=S and R3P=S) and 
selenium (R3P=Se) increased the rate of the reaction by the most while catalysts 
containing oxygen (R3P=O and R2C=O) have little effect. Denmark and co-
workers observed that the rate varies according to the “softness” of the donor 
atom, with the softer donor atoms (such as S and Se) being the more efficient 
catalysts. 
Bromolactonization is also an important sub-class of halolactonization 
reactions and has gained importance over the years. The reaction, like the 
iodolactonization, was initially carried out using molecular halogen, in this case 
using bromine, as the halogen source. One distinct difference is that halogenated 
organic solvents were initially used as the reaction medium instead of the aqueous 











Table 1.1 Catalyst survey for Lewis base catalyzed iodolactonization.24 
 
It is observed that most of the classic bromolactonization reactions are 
variants of iodolactonization reactions and therefore will not be discussed here. 
Instead, recent developments in expanding the scope of racemic halolactonization 










Table 1.2 Recent efforts in racemic bromolactonization.25 
 
In the past two decades, most efforts were focused on increasing the rate and 
efficiency of bromolactonization. The use of NBS as the electrophilic halogen 
source has also gained popularity over the years due to the ease of handling the 
reagent, as well as the relative unreactivity of the reagent such that uncatalyzed 
and consequently unselective bromolactonization can be minimized. A number of 










have been identified and they consist of diselenides, 2-iodobenzylamides, Lewis 
bases as well as simple molecular sieves (Table 1.2, entries 9-12). 
Chlorolactonization was the latest to be discovered amongst the 
halolactonization reacions and it is also the least developed variant as well. The 
first reported chlorolactonization was carried out with an aqueous mixture of 
CaCl2 and HOCl.15The relatively less reactive alkyl chloride obtained through the 
reaction was probably one of the reasons why bromo- and iodolactonization 
reactions are more developed. Another reason was perhaps the need to work with 
the hazardous chlorine gas, the most obvious and abundant chlorine source. This 
however did not prevent Woodward and Singh from utilizing chlorine gas to 
achieve a chlorolactonization as a key step in the total synthesis of allo-patulin.26 
Later on, chloramin-T was identified as an effective substitute for chlorine gas 
(Scheme 1.7).27 
 











1.5.2 Asymmetric Halolactonization 
One of the earliest work on enantioselective halolactonization was carried out 
by Wirth and co-workers (Scheme 1.8).28 Two equivalents of commercially 
available chiral primary amine 1-22 together with ICl were used to form halogen–
amine complexes that effect the cyclization reaction. The enantioselectivity 
observed for these transformations were moderate and at that point in time, these 

















Scheme 1.8 Iodolactonization using chiral primary amine and ICl. 
Gao and co-workers then reported the asymmetric iodolactonization of trans-
1,2-disubstituted olefin 1-24 (Scheme 1.9).29 In the report, a quaternary 
ammonium salt 1-25 derived from cinchonidine was employed as an effective 
phase-transfer catalyst for the iodolactonization reaction to give a mixture of the 
5-membered ring lactone 1-26 and 6-membered ring lactone 1-27. The authors 
suggested that NaHCO3 first deprotonates the carboxylic acid such that the 










1-25. The bulky chiral cation 1-25 maintains association during the nucleophilic 
capture, inducing chirality of the lactones 1-26 and 1-27 formed in the process. 
The enantioselectivity obtained from the reaction were moderate, with 42% ee 
obtained for the 5-membered ring lactone 1-26 and 31% ee obtained for the 6-
membered ring lactone 1-27. However, these moderate enantioselectivities 
obtained were sufficient as a proof of concept of asymmetric halolactonization at 
that point in time. 
 
Scheme 1.9 Quarternary ammonium salt catalyzed enantioselective 
iodolactonization. 
Next, Borhan and co-workers developed a protocol for the enantioselective 
chlorolactonization  of 1,1-diolefinic acids 1-21, giving the 5-membered 
chlorolactone 1-23 as the sole product in the reaction (Scheme 1.10).21d 
(DHQD)2PHAL 1-28 was utilized as the catalyst while 1,3-dichloro-2,2-
diphenylhydantoin (DCDPH) 1-29 was used as the electrophilic chlorine source in 











Scheme 1.10 Borhan’s (DHQD)2PHAL 1-28 catalyzed enantioselective 
chlorolactonization. 
The authors suggested two possible mechanisms for the reaction. The first 
involved the protonation of the quinidine nitrogen with BzOH followed by the 
formation of the ammonium–DCDPH complex before the transfer of the 
chloronium to the olefin. The second mechanism proposed was via the activation 
of DCDPH by the formation of a tertiary amine–chloronium species. After this 
ionic interaction has been formed, the second equivalent of chlorine can then be 
delivered to the olefin (Figure 1.5).  
 










Concurrently, Tang and co-workers developed a cinchonidine-derived amino-
urea bifunctional catalyst 1-31 for the bromolactonization of enynes (Scheme 
1.11).30 The elegant reaction produced stereospecific allenes as products.  
 
Scheme 1.11 Amino-urea catalyzed bromolactonization of enye 1-30 to yield 
allene 1-32. 
The authors suggested that bifunctionality of the catalyst allows it to effect the 
bromolactonization by deprotonating of the carboxylic acid while forming 
hydrogen bonds with NBS. 
In another example involving chiral ion pair catalysis, Jacobsen and co-
workers utilized an anion binding strategy for the iodolactonization of 1,1-
disubstituted olefin acids 1-33 with a urea type catalyst 1-34 while using N-
iodofluorophthalimide 1-35 as the iodine source (Scheme 1.12).31 It was observed 












Scheme 1.12 Aminourea catalyzed iodolactonization. 
Iodine was added as an additive and it was proposed that its main function is to 
form an activated complex with N-fluorophthalimide 1-35. The mechanism of the 
reaction is believed to be the binding of the urea moiety to N-fluorophthalimide, 
with the amine acting as a Lewis base for the formation of complex A. The 
resulting iodo–ammonium ion delivers the iodonium ion to the olefin 1-33 while 
the N-fluorophthalimide 1-35, which is still hydrogen bonded to the urea, assists 










electron-withdrawing fluorine atom on the phthalimide helps in the formation of 
the iodonium ion by weakening the N–I bond of the phthalimide and enhances the 
rate of reaction. The enantioselectivity was observed to be poor when other 
halogen sources were used instead. 
In the same year, Fujioka reported another attractive C3-symmetric 
trisimidazoline catalyst 1-39 which was used to catalyze the bromolactonization of 
1,1-disubstituted, tri- and tetra-substituted olefins 1-38.32 Stoichiometric amounts 
of 1,3-dibromo-5,5-dimethylhydantoin (DBH) 1-40 was employed as the 
electrophilic bromine reagent. Although all the substrates reported were 5-aryl-5-
hexenoic acids, it was shown that various aromatic and aliphatic groups can be 
accommodated in the R2 and R3 position of the tri- or tetra-substituted olefin 1-38. 
Fujioka further explained the origin of the catalysis by proposing the 
deprotonation of the carboxylic acid forming the imidazolinium–carboxylate ion 
pair. The chiral imidazolinium then directs the carboxylate for the enantioselective 











Scheme 1.13 C3-Symmetric trisimidazoline catalyzed bromolactonization. 
More recently, our group demonstrated that asymmetric bromolactonization 
can be carried out with the use of a novel bifunctional catalyst (Scheme 1.14).33 
The bifunctional catalyst 1-43a consist of a Brønsted base (amino group) and a 
Lewis base (thiocarbamate) on the cinchona alkaloid scaffold. Both 1,1-
disubstituted 1-21 and trans-1,2-disubstituted 1-24 olefinic acid were able to 












Scheme 1.14 Amino-thiocarbamate catalyzed enantioselective 
bromolactonization. 
Some mechanistic insights were obtained through the synthesis of various 
analogues of the catalyst. When the Lewis basic sulfur atom was replaced with an 
oxygen atom (catalyst 1-43f), the reaction produced products with no ee. Simiarly, 
when the N–H of the thiocarbamate was replaced with an oxygen atom, the 
resulting thiocarbonate 1-43d offered no enantioselectivity. When the oxygen 
atom of the thiocarbamate was replaced with the N–H group, the thiourea catalyst 
1-43b furnished no enantioselectivity as well. The enantioselectivity of the 










methylated (catalyst 1-43e). The series of experiments concluded the importance 
of the Lewis basic sulfur atom as well as N–H moiety in achieving high 
enantioselectivity in the bromolactonization reaction.  
 
Scheme 1.15 Enantioselectivity of selected analogues of amino-
thiocarbamates.  
Further experiments also found that aryl substituents on the nitrogen of the 
thiocarbamate were necessary to furnish any enantioselectivity. For example, the 










dimethoxyphenyl substituent. These results suggested that the catalyst reactivity 
might be tunable by modifications to the N-aryl substituents.  
The results from these studies, together with the known reactivity of sulfur 
containing catalyst (from Denmark’s work), were then used as a follow-up in 
suggesting the mode of action of the catalyst. It was proposed that the N–H 
moiety forms a hydrogen bond with NBS such that the Lewis basic sulfur atom of 
the thiocarbamate is in proximity to the bromine atom and can activate it (through 
the Lewis base activation of Lewis acid concept described earlier) (Figure 1.6). 
The catalyst then delivers the bromonium ion to the olefin while the nitrogen atom 
of quinuclidine deprotonates the carboxlic acid and directs the carboxylate 
nucleophile towards the bromiranium enantioselectively. 
 
Figure 1.6 Proposed mechanism of the aminothiocarbamate catalyzed 
bromolactonization. 
Lastly, an asymmetric iodolactonization of 1,1-disubstituted hexenoic acid 1-










was catalyzed by stilbene bis(4-pyrrolidinylquinolinyl) bisamidine hydrogen 
triflimide 1-52-NHTf2, furnished products in high enantioselectivity and good 
yields. Although the reaction was very selective to 1,1-disubstituted alkenes, it 
appears that the enantioselectivity of the catalyst is not significantly affected by 
the electronic properties of the substrates. Interestingly, the reaction rates for 
electron-rich aryl substituents were much higher than electron-deficient aryl 
substituents. The authors suggested that the substrate is activated by a Brønsted 
base through the deprotonation of the carboxylic acid to generate the carboxylate, 
whereas NIS is activated by a Brønsted acid. However, since there are several 
Brønsted basic sites on the catalyst, it was difficult for the authors to pin-point the 











Scheme 1.16 Iodolactonization catalyzed by 1-52-HNTf2. 
 
1.6 Haloetherification Reactions 
Haloetherification is an extremely important synthetic transformation that can 
produce substituted cyclic ethers such as oxetanes, tetrahydrofurans, 
tetrahydropyrans and larger ring systems. Although it is a reaction that was 
discovered later in compared halolactonization, its development has been similar 
to that of halolactonization. Effective racemic reactions using stoichmetric 
reagents are well-known and thus less effort is spent on improving them. Instead, 
most of the current efforts are devoted to achieving the more challenging task of 










1.6.1 Racemic Haloetherifications 
The first example of haloetherification was reported by Williams and co-
workers in which 4-pentenyl alcohol was treated with iodine in aqueous potassium 
iodide to furnish the substituted tetrahydrofuran as the sole product.21d It was 
nearly 20 years later that Yoshida and co-workers did a thorough investigation of 
iodoetherification reactions.35 A range of simple olefinic alcohols were subjected 
to several cyclization conditions and it was observed that the iodine–NaHCO3 
system was the preferred protocol.  
More recent efforts in development of racemic iodoetherification focus on 
using catalysts to activate milder iodination reagent such as NIS. One elegant 
piece of work by Morgan and co-workers uses a low loading of (dppf)PdCl2 as 
catalyst (Scheme 1.17).36 The reaction conditions allowed the iodoetherification to 
be completed rapidly with good yields obtained.  
 
Scheme 1.17 (dppf)PdCl2 catalyzed iodoetherification. 
Iodoetherification reactions also proceeded well with Denmark’s Lewis base 










iodoetherification was markedly improved by using Lewis base to activate NIS for 
the reaction.   
 
Scheme 1.18 Selected example of Lewis base catalyzed iodoetherification. 
Apart from the standard olefinic alcohols, it has also been shown that 
iodoetherification can also be carried out on non-alcohol substrates. For example, 
Barluenga demonstrated that the oxygen atom of an aldehyde may behave like a 
nucleophile and attack an iodiranium ion formed on an alkyne (Scheme 1.19).37 
Silyl ketene acetal 1-58 was then added as an external secondary nucleophile to 
quench the oxonium intermediate to furnish the interesting heterocyclic product 1-
59.  
 











In contrast to iodoetherification, there are fewer reports on 
bromoetherification, and thus the bromine variant has been utilized to a much 
lesser extent. The earliest report on such a transformation utilized bromine and a 
base in organic solvent.38 More bromoetherification reagents were subsequently 
shown to be able to effect bromoetherification then after. In particular, 2,4,4,6,-
tetrabromo-2,5-cyclohexadienone (TABCO) has been used as a effective halogen 
source and was used in two natural product total syntheses in the late 1980s and 
early 1990s.39 
 
1.6.2 Asymmetric Haloetherifications 
In contrast to asymmetric halolactonization, there are significantly less 
reports on asymmetric haloetherification. The development of such 
transformations is particularly challenging as an efficient method for asymmetric 
haloetherification lies in improving the rate of nucleopilic capture as opposed to 
the olefin-olefin halogen exchange which causes racemization.40 
One of the first reports of an enantioselective haloetherification was the 
desymmetrization of a diol via a haloetherification process reported by Taguchi 
and co-workers (Scheme 1.20).41 The symmetrical olefinic diol 1-60 was treated 
with Lewis acidic Ti(OiPr)4, iodine, pyridine and L-(+)-diisopropyl tartrate results 
in the desymmetrization of the diol and the formation of an iodoether product 1-61 











Scheme 1.20 Asymmetric desymmetrizing haloetherification catalyzed by 
Ti(OiPr)4. 
Kang and co-workers then reported a Lewis acid catalyzed iodoetherification 
of (Z)-5-substituted-5-pentenols giving 2-substituted tetrahydrofurans with good 
yields and enantioselectivity.12 Salen complexes of cobalt (II) 1-63 and chromium 
(III) 1-64 were used as the Lewis acid catalyst, and it was observed that both 











Scheme 1.21 Co(II) and Cr (III) salen complexes catalyzed iodoetherifications. 
The atypical reaction conditions, in which two electrophilic halogen sources, 
iodine and NCS, were utilized, resulted in the proposal of two plausible 
mechanisms for the reaction. The first postulates that the NCS reacts with iodine 
to form ICl which can be further activated by the Lewis acid catalyst. In this 
proposal, it is important that ICl is formed and released slowly into the system as 
opposed to the use of ICl reagent itself. This is to minimize the uncatalyzed 
reaction when high concentration of ICl is present in the reaction mixture. In the 
second proposal, NCS is thought to oxidize Cr (III) to a chromium species with 
higher oxidation state and this helps to enhance the Lewis acidity. The 
iodoetherification proceeds after this newly formed chormiun species activates the 










Enantioselective fluorocyclization of alkenes are rare; in fact, the only 
example that gave appreciable enantioselectivity was reported by Gouvernuer in 
2009 (Scheme 1.22).42 (DHQ)2PHAL 1-67 was employed to induce the chirality 
while Selectfluor was used as the electrophilic fluorine source. Mechanistically, 
the fluorocyclization pathway differs from typical bromo or iodocyclization 
reactions. The reaction, as postulated by the author, does not form the 3-
membered cyclic fluoronium species, but instead, proceeds via the formation of a 
carbocation intermediate that is stabilized by the silane moiety.  
 
Scheme 1.22 Enantioselective fluorocyclization catalyzed by (DHQ)2PHAL.  
Several reports of enantioselective haloetherification surfaced in 2010. 
Hennecke was the first to introduce chiral phosphate counter anions in 
halocyclization reactions by utilizing chiral sodium phosphates 1-71 in the 











Scheme 1.23 Enantioselective desymmetrizing haloetherification using chiral 
phosphates. 
Despite the lack of substrate scope and moderate enantioselectivities that 
were obtained, this report was an elegant proof of concept. Since the haliranium 
ion formed is meso, the observed enantioselectivity confirms the existance of an 
association of the chiral phosphate anion with the haliranium intermediate until 
nucleophilic capture is accomplished. The author suggested that the phosphate 











Two other enantioselective haloetherification protocols were developed by 
both Denmark and Shi at the same time. Both groups employed the same chiral 
phosphoric acid catalyst (S)-1-76 in their reactions, but there were key differences 
in terms of their reaction conditions, and this also led to possible mechanistic 
differences in the reactions. 
In the Shi system, (S)-1-76 was utilized as the only catalyst in the system 
(Scheme 1.24).44 Generally, it was observed that both the (Z)-olefins 1-75 and (E)-
olefins 1-78 can undergo cyclization to give exocyclic bromofurans with moderate 
to good enantioselectivity.  
 










The author postulated that the observed enantioselectivity is based on a 
transition state whereby the substrate functions as a hydrogen bond donor while 
NBS acts as a hydrogen bond acceptor and coordinates to the catalyst (Figure 1.7). 
The chiral phosphoric acid, possessing both acidic and basic sites, acts as a 
bifunctional catalyst to activate both NBS and the hydroxy group of the substrate 
prior to nucleophilic capture.  
 
Figure 1.7 Proposed transition state for Shi’s bromoetherification. 
 In comparison, in Denmark’s system, triphenylphosphine sulfide was used 
as a co-catalyst that may have invoked in a different reaction pathway. Similar to 
Shi’s case, both (Z)- and (E)-olefins gave the product of exocyclization with good 
to excellent enantioselectivity using the Denmark protocol.45 The efficiency of the 
catalytic system was demonstrated using aryl substituted olefinic substrates as 


















77% yield, 82% ee
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Scheme 1.25 Denmark’s bromoetherification using chiral phosphoric acid. 
 Denmark proposed a cooperative activation of NBS by both the chiral 
phosphoric acid and the Lewis basic triphenylphosphine sulfide (Figure1.8). He 
postulated that a phosphate hypobromite species which is initially formed 
transfers bromine to the substrate while using hydrogen bonding to maintain 
association with the substrate. 
 
Figure 1.8 Proposed transition state for Denmark’s bromoetherification. 
The distinct lack of asymmetric haloetherification methods shown in this 
discussion above (five examples with only three that gives any useful 
enantioselectivity) can be attributed to the slow rate of nucleophilic capture as 
opposed to the rate of catalyst-bromonium ion dissociation. As such, this triggers 










that there will be continued interest in developing enantioselective 
haloetherification strategies in the near future. 
 
1.7 Halolactamization and Haloamination Reactions 
The two halocyclization reactions introduced thus far in this discussion 
belong to the class of halo-O-cyclization. It is also important to emphasize the 
importance of halo-N-cyclization as it allows the addition of a halogen together 
with a nitrogen functionality across a carbon-carbon double bond. This is viewed 
as an extremely important transformation to synthetic chemists as it provides 
access to important pharmaceutical intermediates as well as biologically active 
natural products.46  
Such transformations, however, are usually far more challenging to execute 
than it may appear to be. This is due to the inherent nature of the relatively more 
electronegative amide oxygen atom that causes the O-cyclization to be more 
favourable as compared to the N-cyclization (Scheme 1.26). As such, most 
attempts in the development of halolactamization have focused on enhancing the 
electronegativity of the nitrogen atom such that its nucleophility is higher than that 











Scheme 1.26 Competing halo-N-cyclization and halo-O-cyclization for olefinic 
amides. 
 
1.7.1 Racemic Halolactamization and Haloamination Reactions 
The earliest halolactamization was demonstrated by Durst and co-workers 
who avoided the fundamental reactivity issue by choosing a highly constrained 
olefinic lactam 1-85 as the substrate (Scheme 1.27).47 The reaction was conducted 
in CH2Cl2 with iodine used as the electrophilic halogen source and Na2CO3 a 
proton scavenger. For this geometrically constrained system, the oxygen atom is 
positioned far from the cyclic iodonium ion such the O-cyclization will not 











Scheme 1.27 Halolactamization performed on a highly constrained olefinic 
lactam. 
The genuine solution was however presented by Ganem and co-workers when 
N-tosylated amide 1-87 was used instead of the unfuctionalized amide (Scheme 
1.28).48 The tosylation of the amide increased the electronegativity on the nitrogen 
atom which resulted in the nitrogen becoming more nucleophilic as compared to 
the oxygen atom. Thus, the resulting product 1-88 formed was predominantly N-
cyclized. 
 
Scheme 1.28 N-tosylated amide bromolactamization. 
With this report setting a precedent, soon after, more N-haloamination 
reactions were discovered, many of which were by simple modifications of the 
functional group attached on the nitrogen atom as well as the type of halogen 
used. The typical starting materials include ureas49, thioimidates50, and 










More recently, Widenhoefer and Li used N-toyslated ureas with NIS to 
produce bicyclic ureas 1-91 and isoureas 1-92 (Scheme 1.29).49 The first step 
involves an N-iodocyclization to form the N-protected pyrrolidine 1-90. The use of 
AgOTf in the subsequent step enabled the bicyclic urea 1-91 to be formed, while 
switching to the use of NaHCO3 produced the isourea derivative 1-92.  
 
 
Scheme 1.29 Synthesis of bicyclic ureas and isoureas using double cyclization 
strategy. 
Lastly, several groups also utilized palladium catalysis to effect the N-
halocyclization reaction. For example, Lu and co-workers demonstrated the use of 
CuBr2 and LiBr in the presence of catalytic amounts of Pd(OAc)2 for the 
bromolactamization of isoureas 1-93 (Scheme 1.30, equation 1).53 The procedure 
was also readily adapted for chlorolactamization by using CuCl2 and LiCl instead. 
Concurrently, Chemler and co-workers worked on the intramolecular 










Indolines 1-97 were obtained as the products in the reaction which utilized 
catalytic amount of Pd(TFA)2 and stoichmetric amount of CuBr2  in the reaction 
system. More recently, Michael and co-workers showed the feasibility of using 
catalytic PdCl2(MeCN)2 with NCS as the halogen source for the 5-exo-
chloroamination of N-Boc-ortho-allyl anilines 1-98 (Scheme 1.30, equation 3).55 
 












1.7.2 Asymmetric Halolactamization and Haloamination 
Reactions 
To the best of my knowledge, it was not until the 2004 that the first 
enantioselective halolactamization reaction was reported (Scheme 1.31).56 In the 
account, an acyclic imide, attached with a chiral oxazolidine auxiliary was used 
for the induction of enantioselectivity, was utilized as the starting material. The 
cyclization was carried out firstly by the deprotonation of the imide 1-100 using 
LiH. Addition of iodine subsequently yielded the cyclic iodo-imides 1-101 in 
good yields and diastereoselectivity. The highly effective and stereoselective 
nature of the reaction was postulated to be due to the coordination of the lithium 
counterion to the oxygen atoms of the imide, creating a rigid intermediate.  
 
Scheme 1.31 Chiral auxiliary induced enantioselective iodolactamization. 
There was no follow-up of any enantioselective haloamination work until 
2010 when Yeung and co-workers developed highly enantioselective 










(Scheme 1.32).57 This class of organocatalysts was previously reported as efficient 
catalyst for asymmetric bromolactonization reactions (Scheme 1.14). The 
aminocyclization reactions were somewhat analogous to the lactonization 
reactions, with the carboxylic acid functionality now exchanged for the 
sulfonamide moiety. To achieve high enantioselectivity, modified catalysts 1-103, 
1-107 were used, but the general structure of the catalysts remained the same. 
Both 1,1-disubstituted 1-102 and 1,2-trans-disubstituted 1-105 olefinic 
sulfonamides were subjected to the cyclization conditions yielding the 2,2-












Scheme 1.32 Amino-thiocarbamate catalyzed bromoaminoocyclization. 
 
1.8 Other Halocyclization Reactions 
Besides the three main classes of halocyclization reactions discussed above, 
there two other types of reactions that are worth a discussion here. In 2007, 
Ishihara and co-workers showcased the catalytic ability of chiral phosphoramidite 
1-110 in a highly enantioselective halopolyene cyclization reaction (Scheme 
1.33).58 Polyprenoids were utilized as the starting materials in the reaction with 











Scheme 1.33 Enantioselective polyenecyclization catalyzed by chiral 
phosphoramidites. 
The authors suggested that the chiral nucleophilic phosphoramidite 1-110, 
used in stoichmetric quantities, activates the NIS such that it is held in place in a 
chiral environment. In dichloromethane, it was observed that only the racemic 
products were obtained. In toluene, however, the authors suggested that a stronger 
ion pair is formed such that hydrogen bonding between the succinimide 
counterion and the phosphoramdite N–H further restricted the rotation around the 











Figure 1.9 Ishihara’s stereochemical model for the observed enantioselectivity. 
Ishihara built a stereochemical model to explain the enantioselectivity 
obtained in the reaction (Figure 1.9). The reactive site is divided into three sectors 
as shown above with the most favourable conformation putting the sterically-
demanding gem-dimethyl group in the least hindered position and the hydrogen 
atom in the most hindered position. This model was developed based on the 
assumption that any enantioselectivity obtained is kinetically controlled and the 
capture of the iodonium ion by the weak nucleophile is highly unlikely. In 
addition, the formation of a tricyclic product also suggests that the cyclic 
iodonium ion formation is reversible. The strategy was applied in the 
enantioselective syntheses of several halogenated cyclic terpenoids which are 
bioactive natural products isolated from marine organisms.  
Such halocyclization reactions involving the intramolecular addition of a 
carbon nucleophile on an olefin that is activated by a halogenating reagent are 










enantioselective iodocarbocyclization of 4-alkenylmalonate derivatives 1-112 
reported by Taguchi and co-workers using a chiral titanium complex 1-113.59  
 
Scheme 1.34 Chiral titanium complex catalyzed iodocarbocyclization. 
It was postulated that the chiral spiro-titanate catalyst 1-113 most likely 
functions as a base instead of a Lewis acid, producing the chiral Ti(IV) enolate by 
deprotonation of the malonate substrate. The transition state is postulated to be 
chair-like with one side of the enolate moiety shielded by the chiral ligand such 
that during iodocarbocyclization, the olefinic moiety of the carbon chain faces the 
opposite face. The iodine and the enolate can then approach and add to the 
equatorial position in a trans-addition fashion, resulting in the formation of the 










1.9 Aims & Approach 
From the examples of halocyclization reactions mentioned above, it can be 
observed that asymmetric halolactonization reactions have already been very well-
reported. In contrast, there are significantly less reports on asymmetric 
haloetherification and haloamination reactions, owing to the extremely 
challenging task of developing an efficient method. A successful 
haloetherification strategy lies in improving the rate of the nucleophilic capture 
relative to the rate of catalyst-halonium ion dissociation which forms racemic 
products. In contrast, an efficient haloamination methodology needs to circumvent 
the inherent possibility of O-cyclization rather than N-cyclization of an amide 
substrate. Both of these reactions are viewed as extremely important synthetic 
transformations to organic chemists as it enables entry to valuable pharmaceutical 
intermediates and bioactive natural products. As such, the aim of this project is to 
develop and explore new enantioselective halocyclization strategies, in particular, 
haloetherification and haloamination that can lead to access to important 
intermediates or functional molecules.  
Our approach is to carry out a systematic search for new or existing 
organocatalysts that can efficiently carry out these reactions enantioselectively. 
Upon identifying suitable catalysts, the reactions will be optimized to furnish 










While it is our primary objective to develop and explore new halocyclization 
reactions, it is also our aim to showcase the value of these synthetic 
transformations by applying these protocols in useful applications. As such, we 
also aim to apply these developed protocols to the synthesis of important 
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Enantioselective Synthesis of 2-
Substituted and 3-Substituted 















Piperidine is an important cyclic amine motif that is present in various areas. 
For instance, 2- and 3-substituted piperidines are the fundamental units of many 
pharmaceuticals and biologically relevant molecules.1 Some examples of these 
bioactive compounds are shown in Figure 2.1. 
 
Figure 2.1 Examples of bioactive substituted piperidines. 
Significant efforts have been devoted to the synthesis of non-racemic 
piperidine derivatives over the past few decades.2 Reagent-controlled methods for 
the enantioselective piperidine synthesis, such as dynamic kinetic resolution using 
phenylglycinol3, sugar chiral auxiliary4, and N-sulfinyl imidate synthons5, are well 
documented. Nonetheless, catalytic enantioselective synthesis of piperidine 
derivatives, in particular 3-substituted piperidines, is still a challenging task.6  
Halocyclization of olefinic amine/amide provides a direct access to piperidine 
and the halogen on the piperidine ring can offer a handle for subsequent 
manipulation.7 However, a catalytic enantioselective entry towards 









remains nontrivial.8,9 Herein we disclose a facile and efficient asymmetric 
cyclization of olefinic amide 2-5 using 1,3-dibromo-5,5-dimethylhydantoin 
(DBH) as the stoichiometric halogen source and amino-thiocarbamates as the 
catalyst, yielding 2-substituted-3-bromopiperidines 2-7 in good yields and ees. In 
addition, it was found that 2-7 can readily undergo rearrangement to give 3-
substituted piperidines 2-8 in the presence of a silver salt (Scheme 2.1). This 
approach was applied to the synthesis of a dopaminergic drug, Preclamol.  
 
Scheme 2.1 Bromocyclization of olefinic amides. 
 
2.2 Results and Discussion 
2.2.1 Catalyst Screening 
Recently, we reported a thiocarbamate-catalyzed asymmetric 
bromoaminocyclization of 2-9 resulting in the formation of enantioenriched 2-












Scheme 2.2 Asymmetric bromoaminocyclization of 2-9. 
However, when the same conditions were applied to the homolog substrate 2-
5, the reaction was sluggish and neglectable enantioselectivity was observed 
(Table 2.1, entry 1). As such, we revisited our catalyst library in an attempt to 
search for a suitable catalyst. We first looked at the cinchonine catalyst analogue 
2-11b and found that it behaves like the cinchonidine catalyst 2-11a giving poor 
yields and enantioselectivity (Table 2.1, entry 2). Instead, the quinine version 2-
11c gave products with moderate enantioselectivity (Table 2.1, entry 3). When the 
pseudo-enantiomeric quinidine thiocarbamte catalyst 2-11d was used instead, it 
was observed that the ee was low (Table 2.1, entry 4).  
It was interesting to observe that the olefinic amide homologs 2-5 and 2-9 
gave opposite enantiomeric products 2-12 and 2-7a when using the catalysts with 
the same configuration. This was unexpected as they did not follow the same trend 
in the catalysis. The reasons for this unusual phenomenon, however, remain 
unclear and are subject to further investigation.10  
Next, we proceeded to examine the handles on catalyst 2-11c. It was 









trimethoxyphenyl (catalyst 2-11f), 2,4-dichlorophenyl (catalyst 2-11g), 2,4-
dimethylphenyl (catalyst 2-11h) and 4-dimethylaminophenyl (catalyst 2-11i) 
substituents on the thiocarbamate caused the reaction to produce no products 
(Table 2.1, entries 5-9). Instead, substrate 2-5a was recovered quantitatively from 
these reactions. It was deduced that the 2,4-dimethoxyphenyl substituent remained 
the superior choice for the thiocarbamate aryl-substituent.  
We then turned our attention to the 6-alkoxy group of the quinoline system. 
When the isopropyl group (catalyst 2-11j) was installed to replace the methyl 
substituent, the reaction yield increased drastically to 81% and the resulting 
product was observed to have 63% ee (Table 2.1, entry 10). The encouraging 
results prompted us to further investigate how different substituents at this 
position can influene the yield and enantioselectivity of the reaction. We increased 
the steric bulk of the alkoxy substituent using the triphenyl group (catalyst 2-11k) 
and noticed that yield dropped slightly to 67% but the ee increased to 68% (Table 
2.1, entry 11). When the isoamyl (catalyst 2-11l) and the neopentyl groups 
(catalyst 2-11m) were installed, the products had 55% ee and 73% ee respectively 
(Table 2.1, entries 12-13). Catalyst 2-11m due to its high enantioselectivity 
observed was then identified as a potential catalyst for further optimization to be 






















2.2.2 Reaction Conditions Optimization 
Once we had identified catalyst 2-11m as the most promising catalyst, 
different brominating reagents, solvent systems and reaction temperatures were 
investigated. The efficiency of three brominating reagents in the form of NBS, 
NBP and DBH were first investigated, using chloroform as the reaction solvent. 
Of the three bromine sources, DBH gave the highest yield of 97%, while NBP was 
the most promising in terms of enantioselectivity, giving products with 86% ee 
(Table 2.2, entries 1-3). Next, a series of solvents and solvent blends were looked 
into and it was observed that the reaction did not proceed in toluene at -60 oC 
(Table 2.2, entries 4 and 5). When the reactions were carried out with NBS in 
chloroform/toluene (1:1) and chloroform/hexane (1:1) blends, it was observed that 
the yield and ee were distinctively higher for the latter (Table 2.2, entries 6 and 7). 
With NBP, the ee of product remained the same when temperature was decreased 
from -60 to -78 oC (Table 2.2, entries 8-9). Further optimizations looked into 
varying the ratio of chloroform to hexane to find the ideal composition.  When the 
ratio of chloroform is increased, the ee increased to 88% (Table 2.2, entry 11), and 
when the ratio of hexane is increased, 92% ee was obtained for the products when 
the reaction was ran at -78 oC (Table 2.2, entry 12). Although the ee values 
obtained were encouraging, the yields obtained were poor. When we attempted 
using DBH as the brominating source, similar trends were observed (Table 2.2, 
entries 15-18). After extensive consideration, we took a balance between 










chloroform/hexane (1:1)/DBH systems to be the optimum conditions for the 
asymmetric cyclization of 2-5a.  












2.2.3 Substrate Scope 
Next, aryl substrates with different electronic properties were examined and 
the results are shown in Table 2.3. Substrates with electron-deficient phenyl 
substituents such as 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl produced 
products of good yields and ees (Table 2.3, entries 1-3). In contrast, the electron-
rich 4-methoxyphenyl substituent produced product with low ee (Table 2.3, entry 
4). This was consistent with the results obtained for electron-rich substrate 2-5i 
where relatively low ee was observed (Table 2.3, entry 8). 
When the 3-substituted aryl substrates were subject to the reaction conditions, 
both electron-rich and electron-poor aryl substituents gave products with good 
yields and ees (Table 2.3, entries 5-7).  
Heterocyclic aromatic substitutents were next investigated. 3-Thienyl 
substrate 2-5j returned with good ee while the 2-thienyl substrate 2-5k gave  
lower enantioselectivity (Table 2.3 , entries 9 and 10).  
The absolute configuration of piperidines 2-7 was confirmed by an X-ray 























Figure 2.2 X-ray crystal structure of 2-7a. 
 
2.2.4 Scale-up Synthesis and Synthesis of Enantiomer of 2-7 
Enantiomer of 2-7a (ent-2-7a) could be prepared (84% ee) by using the 
pseudo-enantiomer quinidine catalyst 2-11n. This reaction was also readily 













Scheme 2.3 Synthesis of ent-2-5a using catalyst 2-11n.  
 
2.2.5 Silver Salt Promoted Rearrangement 
In an attempt to synthesize (+)-L-733,060 2-3, we treated ent-2-7a with silver 
nitrate under acetone/water (3:1) conditions and obtained a product that matches 
the 1H and 13C NMR spectra of compound 2-13.  
 









However, on further examination, we realized that the product obtained was 
not compound 2-13, but a product that had undergo a 1,2-aryl shift. The structure 
and absolute configuration of ent-2-8a was established by an X-ray 
crystallography study (Figure 2.3) 
 
Figure 2.3 X-ray crystal structure of ent-2-8a. 
In fact, similar reactions were documented and they involved the use of silver 
nitrate in MeOH. Thereafter, an acidic work-up resulted in the formation of the 











Scheme 2.5 1,2-Aryl shift for the synthesis of unsaturated piperidine 2-15. 
However, by modifying the work-up conditions to use a basic work-up, we 
were able to obtain the 2-hydroxy-3-aryl product ent-2-8a exclusively. When we 
proceeded to check the ee of the resulting product, we were pleased to observe 
that the product formed with the retention of the chirality.  
A survey on various silver salts was performed and it was observed that silver 
acetate (AgOAc), silver carbonate (Ag2CO3), silver phosphate (Ag3PO4) and 
silver sulfate (Ag2SO4) resulted in no product being formed when they were 
utilized (Table 2.4, entries 1, 2, 4 and 5). When silver triflate (AgOTf) and silver 
tosylate (AgOTs) were used, moderate yields of 43% and 37% were obtained 
(Table 2,4, entries 6 and 7). Of all, silver nitrate (AgNO3) and silver 
trifluoroacetate (Ag(O2CCF3)) were found to be optimal, with the latter giving 










Table 2.4 Survey of silver salts on rearrangement of 2-7a. 
 
Some substrates 2-7 were subject to investigation, and the results are 
presented in Table 2.5 (entries 1–5). Generally, good yields were achieved and the 











Table 2.5 Silver-salt promoted rearrangement of 2-7. 
 
We proposed that the rearrangement was initiated by the coordination of the 
silver ion with the bromide, resulting in concerted 1,2-aryl shift, in the process 
eliminating silver bromide and forming the iminium ion 2-17. Subsequently, a 
molecule of water quenches the iminium ion 2-17 by attacking the adjacent carbon 
atom. The attack may lead to the formation of two possible products, one via a 
boat-like transition state 2-18, while the other through a chair-like transition state 
2-19. The chair-like transition state is more favoured and hence the product 2-8a 
is formed. In addition, product 2-8a also exhibits anomeric effect which adds extra 
stability to the product formed. This may be another contributing reason to why 
































































Scheme 2.6 Possible explanation for the observed stereoselectivity.  
 
2.2.6 Applications – Syntheses of Chiral Pharmaceutical Building 
Blocks 
2-Phenyl 3-bromopiperidine ent-2-7a could be transformed to other useful 
building blocks. Treatment of ent-2-7a with DBU in refluxing toluene offered 
unsaturated piperidine 2-21. On the other hand, when ent-2-7a was treated with 
LiOH and PhSH in acetonitrile, the Ns group was removed and further 
intramolecular displacement occurred to yield bicycle 2-22.12 These molecules 










(+)-CP-99,994, (+)-CP-113,054, and (+)-L-733,060 (Scheme 2.7).13 
 
Scheme 2.7 Synthesis of pharmaceutical intermediates. 
 
2.2.7 Applications – Synthesis of Preclamol 
Preclamol is a dopaminergic drug currently undergoing preclinical trials for 
schizophrenic treatment.14  This drug was previously synthesized using dynamic 
kinetic resolution via the stereoselective cyclodehydration of racemic γ-aryl-δ-
oxoesters with (S)-phenylglycinol (Scheme 2.8).14a  Chiral bicyclic δ-lactams were 
obtained in the process and subsequent reduction of the lactams resulted in 










Scheme 2.8 Synthesis of Preclamol using kinetic resolution. 
Initially, diastereomeric imines 2-27 and 2-29 were formed after racemic 
oxoester 2-23 was subject to condensation with (S)-phenylglycinol 2-24 (Scheme 
2.9). The two imines are in equilibrium via the enamine 2-28. Lactamization 
occurs through a transition state, in which the aryl substituent lies in the equatorial 
position of a chair-like six-membered transition state, leading to the formation of 
isomers 2-25 (major) and 2-32 (minor). The preferential formation of 2-25 is a 
consequence of a faster lactamization from the diastereomeric oxazolidine 2-30 as 
it allows a less hindered approach of the nitrogen atom to the ester moiety. The 
major product 2-25 was easily converted to (S)-3-arylpiperidine 2-26 by LiAlH4 
reduction. Subsequent debenzylation by hydrogenolysis, demethylation and N-












Scheme 2.9 Synthesis of intermediate of Preclamol using dynamic kinetic 
resolution. 
The poor atom economy of this procedure prompted the need for an efficient 
alternative way of synthesizing Preclamol. One elegant strategy to synthesize 
Preclamol is via utilizing the combination of both the bromoaminocyclization and 
silver salt rearrangement protocols developed. As discussed above, 2-8h can be 
synthesized in two steps starting from 2-5h with good yield and ee (Scheme 2.10). 









protocol gave piperdine 2-33 in good yield. Subsequent deprotection gave 2-34, a 
key intermediate in the synthesis of the dopaminergic drug Preclamol. 
 
Scheme 2.10 Synthesis of Preclamol.  
Under similar conditions, ent-2-8a could also be converted to 2-35 which is a 
demethoxy antipode of 2-33 (Scheme 2.11). 
 












In summary, we have developed an efficient and enantioselective 
bromocyclization of olefinic amides 2-5 resulting in the formation of 
enantioenriched 2-substituted-3-bromopiperidines 2-7. In the presence of silver 
trifluoroacetate, 2-7 undergoes a 1,2-aryl shift to give the corresponding valuable 
3-substituted piperidines 2-8. The importance of these methodologies were 
showcased in the synthesis of the dopaminergic drug Preclamol 2-4. 
 
2.4 Experimental  
(A) Catalysts 6a-6i were synthesized according to the report procedure.9i 
Amino-thiocabamate (2-11j): 
 
Yield: 72%; light yellow solid, [] 28D  +155.9 (c 1.0, CH2Cl2); IR (KBr): 2939, 
1618, 1524, 1307, 1209, 1161 cm-1; 1H NMR (the compound existed as a mixture 









= 4.1 Hz, 1H), 8.50-8.45 (m, 1H), 7.98 (d, J = 9.1 Hz, 1H), 7.50-7.29 (m, 5H), 
6.45 (s, 2H), 5.85-5.77 (m, 1H), 4.97-4.94 (m, 2H), 4.78-4.63 (m, 1H), 3.80 (s, 
6H), 3.46-3.42 (m, 1H), 3.20-3.01 (m, 2H), 2.69-2.49 (m, 2H), 2.18-2.04 (m, 1H), 
1.90-1.52 (m, 5H), 1.39 (d, J = 3.5 Hz, 6H); 13C NMR (75 MHz, CDCl3):  188.0, 
158.6, 155.9, 151.9, 147.1, 144.5, 141.7, 131.5, 127.1, 124.6, 123.1, 122.9, 119.4, 
118.9, 114.3, 103.9, 103.5, 98.7, 81.7, 70.0, 59.8, 56.6, 55.4, 42.5, 39.6, 27.5, 




Yield: 69%; light yellow solid, [] 28D  +72.6 (c 1.0, CH2Cl2); IR (KBr): 2941, 
1639, 1526, 1209, 1159, 1034 cm-1; 1H NMR (the compound existed as a mixture 
of rotamers and the major rotamer was assigned) (400 MHz, CDCl3):  8.90 (brs, 
1H), 8.71 (d, J = 4.5 Hz, 1H), 7.99 (d, J = 9.2 Hz, 1H), 7.48-7.28 (m, 5H), 6.43 (s, 
2H), 5.79-5.72 (m, 1H), 4.97-4.94 (m, 2H), 3.77-3.62 (m, 8H), 3.41-3.39 (m, 1H), 
3.13-3.01 (m, 2H), 2.67-2.57 (m, 2H), 2.28-2.15 (m, 1H), 1.84-1.42 (m, 5H), 1.07 










141.9, 129.0, 127.9, 127.3, 126.3, 126.0, 114.2, 113.0, 103.9, 98.8, 91.2, 81.7, 
60.0, 59.1, 55.5, 42.5, 42.2, 39.8, 27.7, 27.6, 24.1; HRMS (ESI) calcd for 
C47H46N3O4S m/z [M + H]+: 748.3204; found: 748.3231. 
Amino-thiocabamate (2-11l): 
 
Yield: 73%; light yellow solid, [] 28D  +149.4 (c 1.6, CH2Cl2); IR (KBr): 2951, 
1619, 1513, 462, 1209, 1160, 1034 cm-1; 1H NMR (the compound existed as a 
mixture of rotamers and the major rotamer was assigned) (400 MHz, CDCl3):  
8.71 (d, J = 4.3 Hz, 1H), 8.44 (br, 1H), 7.98 (d, J = 9.2 Hz, 1H), 7.64-7.31 (m, 
5H), 6.47-6.44 (m, 2H), 5.83-5.77 (m, 1H), 5.00-4.95 (m, 2H), 4.16-4.01 (m, 2H), 
3.86-3.68 (m, 6H), 3.45-3.42 (m, 1H), 3.14-2.99 (m, 2H), 2.62-2.56 (m, 2H), 2.24-
2.15 (m, 1H), 1.92-1.43 (m, 8H), 0.99 (d, J = 6.5 Hz, 6H); 13C NMR (100 MHz, 
CDCl3):  188.1, 158.6, 157.3, 151.9, 147.2, 144.7, 143.0, 141.8, 131.5, 127.2, 
124.6, 122.3, 119.4, 119.3, 114.3, 103.9, 103.4, 102.6, 98.7, 81.7, 66.8, 59.7, 56.5, 
55.5, 42.5, 39.7, 37.8, 27.5, 25.1, 24.1, 22.6; HRMS (ESI) calcd for C33H42N3O4S 










Amino-thiocabamate (2-11m):  
 
Yield: 78%; light yellow solid, [] 28D  +149.4 (c 1.6, CH2Cl2); IR (KBr): 2957, 
1620, 1525, 1466, 1215, 1037 cm-1; 1H NMR (the compound existed as a mixture 
of rotamers and the major rotamer was assigned) (400 MHz, CDCl3):  8.90 (brs, 
1H), 8.71 (d, J = 4.5 Hz, 1H), 7.99 (d, J = 9.2 Hz, 1H), 7.48-7.28 (m, 5H), 6.43 (s, 
2H), 5.79-5.72 (m, 1H), 4.97-4.94 (m, 2H), 3.77-3.62 (m, 8H), 3.41-3.39 (m, 1H), 
3.13-3.01 (m, 2H), 2.67-2.57 (m, 2H), 2.28-2.15 (m, 1H), 1.84-1.42 (m, 5H), 1.07 
(s, 9H); 13C NMR (100 MHz, CDCl3):  188.0, 170.8, 158.6, 157.6, 152.3, 146.9, 
144.4, 143.0, 141.5, 131.1, 126.8, 125.1, 122.1, 119.1, 114.1, 103.8, 102.4, 98.6, 
81.2, 78.0, 60.1, 59.2, 56.3, 55.2, 42.4, 39.4, 31.7, 27.3, 26.4, 23.6; HRMS (ESI) 

























Yield: 75%; light yellow solid, [] 28D  –150.2 (c 0.9, CH2Cl2); IR (KBr): 2953, 
1620, 1525, 1463, 1209, 1036 cm-1; 1H NMR (the compound existed as a mixture 
of rotamers and the major rotamer was assigned) (300 MHz, CDCl3):  8.76-8.72 
(m, 2H), 8.00 (d, J = 9.2 Hz, 1H), 7.62-7.56 (m, 1H), 7.41-7.30 (m, 4H), 6.54-6.44 
(m, 2H), 6.13-5.92 (m, 1H), 5.25-5.06 (m, 2H), 3.81-3.67 (m, 8H), 3.42-3.39 (m, 
1H), 2.92-2.76 (m, 4H), 2.26-2.00 (m, 2H), 1.81-1.77 (m, 1H), 1.56-1.52 (m, 3H), 
1.10 (s, 9H); 13C NMR (75 MHz, CDCl3):  187.9, 157.6, 151.6, 147.0, 144.4, 
143.4, 140.2, 131.1, 127.3, 124.3, 123.4, 122.2, 119.3, 118.4, 114.5, 103.8, 102.5, 
98.6, 80.4, 78.0, 60.1, 59.7, 55.3, 49.1, 40.0, 31.7, 27.8, 26.5, 26.2, 24.0; HRMS 













(B) General procedure for the preparation of olefinic amide 2-5. 
 
To a solution of acid A (1.0 mmol, 1.0 eq) (synthesized according to the literature 
procedure3) in THF (10 mL) was added LiAlH4 (76 mg, 2.0 mmol, 2.0 eq) at 0 C 
under N2. The resulting mixture was stirred at 0 C for 10 min and then was 
warmed to 25 C and stirred for another 3 h. After TLC revealed the absence of 
the starting material, the reaction was quenched with crushed ice. The mixture was 
filtered through a thin pad of silica gel and eluted with EtOAc (20 mL). The 
filtrate was concentrated in vacuo, which was used directly without further 
purification, or purified by a short column (hexane/EtOAc 3:1) to give alcohol B.  
To a solution of alcohol B (1.0 mmol, 1.0 eq) and triethylamine (418 L, 3.0 
mmol, 3.0 eq) in CH2Cl2 (5 mL) was added MsCl (116 L, 1.5 mmol, 1.5 eq) at 0 
C. The resulting mixture was stirred at 0 C for 10 min and then was warmed to 
25 C and stirred for another 2 h. After TLC revealed the absence of the starting 
material, the reaction was quenched with water (4 mL) and extracted with CH2Cl2 










concentrated. The residue was purified by flash column chromatography 
(hexane/EtOAc 3:1) to give the compound C. 
A modified literature2 procedure was used for the direct conversion of Ms-
activated alcohols to the corresponding 4-nitrobenzenesulfonamides. A solution of 
compound C (1.0 mmol, 1.0 eq), NsNH2 (404 mg, 2.0 mmol, 2.0 eq) and K2CO3 
(276 mg, 2.0 mmol, 2.0 eq) in DMF (5 mL) was stirred at 90 C for 12 h. The 
reaction mixture was diluted with water (10 mL) and extracted with Et2O (3 × 15 
mL). The combined organic extracts were washed with water (3 × 10 mL) and 
brine, dried over Na2SO4, filtered and concentrated. The residue was purified by 




Yellow solid, IR (KBr): 3259, 3103, 1546, 1350, 1160, 1061 cm-1; 1H NMR (300 
MHz, CDCl3):  8.30 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 9.0 Hz, 2H), 7.29-7.19 (m, 
5H), 6.34 (d, J = 15.8 Hz, 1H), 6.08 (dt, J = 15.8, 6.9 Hz, 1H), 5.18 (t, J = 5.8 Hz, 
1H), 3.06 (dt, J = 6.7 Hz, 2H), 2.23 (dt, J = 6.9 Hz, 2H), 1.74-1.65 (m, 2H); 13C 









125.8, 124.3, 42.6, 29.6, 29.0; HRMS (ESI) calcd for C17H17N2O4S m/z [M – H]–: 
345.0915; found: 345.0920. 
(E)-N-[5-(4-Fluorophenyl)pent-4-enyl]-4-nitrobezenesulfonamide (2-5b): 
 
Yellow solid, IR (KBr): 3258, 1531, 1351, 1307, 1162, 1091 cm-1; 1H NMR (500 
MHz, CDCl3):  8.32 (d, J = 8.2 Hz, 2H), 8.05 (d, J = 8.5 Hz, 2H), 7.23 (dd, J = 
8.2, 5.7 Hz, 2H), 6.96 (dd, J = 8.5 Hz, 2H), 6.29 (d, J = 15.8 Hz, 1H), 5.98 (dt, J = 
15.1, 6.9 Hz, 1H), 5.06 (t, J = 5.8 Hz, 1H), 3.06 (dt, J = 6.3 Hz, 2H), 2.21 (dt, J = 
7.0 Hz, 2H), 1.71-1.65 (m, 2H); 13C NMR (125 MHz, CDCl3):  162.0 (d, J = 
245.0 Hz), 150.0, 145.8, 133.3 (d, J = 3.6 Hz), 130.0, 128.2, 128.2 (d, J = 1.8 Hz), 
127.3 (d, J = 7.3 Hz), 124.4, 115.4 (d, J = 21.9 Hz), 42.7, 29.6, 29.1; HRMS (ESI) 
calcd for C17H16FN2O4S m/z [M – H]–: 363.0820; found: 363.0813. 
(E)-N-[5-(4-Chlorophenyl)pent-4-enyl]-4-nitrobezenesulfonamide (2-5c): 
 
Yellow solid, IR (KBr): 3278, 1530, 1350, 1314, 1164, 1088 cm-1; 1H NMR (500 
MHz, CDCl3):  8.34 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8, Hz, 2H), 7.25 (d, J = 










6.9 Hz, 1H), 4.69 (t, J = 6.0 Hz, 1H), 3.08 (dt, J = 6.9 Hz, 2H), 2.23 (dt, J = 6.4 
Hz, 2H), 1.73-1.58 (m, 2H); 13C NMR (125 MHz, CDCl3):  150.1, 145.9, 135.6, 
132.9, 130.2, 129.1, 128.7, 128.3, 127.2, 124.4, 42.8, 29.7, 29.2; HRMS (ESI) 
calcd for C17H16ClN2O4S m/z [M – H]–: 379.0525; found: 379.0516. 
(E)-N-[5-(4-Bromophenyl)pent-4-enyl]-4-nitrobezenesulfonamide (2-5d): 
 
Yellow solid, IR (KBr): 3279, 1529, 1412, 1349, 1163, 1050 cm-1; 1H NMR (300 
MHz, Acetone-d6):  8.42 (dd, J = 9.0 Hz, 2H), 8.13 (d, J = 9.0 Hz, 2H), 7.45 (d, J 
= 8.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 6.90 (brs, 1H), 6.37 (d, J = 16.1 Hz, 1H), 
6.26 (dt, J = 15.8, 6.3 Hz, 1H), 3.06 (dt, J = 6.8 Hz, 2H), 2.24 (dt, J = 7.1 Hz, 2H), 
1.74-1.65 (m, 2H); 13C NMR (125 MHz, Acetone-d6):  149.8, 146.6, 136.7, 
131.2, 130.3, 129.1, 128.1, 127.5, 124.1, 119.8, 42.2, 29.5, 29.0; HRMS (ESI) 
calcd for C17H16BrN2O4S m/z [M – H]–: 423.0020; found: 423.0016. 
(E)-N-[5-(4-methoxyphenyl)pent-4-enyl]-4-nitrobenzenesulfonamide (2-5e): 
 
Yellow solid, IR (KBr): 3282, 1529, 1349, 1240, 1165, 1041 cm-1; 1H NMR (300 









2H), 6.82 (dd, J = 6.8, 2.0 Hz, 2H), 6.26 (d, J = 15.8 Hz, 1H), 5.91 (dt, J = 15.6, 
6.9 Hz, 1H), 4.91 (t, J = 6.0 Hz, 1H), 3.80 (s, 3H), 3.05 (dt, J = 6.9 Hz, 2H), 2.20 
(dt, J = 7.0 Hz, 2H), 1.72-1.62 (m, 2H); 13C NMR (75 MHz, CDCl3):  158.9, 
150.0, 145.8, 130.6, 128.2, 127.0, 126.1, 126.0, 124.3, 113.9, 55.3, 42.6, 29.7, 




Yellow solid, IR (KBr): 32608, 1534, 1351, 1310, 1160, 1091 cm-1; 1H NMR (400 
MHz, CDCl3):  8.29 (d, J = 8.9 Hz, 2H), 8.01 (d, J = 9.0 Hz, 2H), 7.23-7.08 (m, 
4H), 6.24 (d, J = 15.9 Hz, 1H), 6.05 (dt, J = 15.8, 6.9 Hz, 1H), 4.97 (t, J = 6.1 Hz, 
1H), 3.02 (dt, J = 6.9 Hz, 2H), 2.19 (dt, J = 7.3, 1.2 Hz, 2H), 1.69-1.61 (m, 2H); 
13C NMR (100 MHz, CDCl3):  150.0, 145.8, 139.0, 134.4, 130.0, 129.9, 129.7, 
128.2, 127.1, 125.8, 124.4, 124.2, 42.6, 29.6, 29.0; HRMS (ESI) calcd for 















Yellow solid, IR (KBr): 3280, 1530, 1413, 1351, 1162, 1049 cm-1;1H NMR (400 
MHz, CDCl3):  8.30 (d, J = 9.0 Hz, 2H), 8.04 (d, J = 9.0 Hz, 2H), 7.17 (d, J =7.5 
Hz, 1H), 7.09-7.02 (m, 3H), 6.29 (d, J = 15.8 Hz, 1H), 6.06 (dt, J = 15.8, 6.9 Hz, 
1H), 5.17 (t, J = 6.0 Hz, 1H), 3.06 (dt, J = 6.9 Hz, 2H), 2.33 (s, 3H), 2.22 (dt, J = 
6.4, 1.1 Hz, 2H), 1.70-1.67 (m, 2H); 13C NMR (100 MHz, CDCl3):  149.9, 145.7, 
138.0, 137.0, 131.2, 128.4, 128.2, 128.1, 128.0, 126.6, 124.3, 123.0, 42.6, 29.6, 




Yellow solid, IR (KBr): 3264, 1533, 1349, 1162, 1090 cm-1; 1H NMR (300 MHz, 
CDCl3):  8.31 (d, J = 8.9 Hz, 2H), 8.03 (d, J = 9.0 Hz, 2H), 7.20 (dd, J = 7.7 Hz, 
1H), 6.88-6.74 (m, 3H), 6.30 (d, J = 15.9 Hz, 1H), 6.06 (dt, J = 15.7, 6.9 Hz, 1H), 
4.97 (t, J = 6.1 Hz, 1H), 3.80 (s, 3H), 3.05 (dt, J = 6.9 Hz, 2H), 2.22 (dt, J = 6.9 









138.5, 131.1, 129.5, 128.7, 128.2, 124.4, 118.6, 112.6, 111.5, 55.2, 42.6, 29.6, 





Yellow solid, IR (KBr): 3255, 1532, 1349, 1309, 1159, 1061 cm-1;  1H NMR 
(300 MHz, Acetone-d6):  8.42 (d, J = 8.9 Hz, 2H), 8.15 (d, J = 8.9 Hz, 2H), 7.84-
7.79 (m, 3H), 7.72 (s, 1H), 7.61 (dd, J = 8.6, 1.7 Hz, 1H), 7.50-7.40 (m, 2H), 6.92 
(t, J = 5.6 Hz, 1H), 6.56 (d, J = 15.8 Hz, 1H), 6.37 (dt, J = 15.8, 6.9 Hz, 1H), 3.10 
(dt, J = 6.8 Hz, 2H), 2.30 (dt, J = 6.9 Hz, 2H), 1.78-1.68 (m, 2H); 13C NMR (75 
MHz, Acetone-d6):  149.8, 146.6, 135.0, 133.6, 132.6, 130.5, 129.7, 128.1, 
127.8, 127.6, 127.4, 126.0, 125.4, 125.2, 124.2, 123.2, 42.3, 29.5, 29.0; HRMS 
















Yellow solid, IR (KBr): 3254, 1546, 1349, 1159, 1063, 967 cm-1; 1H NMR (300 
MHz, CDCl3):  8.28 (d, J = 8.9 Hz, 2H), 8.00 (d, J = 9.0 Hz, 2H), 7.22-7.19 (m, 
1H), 7.07 (dd, J = 4.9, 1.0 Hz, 1H), 6.99 (dd, J = 3.0, 1.1 Hz, 1H), 6.30 (d, J = 
15.8 Hz, 1H), 5.88 (dt, J = 15.8, 6.9 Hz, 1H), 4.98 (t, J = 6.1 Hz, 1H), 3.01 (dt, J = 
6.9 Hz, 2H), 2.15 (ddd, J = 8.4, 7.2, 1.3 Hz, 2H), 1.69-1.58 (m, 2H); 13C NMR (75 
MHz, CDCl3):  150.0, 145.8, 139.7, 128.3, 128.2, 126.0, 125.5, 124.7, 124.4, 
121.0, 42.6, 29.5, 29.1; HRMS (ESI) calcd for C15H16N2O4S2 m/z [M – H]–: 
351.0479; found: 351.0461. 
(E)-4-nitro-N-[5-(thiophen-2-yl)pent-4-enyl]benzenesulfonamide (2-5k): 
 
Yellow solid, IR (KBr): 3249, 1531, 1348, 1310, 1159, 1065 cm-1; 1H NMR (300 
MHz, CDCl3):  8.33 (d, J = 9.0 Hz, 2H), 8.04 (d, J = 9.1 Hz, 2H), 7.10 (d, J = 5.1 
Hz, 1H), 6.92 (dd, J = 5.1, 3.5 Hz, 1H), 6.83 (d, J = 3.3 Hz, 1H), 6.45 (d, J = 15.6 
Hz, 1H), 5.89 (dt, J = 15.6, 7.1 Hz, 1H), 4.86 (t, J = 5.8 Hz, 1H), 3.05 (dt, J = 6.7 
Hz, 2H), 2.19 (ddd, J = 8.4, 7.1, 1.1 Hz, 2H), 1.72-1.62 (m, 2H); 13C NMR (125 









123.6, 42.6, 29.5, 29.0; HRMS (ESI) calcd for C15H15N2O4S2 m/z [M – H]–: 
351.0479; found: 351.0461. 
 
(C) General Procedure for the Bromoamidation.  
To a solution of olefinic amide 2-5 (0.1 mmol, 1.0 equiv), catalyst 2-11m (0.01 
mmol, 0.1 equiv) in the corresponding solvent (0.02 M) at corresponding 
temperature in dark under N2 was added brominating source (0.12 mmol, 1.2 
equiv). The resulting mixture was stirred at that temperature and monitored by 
TLC. The reaction was quenched with saturated Na2SO3 (2.0 mL) and then was 
warmed to 25 C. The solution was diluted with water (3.0 mL) and extracted 
with CH2Cl2 (3 × 5 mL). The combined extracts were washed with brine (5.0 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by 
flash column chromatography on silica gel (CH2Cl2/hexane 2:1) to yield the 
corresponding piperidine 2-7. 
(2S,3R)-3-Bromo-1-(4-nitrophenylsulfonyl)-2-phenylpiperidine (2-7a): 
 
White solid, [] 26D  –17.6 (c 1.4, CH2Cl2, 90% ee); IR (KBr): 2939, 1526, 1349, 










8.06 (d, J = 9.0 Hz, 2H), 7.39-7.29 (m, 5H), 5.51 (s, 1H), 4.97 (d, J = 2.6 Hz, 1H), 
3.90 (d, J = 15.7 Hz, 1H), 3.33 (ddd, J = 15.2, 12.2, 2.9 Hz, 1H), 2.04-1.81 (m, 
3H), 1.52-1.48 (m, 1H); 13C NMR (75 MHz, CDCl3):  149.9, 146.2, 136.9, 129.1, 
128.8, 128.0, 126.7, 123.9, 63.8, 51.5, 42.2, 27.2, 19.5; HRMS (EI) calcd for 
C17H17BrN2O4S m/z [M]+: 424.0087; found: 424.0080. HPLC (Daicel Chiralpak 
































White solid, [] 26D  –12.6 (c 1.0, CH2Cl2, 83% ee); IR (KBr): 2962, 1605, 1531, 
1347, 1164, 1010 cm-1; 1H NMR (300 MHz, CDCl3):  8.34 (d, J = 9.0 Hz, 2H), 
8.04 (d, J = 9.1 Hz, 2H), 7.34-7.29 (m, 2H), 7.07 (dd, J = 8.5 Hz, 2H), 5.47 (s, 
1H), 4.93 (dd, J = 5.4, 2.3 Hz, 1H), 3.86 (dd, J = 14.3, 2.9 Hz, 1H), 3.30 (ddd, J = 
14.2, 12.2, 3.0 Hz, 1H), 1.95-1.83 (m, 3H), 1.54-1.48 (m, 1H); 13C NMR (75 
MHz, CDCl3):  162.2 (d, J = 247.1), 150.0, 146.0, 132.6, 128.8, 128.5 (d, J = 7.6 
Hz), 124.0, 116.1 (d, J = 21.8), 63.3, 51.2, 42.1, 27.2, 19.4; HRMS (EI) calcd for 
C17H16FBrN2O4S m/z [M]+: 441.9993; found: 441.9992. HPLC (Daicel Chiralpak 













White solid, [] 26D  –15.4 (c 0.57, CH2Cl2, 73% ee); IR (KBr): 2958, 1607, 1530, 
1346, 1162, 1108 cm-1; 1H NMR (500 MHz, CDCl3):  8.34 (d, J = 8.8 Hz, 2H), 
8.10 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 5.46 
(s, 1H), 4.92 (d, J = 3.2 Hz, 1H), 3.86 (d, J = 12.6 Hz, 1H), 3.29 (ddd, J = 14.5, 










CDCl3):  150.0, 146.0, 135.4, 134.1, 129.3, 128.8, 128.2, 124.0, 63.3, 51.0, 42.2, 
27.3, 19.4; HRMS (EI) calcd for C17H16ClBrN2O4S m/z [M]+: 457.9697; found: 
457.9693. HPLC (Daicel Chiralpak IC, i-PrOH/hexane = 45/55, 0.6 mL/min, 230 

















White solid, [] 25D  –17.4 (c 1.0, CH2Cl2, 72% ee); IR (KBr): 2927, 1523, 1489, 
1350, 1160, 1109 cm-1; 1H NMR (500 MHz, CDCl3):  8.34 (d, J = 8.7 Hz, 2H), 
8.10 (d, J = 8.7 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 5.43 
(s, 1H), 4.92 (d, J = 2.5 Hz, 1H), 3.86 (d, J = 13.3 Hz, 1H), 3.29 (ddd, J = 14.9, 
12.2, 2.8 Hz, 1H), 1.93-1.79 (m, 3H), 1.51-1.25 (m, 1H); 13C NMR (100 MHz, 
CDCl3):  150.1, 146.0, 136.0, 132.3, 128.9, 128.5, 124.0, 122.2, 63.4, 50.9, 42.2, 
27.4, 19.5; HRMS (EI) calcd for C17H16Br2N2O4S m/z [M]+: 501.9192; found: 
501.9200. HPLC (Daicel Chiralpak IC, i-PrOH/hexane = 40/60, 0.6 mL/min, 230 













White solid, [] 25D  –4.0 (c 0.5, CH2Cl2, 34% ee); IR (KBr): 2954, 1607, 1525, 
1351, 1162, 1107 cm-1; 1H NMR (500 MHz, CDCl3):  8.32 (d, J = 8.8 Hz, 2H), 
8.04 (d, J = 8.9 Hz, 2H), 7.34 (d, J = 1.9 Hz, 1H), 7.26-7.24 (m, 2H), 6.87 (d, J = 
8.8 Hz, 2H), 7.04 (s, 1H), 5.40 (s, 1H), 4.85 (dd, J = 5.6, 2.9 Hz, 1H), 3.89 (s, 









1.55-1.42 (m, 1H); 13C NMR (125 MHz, CDCl3):  155.5, 150.0, 146.0, 131.6, 
130.2, 128.7, 127.3, 124.0, 112.2, 112.1, 62.9, 56.3, 51.0, 42.3, 27.3, 19.6; HRMS 
(EI) calcd for C18H19BrN2O5S m/z [M]+: 454.0193; found: 454.0190. HPLC 
(Daicel Chiralpak IB, i-PrOH/hexane = 45/55, 0.6 mL/min, 230 nm) t1 = 20.8 min 

















White solid, [] 25D  –24.2 (c 1.0, CH2Cl2, 90% ee); IR (KBr): 2928, 1526, 1346, 
1160, 1108, 951 cm-1; 1H NMR (400 MHz, CDCl3):  8.33 (d, J = 8.9 Hz, 2H), 
8.07 (d, J = 8.9 Hz, 2H), 7.34-7.28 (m, 2H), 7.26-7.21 (m, 2H), 5.46 (s, 1H), 4.90 
(dd, J = 5.6, 2.8 Hz, 1H), 3.90 (dd, J = 13.8, 2.8 Hz, 1H), 3.31 (ddd, J = 13.9, 
12.0, 2.9 Hz, 1H), 2.04-1.82 (m, 3H), 1.55-1.50 (m, 1H); 13C NMR (100 MHz, 
CDCl3):  150.0, 145.9, 139.0, 135.2, 130.5, 128.8, 128.3, 127, 125.0, 124.1, 63.3, 
50.8, 42.3, 27.3, 19.4; HRMS (EI) calcd for C17H16ClBrN2O4S m/z [M]+: 
457.9697; found: 457.9693. HPLC (Daicel Chiralpak AD, i-PrOH/hexane = 












White solid, [] 25D  –17.5 (c 1.0, CH2Cl2, 88% ee); IR (KBr): 2927, 1526, 1346, 
1160, 1108 cm-1; 1H NMR (500 MHz, CDCl3):  8.30 (d, J = 8.8 Hz, 2H), 8.05 (d, 
J = 8.8 Hz, 2H), 7.23 (dd, J = 7.7 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 7.04 (s, 1H), 
5.47 (s, 1H), 4.95 (dd, J = 5.6, 2.9 Hz, 1H), 3.90 (dd, J = 14.0, 2.9 Hz, 1H), 3.35 










1H); 13C NMR (125 MHz, CDCl3):  149.8, 146.2, 138.9, 136.8, 129.0, 128.8, 
128.7, 127.4, 123.9, 123.8, 63.8, 51.7, 42.3, 27.2, 21.6, 19.5; HRMS (EI) calcd for 
C18H19BrN2O4S m/z [M]+: 438.0243; found: 438.0233. HPLC (Daicel Chiralpak 

















White solid, [] 25D  –11.8 (c 1.0, CH2Cl2, 86% ee); IR (KBr): 3021, 1531, 1349, 
1216, 1164 cm-1; 1H NMR (400 MHz, CDCl3):  8.30 (d, J = 9.0 Hz, 2H), 8.02 (d, 
J = 9.0 Hz, 2H), 7.29-7.25 (m, 1H), 6.88-6.80 (m, 3H), 5.48 (s, 1H), 4.95 (dd, J = 
5.5, 2.9 Hz, 1H), 3.88 (dd, J = 13.8, 2.8 Hz, 1H), 3.78 (s, 3H), 3.33 (ddd, J = 13.9, 
12.0, 2.9 Hz, 1H), 1.99-1.86 (m, 3H), 1.53-1.49 (m, 1H); 13C NMR (100 MHz, 
CDCl3):  160.2, 149.9, 146.1, 138.5, 130.2, 128.8, 123.9, 118.9, 113.2, 112.8, 
63.7, 55.3, 51.5, 42.3, 27.2, 19.4; HRMS (EI) calcd for C18H19BrN2O5S m/z [M]+: 
454.0193; found: 454.0190. HPLC (Daicel Chiralpak IA, i-PrOH/hexane = 40/60, 













White solid, [] 25D  –19.6 (c 1.0, CH2Cl2, 72% ee); IR (KBr): 2943, 1532, 1351, 
1310, 1161, 1107 cm-1; 1H NMR (400 MHz, CDCl3):  8.25 (d, J = 8.8 Hz, 2H), 
8.06 (d, J = 8.8 Hz, 2H), 7.85-7.82 (m, 2H), 7.73 (d, J = 5.8 Hz, 1H), 7.67 (s, 1H), 
7.53-7.48 (m, 2H), 7.41 (dd, J = 8.6, 1.8 Hz, 1H), 5.64 (s, 1H), 5.90 (dd, J = 5.8, 









2.04-1.91 (m, 3H), 1.57-1.53 (m, 1H); 13C NMR (100 MHz, CDCl3):  149.9, 
146.2, 134.2, 133.1, 132.6, 129.1, 128.8, 128.0, 127.6, 126.78, 126.76, 126.2, 
124.3, 123.9 64.1, 51.4, 52.6, 27.5, 19.7; HRMS (EI) calcd for C21H19BrN2O4S 
m/z [M]+: 474.0243; found: 474.0233. HPLC (Daicel Chiralpak IC, i-

















White solid, [] 25D  –17.8 (c 0.5, CH2Cl2, 83% ee); IR (KBr): 2960, 1525, 1344, 
1168, 1093 cm-1; 1H NMR (400 MHz, CDCl3):  8.32 (d, J = 8.8 Hz, 2H), 8.08 (d, 
J = 8.9 Hz, 2H), 7.34 (dd, J = 5.0, 2.9 Hz, 1H), 7.17-7.16 (m, 1H), 7.02 (d, J = 5.0 
Hz, 1H), 5.51 (s, 1H), 4.87 (brs, 1H), 3.78 (d, J = 13.0 Hz, 1H), 3.24 (ddd, J = 
13.9, 12.0, 2.7 Hz, 1H), 1.99-1.88 (m, 3H), 1.54-1.48 (m, 1H); 13C NMR (100 
MHz, CDCl3):  149.9, 146.0, 138.1, 128.8, 127.1, 126.4, 124.0, 123.0, 61.0, 50.8, 
41.7, 27.4, 19.5; HRMS (EI) calcd for C15H15BrN2O4S2 m/z [M]+: 429.9651; 
found: 429.9654. HPLC (Daicel Chiralpak IB, i-PrOH/hexane = 30/70, 0.6 












White solid, [] 25D  –20.2 (c 1.0, CH2Cl2, 59% ee); IR (KBr): 2944, 1532, 1350, 
1162, 1092 cm-1; 1H NMR (500 MHz, CDCl3):  8.26 (d, J = 8.9 Hz, 2H), 7.97 (d, 
J = 8.7 Hz, 2H), 7.23 (dd, J = 5.1, 1.2 Hz, 1H), 7.02 (dd, J = 2.5, 1.2 Hz, 1H), 6.98 
(dd, J = 5.1, 3.7 Hz, 1H), 5.73 (s, 1H), 4.72 (d, J = 2.3 Hz, 1H), 3.83 (dd, J = 13.3, 










(m, 1H); 13C NMR (125 MHz, CDCl3):  149.9, 145.7, 139.6, 128.7, 127.1, 127.0, 
125.9, 123.9, 60.5, 50.8, 41.6, 27.2, 19.4; HRMS (EI) calcd for C15H15BrN2O4S2 
m/z [M]+: 429.9651; found: 429.9666. HPLC (Daicel Chiralpak IC, i-
PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) t1 = 62.3 min (major), t2 = 70.9 min 
(minor). 
 
(D) Representative procedure for the silver salt mediated rearrangement. 
A solution of ent-2-7a (85 mg, 0.2 mmol, 1.0 eq) and silver trifluoroacetate (133 
mg, 0.6 mmol, 3.0 eq) in acetone (3.0 mL) and water (1.0 mL) was stirred at 60 
C for 8 h in dark. After the mixture was cooled to room temperature, to the 









filtered by celite and washed with EtOAc. The filtrate was separated and the 
aqueous phase was extracted with EtOAc (3 × 5 mL). The combined extracts were 
washed with brine, dried and concentrated in vacuo. The residue was purified by 




 [] 25D  −110.9 (c 1.0, CH2Cl2, 99% ee); IR (KBr): 3491, 2946, 1527, 1348, 1165, 
1089 cm-1; 1H NMR (400 MHz, CDCl3):  8.31 (d, J = 8.9 Hz, 2H), 8.04 (d, J = 
8.9 Hz, 2H), 7.37-7.34 (m, 2H), 7.28-7.25 (m, 3H), 5.64 (t, J = 2.9 Hz, 1H), 3.69 
(dt, J = 12.7, 2.9 Hz, 1H), 3.05-2.97 (m, 2H), 2.16-2.05 (m, 1H), 1.98-1.93 (m, 
1H), 1.86-1.75 (m, 3H); 13C NMR (100 MHz, CDCl3):  150.0, 145.3, 140.2, 
129.1, 128.9, 128.0, 127.6, 124.0, 79.9, 47.5, 40.2, 25.1, 21.8; HRMS (ESI) calcd 
for C17H17N2O5S m/z [M – H]–: 361.0864; found: 361.0864. HPLC (Daicel 
Chiralpak IA, i-PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) t1 = 9.0 min (major), 













Yellow oil. [] 25D  +18 (c 1.0, CHCl3, 83% ee); IR (film): 3498, 2929, 1530, 1349, 
1164, 1091 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H), 8.05 (d, 
J = 8.8 Hz, 2H), 7.25 – 7.21 (m, 2H), 7.05 (d, J = 8.6 Hz, 2H), 5.61 (s, 1H), 3.70 
(d, J = 11.3 Hz, 1H), 3.04 – 2.98 (m, 2H), 2.07 (dd, J = 13.0, 3.6 Hz, 1H), 1.95 (d, 
J = 13.6 Hz, 1H), 1.81 – 1.73 (m, 3H) ; 13C NMR (150 MHz, CDCl3) δ 162.9, 
161.3, 150.1, 145.3, 136.0, 129.6, 129.5, 129.0, 124.1, 115.8, 115.7, 79.6, 46.8, 









403.0734; found: 403.0740. HPLC (Daicel Chiralpak IC, i-PrOH/hexane = 15/85, 
0.6 mL/min, 230 nm) t1 = 19.9 min (major), t2 = 21.7 min (minor). 
 
      
 
















Yellow oil. [] 25D  +27 (c 1.0, CHCl3, 72% ee); IR (film): 3369, 2923, 1532, 1349, 
1162, 1009 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H), 8.04 (d, 
J = 8.8 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 5.63 – 5.59 (m, 
1H), 3.69 (d, J = 11.8 Hz, 1H), 3.02 (dd, J = 16.9, 7.5 Hz, 1H), 2.98 – 2.93 (m, 
1H), 2.05 (dd, J = 12.0, 4.6 Hz, 1H), 1.95 (d, J = 13.7 Hz, 1H), 1.82 – 1.73 (m, 
3H); 13C NMR (151 MHz, CDCl3) δ 150.1, 145.3, 139.3, 132.0, 129.8, 129.0, 
124.1, 121.6, 79.5, 47.1, 40.1, 24.98, 22.0; HRMS (ESI) calcd for 
C17H17BrN2O5SNa m/z [M + Na]+: 462.9934; found: 462.9924. HPLC (Daicel 
Chiralpak IC, i-PrOH/hexane = 15/85, 0.6 mL/min, 230 nm) t1 = 22.9 min 














(2R,3R)- 1-(4-nitrophenylsulfonyl)-3-(m-tolyl)piperidin-2-ol (2-8g): 
 
Yellow oil. [] 25D  +77 (c 1.0, CHCl3, 82% ee); IR (film): 3494, 2935, 1529, 1349, 
1162, 1091 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.31 (d, J = 8.8 Hz, 2H), 8.05 (d, 
J = 8.8 Hz, 2H), 7.24 (d, J = 7.6 Hz, 1H), 7.12 – 7.03 (m, 3H), 5.64 (s, 1H), 3.70 
(d, J = 10.9 Hz, 1H), 2.99 (dd, J = 16.9, 13.1 Hz, 2H), 2.35 (s, 3H), 2.09 (dd, J = 










MHz, CDCl3) δ 150.0, 145.3, 140.1, 138.8, 129.2, 128.9, 128.8, 128.4, 124.8, 
123.98, 79.9, 47.3, 40.2, 25.0, 21.7, 21.4; HRMS (ESI) calcd for C18H20N2O5SNa 
m/z [M + Na]+: 399.0985; found: 399.0977. HPLC (Daicel Chiralpak IC, i-















(2R,3R)- 1-(4-nitrophenylsulfonyl)-3-methoxypiperidin-2-ol (2-8h): 
 
Yellow oil. [] 25D  +92 (c 0.2, CHCl3, 83% ee); IR (film): 3513, 2931, 1529, 1349, 
1161, 1090 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.32 (d, J = 8.8 Hz, 2H), 8.05 (d, 
J = 8.8 Hz, 2H), 7.28 (d, J = 7.9 Hz, 1H), 6.86 – 6.79 (m, 3H), 5.65 (s, 1H), 3.81 
(s, 3H), 3.69 (d, J = 9.7 Hz, 1H), 3.03 – 2.96 (m, 2H), 2.09 – 2.04 (m, 1H), 1.98 – 
1.91 (m, 1H), 1.83 – 1.75 (m, 3H); 13C NMR (151 MHz, CDCl3) δ 160.0, 150.0, 
145.2, 141.8, 130.0, 129.1, 124.0, 120.1, 114.0, 112.7, 79.8, 55.3, 47.5, 40.2, 25.0, 
21.8; HRMS (ESI) calcd for C18H20N2O6SNa m/z [M + Na]+: 415.0934; found: 
416.0946. HPLC (Daicel Chiralpak IC, i-PrOH/hexane = 40/60, 0.6 mL/min, 230 
















White solid, [] 25D  +264.6 (c 1.0, CH2Cl2, 99% ee); IR (KBr): 2932, 1532, 1346, 
1163, 1097, 940 cm-1; 1H NMR (400 MHz, CDCl3):  8.21 (d, J = 8.9 Hz, 2H), 
7.85 (d, J = 8.9 Hz, 2H), 7.37-7.35 (m, 2H), 7.31-7.28 (m, 3H), 5.93-5.89 (m, 1H), 
5.85-5.80 (m, 1H), 5.53 (s, 1H), 3.85 (ddd, J = 13.8, 6.2, 1.0 Hz, 1H), 3.15 (ddd, J 
= 16.2, 11.3, 5.0 Hz, 1H), 2.14-1.97 (m, 2H); 13C NMR (100 MHz, CDCl3):  
149.7, 146.9, 138.7, 128.5, 128.3 (2 carbons), 128.2, 128.1, 126.0, 124.0, 56.6, 
38.7, 23.8; HRMS (EI) calcd for C17H16N2O4S m/z [M]+: 344.0825; found: 
344.0834. HPLC (Daicel Chiralpak IA, i-PrOH/hexane = 40/60, 0.6 mL/min, 230 












1H NMR (400 MHz, CDCl3):  7.29-7.18 (m, 5H), 3.20 (ddd, J = 12.2, 8.4, 1.3 
Hz, 1H), 3.05 (dt, J = 11.5, 7.6 Hz, 1H), 2.44 (d, J = 4.8, 2.8 Hz, 1H), 2.35 (d, J = 
2.6 Hz, 1H), 2.23 (d, J = 13.3, 8.1 Hz, 1H), 2.03-1.93 (m, 1H), 1.78-1.70 (m, 1H), 
1.65-1.56 (m, 1H); 13C NMR (100 MHz, CDCl3):  140.2, 128.2, 126.7, 126.0, 
53.1, 50.6, 39.7, 26.6, 20.7; HRMS (ESI) calcd for C11H14N m/z [M + H]+: 












[] 25D  +215 (c 1.0, CHCl3, 83% ee); IR (film): 2936, 1529, 1349, 1170, 1089, 
1047, 960 cm-1; 1H NMR (600 MHz, CDCl3): 1H NMR (600 MHz, CDCl3) δ 8.37 
(d, J = 8.9 Hz, 2H), 7.93 (d, J = 8.9 Hz, 2H), 7.25 – 7.21 (m, 1H), 6.79 (ddd, J = 
8.3, 2.6, 0.6 Hz, 1H), 6.75 (d, J = 7.6 Hz, 1H), 6.73 – 6.69 (m, 1H), 3.94 – 3.89 
(m, 2H), 3.79 (s, 3H), 2.86 (tt, J = 11.7, 3.7 Hz, 1H), 2.35 (td, J = 12.0, 2.9 Hz, 
1H), 2.28 (t, J = 11.4 Hz, 1H), 2.03 – 1.95 (m, 1H), 1.88 (ddd, J = 12.9, 6.4, 3.2 
Hz, 1H), 1.83 – 1.74 (m, 1H), 1.45 (ddd, J = 25.6, 12.6, 3.9 Hz, 1H). 13C NMR 
(151 MHz, CDCl3) δ 159.8, 150.1, 143.6, 142.5, 129.7, 128.7, 124.3, 119.4, 
113.3, 112.0, 55.2, 52.5, 46.4, 42.2, 30.3, 25.0; HRMS (ESI) calcd for 
















To a stirred solution of 9 (18 mg, 0.05 mmol, 1.0 eq) in 0.5 mL of MeCN was 
added thiophenol (16 μL, 0.25 mmol, 5.0 eq) followed by K2CO3 (35 mg, 0.25 
mmol, 5.0 eq). After the reaction was stirred for 12 hours, the reaction was 
quenched with saturated NaHCO3 (2 mL) and extracted with EtOAc (3 x 5 mL). 
The combined organic layer was dried using MgSO4, filtered, and concentrated 
under reduced pressure.  
[] 25D  +8.0 (c 1.0, MeOH, 83% ee); IR (film): 2931, 1601, 1436, 1160, 1089, 
1046, 750 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.25 – 7.19 (m, 1H), 6.80 (d, J = 
7.5 Hz, 1H), 6.78 – 6.71 (m, 2H), 3.80 (s, 3H), 3.25 (dd, J = 25.6, 11.8 Hz, 3H), 
2.81 (ddd, J = 15.1, 11.6, 8.2 Hz, 1H), 2.77 – 2.66 (m, 2H), 2.07 – 1.99 (m, 1H), 
1.92 – 1.81 (m, 1H), 1.80 – 1.70 (m, 1H), 1.62 (ddd, J = 16.2, 12.9, 3.9 Hz, 1H). 
13C NMR (151 MHz, CDCl3) δ 159.71, 145.27, 129.50, 119.37, 113.06, 111.69, 
77.21, 77.00, 76.79, 55.17, 52.43, 45.73, 42.90, 31.50, 25.68. HRMS (ESI) calcd 














To a stirred solution of ent-2-8a (36 mg, 0.1 mmol, 1.0 eq) in 4 mL of CH2Cl2 
was added triethylsilane (80 μL, 0.5 mmol, 5.0 eq) at -78oC. The mixture was 
added trifluoroacetic acid (38 μL, 0.5 mmol, 5.0 eq), stirred and allowed to warm 
up to room temperature overnight. The reaction was quenched with NaHCO3 and 
extracted with CH2Cl2. The organic phase was dried with MgSO4, filtered and 
removed under reduced pressure. The residue was purified by column 
chromatography to yield the desired product 11 as a yellow solid (31 mg, 91%).  
[] 25D  −18.0 (c 1.0, CHCl3, 99% ee); IR (film): 2935, 1529, 1350, 1168, 1089 cm-
1; 1H NMR (600 MHz, CDCl3): 1H NMR (600 MHz, CDCl3) δ 8.37 (d, J = 8.7 Hz, 
2H), 7.93 (d, J = 8.7 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 7.25 (d, J = 7.4 Hz, 1H), 
7.17 (d, J = 7.2 Hz, 2H), 3.92 (d, J = 11.5 Hz, 2H), 2.92 – 2.85 (m, 1H), 2.35 (td, J 
= 12.0, 2.5 Hz, 1H), 2.29 (t, J = 11.4 Hz, 1H), 1.99 (d, J = 13.3 Hz, 1H), 1.92 – 
1.86 (m, 1H), 1.86 – 1.75 (m, 1H), 1.47 (ddd, J = 25.6, 12.7, 3.8 Hz, 1H); 13C 
NMR (150 MHz, CDCl3) δ 150.13, 142.51, 141.97, 128.72, 127.19, 127.10, 
124.33, 52.59, 46.40, 42.17, 30.31, 25.04; HRMS (ESI) calcd for C18H20N2O3S 
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Bromoetherification of Diolefinic 
Diols–Application to the Synthesis of 











Chiral spirocycles are a special class of compounds that have attracted much 
attention over the past decades. Due to the inherent rigidity and well-defined 
three-dimensional molecular structure, chiral non-racemic spiro molecules have 
been applied in various areas including catalysis, metal complexation, and 
molecular architecture.1  
 
Figure 3.1 Examples of chiral ligands with spirocyclic backbone. 
The unique structural features of spirocycles also open a new avenue for 
exploring new pharmacological space. In fact, many bioactive natural products 
have been identified to possess the spirocyclic scaffold.2  
 
Figure 3.2 Examples of bioactive natural products with spirocyclic scaffolds. 
Recently, multifunctional chiral hetero spirocycles with readily modifiable 









discovery.3 However, facile and efficient asymmetric pathways towards 
enantioenriched spirocycles remain sporadic. The tremendous difficulty 
encountered in controlling the regio- and stereochemistry of quaternary carbon 
centres has caused the synthesis of these privileged scaffolds to remain as a huge 
challenge for synthetic chemists.1 
Halocyclization of olefinic compounds, an important synthetic transformation 
that was discovered more than a century ago,4 is a powerful method for the 
construction of heterocycles. However, it was not until recently that significant 
efforts were devoted to the development of catalytic enantioselective 
halolactonization, haloetherification, and haloaminocyclization.5 The resulting 
heterocyclic intermediates with modifiable halogen handles are important building 
blocks to synthetic chemists as it typically resembles the fundamental core of 
many valuable pharmaceutical intermediates as well as biologically active natural 
products.6 
The challenge in developing an efficient method for halocyclization lies in 
improving the rate of nucleopilic capture as opposed to the olefin-olefin halogen 
exchange racemization.7 Recently, we reported the asymmetric 
bromolactonization and bromo-aminocyclization reactions using amino-
thiocarbamate catalysts.8 
Herein we are pleased to disclose the catalytic enantioselective synthesis of 
hetero spirocycles through a double-halocyclization strategy. The first cyclization 










two quaternary stereogenic carbons in the cyclic ether products 3-8. Subsequently, 
a diastereoselective bromoetherificaton can be performed to yield a series of chiral 
hetero spiro systems 3-9 (Scheme 3.1). This protocol allow us to access a class of 
chiral novel spirocycles that is distinctively missing in the literature.1 
 
Scheme 3.1 Synthesis of hetero spirocycles through the asymmetric bromination 
and desymmetrization of diolefinic diol. 
 
3.2 Results and Discussion 
3.2.1 Catalyst Screening 
At the initial stage of this project, we screened our library of amino-









desymmetrization of the diolefinic diol 3-10a with good enantioselectivity and 
diastereoselectivity. We first screened for a suitable catalyst core and observed 
that quinine (catalyst 3-12c) and quinidine (catalyst 3-12d) gave better dr and er 
as compared to cinchonine (catalyst 3-12a) and cinchonidine (catalyst 3-12b) 
(Table 3.1, entries 1–4). It was also worthy to note that quinine (catalyst 3-12c) 
and quinidine (catalyst 3-12d) gave opposite enantioselectivities (entries 3 and 4).  
We proceeded to examine the aryl handles on catalyst 3-12d. Electron-rich aryl 
substituents were observed to increase the enantioselectivity of the catalysts, with 
the 4-ethoxyphenyl substituent (catalyst 3-12h) on the thiocarbamate proving the 
most selective (Table 3.1 entry 8).  
We also investigated the 6-alkoxy substituent of the quinoline through the use 
of longer straight chain alkyl groups (Table 3.1, entries 10–12) as well as 
branched alkyl group (Table 3.1, entry 13). The n-butyl catalyst 3-12k was 





















3.2.2 Reaction Conditions Optimization 
Once the most effective catalyst was identified, a series of temperature and 
solvent optimization experiments were conducted. The solvent blends 
chloroform/n-hexane (1:1) and chloroform/toluene (1:1) was compared and it was 
observed that n-hexane was more suitable as a co-solvent as compared to toluene, 
yielding products with higher er (Table 3.2, entries 1–2). When the temperature 
was decreased to -60 oC, the er improved slightly but on further reduction of the 
temperature to -65 oC, the reaction yielded virtually no products (Table 3.2, 
entries 3–4). This was not a surprising result as it was observed that the reaction 
mixture had solidified at this temperature. 
We proceeded to examine the ratio of chloroform to n-hexane. When the 
proportion of chloroform was increased, the er was observed to decrease. On the 
contrary, when the proportion of n-hexane was increased, the er appears increase 
with increasing proportion of n-hexane and reaches the highest with CHCl3/n-
hexane (4:7) before decreasing with further increase in proportion of n-hexane 
(Table 3.2, entries 6–8 and 10). Under these conditions, the diastereomeric ratio 










Table 3.2 Solvent and temperature optimization of bromoetherification of 3-10a. 
 
To further improve the enantioselectivity of the reaction further, we turned our 
attention towards alternative halogen sources. After screening, recrystallized N-
bromophthalimide (NBP) was found to be better and returned with 93:7 er, while 
other halogen sources gave much lower enantioselectivity or even no reaction 
(Table 3.3, entries 1–6). Interestingly, it was observed that the addition of 4Å 
molecular sieves can improve the er up to 96:4 (Table 3.3, entries 7–9). The 
reaction was found to be readily scalable without diminishing the yield, dr, and er 









Table 3.3 Effect of halogen source and additives on bromoetherification of 3-10a. 
 
 
3.2.3 Substrate Scope 
Using the optimized conditions, we examined substrates that possess a 
symmetrical diol system. In general, the reactions with different diolefinic diols 3-
10 proceeded smoothly to give the corresponding bromoethers 3-11 with good to 
excellent dr and er, in particular, for those that have electron-rich substituents 






















Diols with unsymmetrical unsaturated systems were also investigated and the 
results are shown in Table 3.5. Again, good to excellent dr were obtained. For the 
relatively bulkier alkyl-substituted olefinic substrates 3-13a and 3-13b, the 
cyclization favoured the phenyl olefin with good er (Table 3.5, entries 1–2). On 
the other hand, the methyl substituted mixed olefin 3-13c gave rise to 3-14c, a 
result of cyclization at the less sterically hindered methyl olefin (Table 3.5, entry 
3). Substrate 3-13d, which contains a 1,1- and a 1,2-disubstituted olefins, returned 
with product 3-14d (94%) in good er of 92:8 (Table 3.5, entry 4). An alkene-
alkyne mixed system 3-13e was also examined, which gave 3-14e exclusively 





















3.2.4 Investigation on Catalyst Loading  
We also examined the catalyst loading that was required to maintain the high er 
and we observed that under a low catalyst loading of 2%, the dr and er of the 
reaction remain almost unchanged (Table 3.6). 
Table 3.6 Investigation on the catalyst loading on reaction. 
 
 
3.2.5 Synthesis of Spirocycles 
Substituted tetrahydrofurans 3-11 and 3-14, which contain two stereogenic 
quaternary carbons, were further cyclized to yield the corresponding hetero 
spirocycles. Treatment of 3-11b with NBS and catalytic amounts of 
triphenylphosphine sulfide in dichloromethane furnished 3-15 with excellent dr 
(94:6). 3-11b-COOH, which was obtained by oxidizing 3-11b using PCC 










cyclic ether-lactone spirocycle 3-16 in 98% yield and 93:7 dr. NIS could also be 
used in place of NBS to give mixed spirocycle 3-17 that contains both bromo and 
iodo handles. The reactivity between Br and I can readily be differentiated which 
is beneficial for subsequent manipulation. Under similar conditions, carboxylic 
acid derivative 3-14e-COOH (obtained by oxidizing 3-14e) could be cyclized to 
yield spirocycle 3-18 which contains a vinyl bromide substituent. A lower 
diastereoselectivity was obtained when cyclizing 3-14b and 3-14d. Next, the 
hydroxyl group in 3-11b was replaced with a N-benzyl group to give 3-11b-
NHBn. Unexpectedly, iodocyclization of 3-11b-NHBn gave rise to the 





















Table 3.7 Synthesis of spirocycles. (cont’d) 
 
The absolute configurations of the bromoethers as well as the corresponding 
spirocycles were established based on the X-ray crystallographic study of 











Figure 3.3 X-ray crystallographic study of compound 3-16. 
 
3.2.6 Mechanistic Studies 
With regards to the reactivity of the substrate, we realized the diol system is 
critical as no reaction occurred when cyclizing olefinic alcohol 3-22 under the 
optimized conditions (Scheme 3.2, eq. 1). In our previous studies on amino-
thiocarbamate catalysis, the nucleophiles (e.g. carboxylic acid) in the olefinic 
substrates have relatively lower pKa that allowed deprotonation by the 
quinucilidine and in turn helps to increase the rate of nucleophilic capture.8 In 
comparison, we believe that the deprotonation of the alcohol is not favourable due 
to its higher pKa, thus disfavour the stereoselective etherification. For diol 
systems, it has been reported that the hydroxyl proton’s acidity is enhanced due to 
the intramolecular hydrogen bonding.9 As such, we believe that the acidic proton 










thiocarbamate catalyst. A plausible mechanistic picture was constructed as 
indicated in Scheme 3.2. We speculate that the transition state A may consist of 
several important components: (1) an intramolecular hydrogen bonding which 
helps to lock the 1,3-diol in a pseudo six-membered ring chair conformation; (2) 
the bulkier substituent sits at the pseudo-equatorial position; and (3) the amino-
thiocarbamate bi-functional pocket helps to restrict the geometry of the 
intermediate.  
 










To gain further information on the mechanism, we prepared substrate 3-24 with 
one of the hydroxyl groups being protected as a TBSO-ether. Subjecting 3-24 
under the optimized bromocyclization conditions returned with sluggish reaction, 
which further supports the importance of the hydrogen bonding (Scheme 3.2, eq. 
2). In fact, we have also examined benzyl substituted substrate 3-26 which also 
returned with good dr and er. Poor diastereo- and enantioselectivity were observed 
when using triphenylphosphine sulfide or potassium carbonate to mediate the 
reaction. This result reinforces the importance of the bi-functionality in which the 
catalyst is controlling the diastereo- and enantioselectivity (Table 3.8). 














3.2.7 Desymmetrizing Halocyclization of Other Substrates 
Next, we attempted to use the same strategy for the synthesis of 
diazaspirocycles 3-29, another class of spirocycles that is absent in the literature.1  
 
Scheme 3.3 Synthesis of diazaspirocycles via desymmetrizing halocyclization. 
We tried to synthesize the diamino diolefin 3-31 from the diol 3-10a via the 
intermediate 3-30, in which the two hydroxyl groups are be converted into leaving 
groups. (Scheme 3.4) The diamino diolefin 3-31 can subsequently be obtained by 
displacing the leaving groups using 4-nitrobenzenesulfonamide. However, various 
attempts to convert the hydroxyl groups into the mesylate, tosylate or bromide 
























Next, we changed our strategy and tried to install the nitrogen atoms using via 
the formation of the amide from the dicarboxylic acid 3-31 (Scheme 3.5). 
Attempts to make the dicarboxylic acid 3-31 from the disubstituted malonate S3-
10a resulted in decarboxylation, furnishing the monocarboxylic acid 3-33 as the 
sole product. 
 
Scheme 3.5 Attempted synthesis of intermediate 3-31. 
Lastly, we attempted to synthesize the dialdehyde 3-34 which can be 
manipulated to form the diamino compound 3-35 during reduction amination 
protocols (Scheme 3.6). Neither the swern nor pyridinium chlorochromate 






























In summary, a facile and highly enantioselective bromoetherication of 
diolefinic diols has been developed using amino-thiocarbamate as the catalyst. 
Further manipulations of the bromoether products enabled entry into a new class 
of spirocycles that are distinctively lacking in the literature. The importance of the 
diol functionality also substantiated mode of action of the catalyst that was 
proposed in earlier studies.  
 
3.4 Experimental 
(A) General procedure for the preparation of diolefinic malonates (S3-10a–g). 
 
To a stirred solution of dimethyl malonate (5.0 mmol, 1.0 eq) in THF (15 mL) was 
added NaH (20.0 mmol, 4.0 eq) at 0 oC under argon. The resulting mixture was 
allowed to warm to 25 oC and stirred for another 1 h before the 2-substituted allyl 
bromide (15.0 mmol, 3.0 eq) was added into the solution. The mixture was stirred 
and refluxed for 12 h. The reaction was quenched with water (10 mL) and 









with brine (10 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was purified using flash column chromatography 
(hexane/EtOAc 10:1) to give the malonate (S3-10). 
 
dimethyl 2,2-bis(2-phenylallyl)malonate (S3-10a) 
 
Colourless oil; IR (film): 2951, 1733, 1626, 1438, 1211, 1092, 907 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 7.31 – 7.26 (m, 8H), 7.23 (d, J = 6.2 Hz, 2H), 5.23 (d, J = 
1.5 Hz, 2H), 5.09 (d, J = 1.1 Hz, 2H), 3.16 (d, J = 1.1 Hz, 4H), 3.13 (s, 6H); 13C 
NMR (151 MHz, CDCl3) δ 170.95, 144.46, 141.86, 127.97, 127.37, 126.95, 
118.72, 56.64, 51.81, 36.96; HRMS (ESI) calcd for C23H24O4Na m/z [M + Na]+: 
387.1567; found: 387.1584.  
dimethyl 2,2-bis(2-(o-tolyl)allyl)malonate (S3-10b) 
 
Colourless oil; IR (film): 2951, 1735, 1627, 1435, 1211, 1093, 913 cm-1; 1H NMR 










2H), 4.96 (d, J = 2.1 Hz, 2H), 3.16 (s, 6H), 3.09 (d, J = 1.0 Hz, 4H), 2.28 (s, 6H); 
13C NMR (151 MHz, CDCl3) δ 170.72, 144.86, 141.68, 135.30, 130.06, 129.13, 
127.06, 125.29, 120.37, 57.20, 51.81, 38.73, 19.97; HRMS (ESI) calcd for 
C25H28O4Na m/z [M + Na]+: 415.1880; found: 415.1894.  
dimethyl 2,2-bis(2-(m-tolyl)allyl)malonate (S3-10c) 
 
Colourless oil; IR (film): 2950, 1735, 1627, 1436, 1217, 1063, 912 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 7.25 – 6.88 (m, 8H), 5.22 (d, J = 2.6 Hz, 2H), 5.05 (d, J = 
3.4 Hz, 2H), 3.19 (s, 6H), 3.15 (s, 4H), 2.33 (d, J = 3.6 Hz, 6H); 13C NMR (151 
MHz, CDCl3) δ 171.03, 144.61, 141.89, 137.39, 128.08, 127.88, 127.59, 124.08, 
118.19, 56.78, 51.76, 36.92, 21.39; HRMS (ESI) calcd for C25H28O4Na m/z [M + 
Na]+: 415.1880; found: 415.1889.  
dimethyl 2,2-bis(2-(p-tolyl)allyl)malonate (S3-10d) 
 
Colourless oil; IR (film): 2950, 1734, 1625, 1437, 1207, 1112, 905 cm-1; 1H NMR 









J = 1.7 Hz, 2H), 5.10 – 5.02 (m, 2H), 3.18 (s, 6H), 3.13 (s, 6H), 2.31 (s, 6H); 13C 
NMR (151 MHz, CDCl3) δ 171.05, 144.36, 139.02, 137.03, 128.63, 128.61, 
126.78, 117.76, 56.82, 51.82, 37.04, 21.06; HRMS (ESI) calcd for C25H28O4Na 
m/z [M + Na]+: 415.1880; found: 415.1900.  
dimethyl 2,2-bis(2-(naphthalen-1-yl)allyl)malonate (S3-10e) 
 
Colourless oil; IR (film): 2950, 1735, 1627, 1436, 1218, 1070, 912 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 7.94 – 7.88 (m, 2H), 7.84 – 7.78 (m, 2H), 7.72 (d, J = 8.0 
Hz, 2H), 7.50 – 7.41 (m, 4H), 7.38 (d, J = 1.3 Hz, 2H), 7.21 (d, J = 6.9 Hz, 2H), 
5.07 (d, J = 2.0 Hz, 2H), 5.00 (s, 2H), 3.31 (s, 4H), 2.93 (s, 6H); 13C NMR (151 
MHz, CDCl3) δ 170.60, 143.78, 140.02, 133.50, 131.07, 128.22, 127.58, 125.99, 
125.84, 125.69, 125.62, 125.06, 121.49, 57.75, 51.56, 39.45; HRMS (ESI) calcd 














dimethyl 2,2-bis(2-(4-fluorophenyl)allyl)malonate (S3-10f) 
 
Colourless oil; IR (film): 2951, 1735, 1602, 1508, 1438, 1251, 1093, 908 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 7.23 (dd, J = 8.8, 5.3 Hz, 4H), 6.96 (t, J = 8.7 Hz, 4H), 
5.20 (d, J = 1.4 Hz, 2H), 5.07 (d, J = 1.2 Hz, 2H), 3.22 (s, 6H), 3.11 (d, J = 1.1 
Hz, 4H); 13C NMR (151 MHz, CDCl3) δ 170.82, 162.22 (d, J = 246.7 Hz) , 
143.45, 137.85 (d, J = 3.2Hz), 128.52 (d, J = 8.0 Hz), 118.66, 114.82 (d, J = 21.4 
Hz) , 56.70, 51.94, 37.21; HRMS (ESI) calcd for C23H22O4F2Na m/z [M + Na]+: 
401.1559; found: 401.1547.  
dimethyl 2,2-bis(2-(4-chlorophenyl)allyl)malonate (S3-10g) 
 
Colourless oil; IR (film): 2951, 1731, 1626, 1435, 1211, 1093, 910 cm-1; 1H NMR 
(600 MHz, Chloroform-d) δ 7.25 (d, J = 8.6 Hz, 4H), 7.18 (d, J = 8.5 Hz, 4H), 
5.23 (d, J = 1.3 Hz, 2H), 5.12 – 5.03 (m, 2H), 3.23 (s, 6H), 3.10 (d, J = 1.1 Hz, 









128.13, 119.01, 77.21, 51.98, 37.03; HRMS (ESI) calcd for C23H22O4Cl2Na m/z 
[M + Na]+: 455.0787; found: 455.0796.  
 
(B) General procedure for the preparation of di-substituted malonates (S3-13 
and S3-26) 
 
To a stirred solution of dimethyl malonate (5.0 mmol, 1.0 eq) in THF (15 mL) was 
added NaH (5.0 mmol, 1.0 eq) at 0 oC under argon. The resulting mixture was 
allowed to warm to 25 oC and stirred for another 1 h before the 2-phenyl allyl 
bromide (5.0 mmol, 1.0 eq) was added into the solution. The mixture was stirred 
at room temperature for 12 h. The reaction was quenched with water (10 mL) and 
extracted with EtOAc (3 x 10 mL). The combined organic extracts was washed 
with brine (10 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was purified using flash column chromatography 










The purified mono-substituted malonate (5.0 mmol, 1.0 eq) was dissolved in THF 
(15 mL) was added NaH (10.0 mmol, 2.0 eq) at 0 oC under argon. The resulting 
mixture was allowed to warm to 25 oC and stirred for another 1 h before the 
corresponding alkylating agent (10.0 mmol, 2.0 eq) was added into the solution. 
The mixture was stirred and refluxed for 12 h. The reaction was quenched with 
water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic 
extracts was washed with brine (10 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified using flash column 
chromatography (hexane/EtOAc 10:1) to give the di-substituted malonate (S3-13). 
dimethyl 2-(2-benzylallyl)-2-(2-phenylallyl)malonate (S3-13a)  
 
Colourless oil; IR (film): 2951, 1731, 1626, 1434, 1198, 1177, 904 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 7.37 – 7.17 (m, 8H), 7.16 – 7.07 (m, 2H), 5.18 (d, J = 1.6 
Hz, 1H), 5.05 (d, J = 1.3 Hz, 1H), 4.84 – 4.81 (m, 1H), 4.77 (d, J = 1.5 Hz, 1H), 
3.42 (s, 6H), 3.29 (d, J = 1.0 Hz, 2H), 3.17 (s, 2H), 2.66 – 2.60 (m, 2H); 13C NMR 
(151 MHz, CDCl3) δ 171.35, 144.39, 144.35, 141.61, 139.13, 129.15, 128.25, 
128.01, 127.40, 126.88, 126.14, 118.50, 114.73, 56.83, 52.13, 43.90, 37.90, 37.36 










dimethyl 2-(3,3-dimethyl-2-methylenebutyl)-2-(2-phenylallyl)malonate (S3-13b)  
 
Colourless oil; IR (film): 2956, 1729, 1626, 1435, 1215, 1100, 911 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 7.34 – 7.26 (m, 4H), 7.23 (d, J = 7.0 Hz, 1H), 5.23 (d, J = 
1.7 Hz, 1H), 5.09 – 5.07 (m, 1H), 4.91 (t, J = 1.4 Hz, 1H), 4.67 (d, J = 1.9 Hz, 
1H), 3.42 (s, 6H), 3.40 (d, J = 0.9 Hz, 2H), 2.66 (s, 2H), 0.99 (s, 9H); 13C NMR 
(151 MHz, CDCl3) δ 171.62, 152.72, 144.55, 141.37, 128.02, 127.43, 126.80, 
118.49, 106.25, 56.38, 52.22, 37.43, 36.56, 32.32, 29.28; HRMS (ESI) calcd for 
C21H28O4Na m/z [M + Na]+: 367.1880; found: 367.1870.  
dimethyl 2-(2-methylallyl)-2-(2-phenylallyl)malonate (S3-13c)  
 
Colourless oil; IR (film): 2952, 1732, 1626, 1435, 1207, 1178, 1071, 901 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 7.30 – 7.27 (m, 4H), 7.25 – 7.21 (m, 1H), 5.25 (d, J = 
1.6 Hz, 1H), 5.17 – 5.14 (m, 1H), 4.85 – 4.83 (m, 1H), 4.67 (dd, J = 1.8, 1.0 Hz, 
1H), 3.42 (s, 6H), 3.24 (d, J = 1.0 Hz, 2H), 2.66 – 2.63 (m, 2H), 1.61 (s, 3H); 13C 










126.94, 118.64, 114.62, 56.74, 52.07, 39.62, 37.70, 23.61; HRMS (ESI) calcd for 
C18H22O4Na m/z [M + Na]+: 325.1410; found: 325.1413.  
dimethyl 2-cinnamyl-2-(2-phenylallyl)malonate (S3-13d)  
 
Colourless oil; IR (film): 2951, 1731, 1626, 1435, 1202, 1176, 967, 908 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 7.41 – 7.17 (m, 10H), 6.25 (dt, J = 15.7, 1.5 Hz, 1H), 
5.94 (dt, J = 15.7, 7.5 Hz, 1H), 5.29 (d, J = 1.6 Hz, 1H), 5.20 – 5.16 (m, 1H), 3.47 
(s, 6H), 3.21 (d, J = 1.0 Hz, 2H), 2.71 (dd, J = 7.5, 1.4 Hz, 2H); 13C NMR (151 
MHz, CDCl3) δ 171.02, 144.53, 141.63, 137.11, 134.02, 128.46, 128.08, 127.52, 
127.36, 127.01, 126.17, 123.95, 118.73, 57.92, 52.16, 37.77, 35.71; HRMS (ESI) 
calcd for C23H24O4Na m/z [M + Na]+: 387.1567; found: 387.1574.  
dimethyl 2-(2-phenylallyl)-2-(prop-2-yn-1-yl)malonate (S3-13e)  
 
Colourless oil; IR (film): 3288, 2952, 1736, 1626, 1436, 1211, 1067, 911 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 7.32 – 7.27 (m, 4H), 7.25 – 7.22 (m, 1H), 5.31 (d, J = 









Hz, 2H), 2.07 – 2.02 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 169.94, 143.81, 
140.87, 128.04, 127.60, 126.91, 119.01, 79.19, 71.72, 56.40, 52.45, 36.88, 22.32; 
HRMS (ESI) calcd for C17H18O4Na m/z [M + Na]+: 309.1097; found: 309.1096.  
dimethyl 2-benzyl-2-(2-phenylallyl)malonate (S3-26)  
 
Colourless oil; IR (film): 2951, 1734, 1628, 1436, 1208, 1083, 910 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 7.33 – 7.29 (m, 4H), 7.24 – 7.18 (m, 4H), 7.06 (s, 2H), 5.32 
(d, J = 1.4 Hz, 1H), 5.22 (d, J = 1.3 Hz, 1H), 3.41 (s, 6H), 3.22 (s, 2H), 3.14 (d, J 
= 1.1 Hz, 2H); 13C NMR (151 MHz, CDCl3) δ 171.10, 144.56, 141.89, 136.25, 
129.99, 128.15, 128.06, 127.46, 126.99, 126.86, 118.68, 58.72, 52.01, 38.37, 
















(C) General procedure for the reduction of malonates to diols. 
 
To a stirred solution of malonate (5.0 mmol, 1.0 eq) in THF (15 mL) was added 
LAH (10.0 mmol, 2.0 eq) at 0 oC under argon. The resulting mixture was allowed 
to warm to 25 oC and stirred for another 2 h it was quenched with water (2 mL) 
and NaOH (2.0M, 2mL). The mixture was filtered over celite to remove the white 
precipitate and the filtrate was concentrated under reduced pressure. The residue 




Colourless oil; IR (film): 3429, 2930, 1623, 1444, 1027, 904 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.36 (dd, J = 8.2, 1.3 Hz, 4H), 7.32 (td, J = 6.8, 6.3, 1.8 Hz, 4H), 
7.29 – 7.26 (m, 2H), 5.28 (d, J = 1.8 Hz, 2H), 5.15 – 5.10 (m, 2H), 3.26 (s, 4H), 
2.63 (d, J = 0.9 Hz, 4H); 13C NMR (151 MHz, CDCl3) δ 146.09, 143.06, 128.57, 
127.63, 126.23, 117.92, 67.25, 44.22, 38.69; HRMS (ESI) calcd for C21H24O2Na 











Colourless oil; IR (film): 3404, 2931, 1625, 1443, 1029, 910 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.24 – 7.14  (m, 8H), 5.23 – 5.14 (m, 2H), 5.08 – 4.99 (m, 2H), 
3.30 (s, 4H), 2.55 (s, 4H), 2.34 (s, 6H), 1.42 (m, 2H); 13C NMR (151 MHz, 
CDCl3) δ 145.91, 143.15, 134.56, 130.90, 128.07, 127.20, 125.82, 119.88, 67.68, 
44.73, 40.20, 20.32; HRMS (ESI) calcd for C23H28O2Na m/z [M + Na]+: 359.1982; 
found: 359.1973.  
2,2-bis(2-(m-tolyl)allyl)propane-1,3-diol (3-10c) 
 
Colourless oil; IR (film): 3378, 2921, 1600, 1446, 1024, 900 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.20 (d, J = 7.5 Hz, 2H), 7.19 – 7.14 (m, 4H), 7.10 – 7.06 (m, 
2H), 5.26 (d, J = 1.9 Hz, 2H), 5.13 – 5.10 (m, 2H), 3.26 (d, J = 6.3 Hz, 4H), 2.61 
(d, J = 0.9 Hz, 4H), 2.35 (s, 6H); 13C NMR (151 MHz, CDCl3) δ 146.25, 143.12, 
138.21, 128.45, 128.40, 127.00, 123.30, 117.64, 67.26, 44.31, 38.77, 21.49; 












Colourless oil; IR (film): 3392, 2937, 1620, 1449, 1027, 913 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.26 (m, 4H), 7.13 (d, J = 7.9 Hz, 4H), 5.25 (d, J = 1.9 Hz, 2H), 
5.08 (d, J = 1.9 Hz, 2H), 3.26 (d, J = 6.3 Hz, 4H), 2.60 (s, 4H), 2.33 (s, 6H), 1.51 
(s, 2H); 13C NMR (151 MHz, CDCl3) δ 146.00, 140.17, 137.42, 129.28, 126.12, 
117.14, 67.18, 44.30, 38.80, 21.08; HRMS (ESI) calcd for C23H28O2Na m/z [M + 
Na]+: 359.1982; found: 359.1995.  
2,2-bis(2-(naphthalen-1-yl)allyl)propane-1,3-diol (3-10e) 
 
Colourless oil; IR (film): 3360, 2941, 1626, 1440, 1029, 911 cm-1; 1H NMR (600 
MHz, CDCl3) δ 8.10 – 8.01 (m, 2H), 7.84 (dd, J = 7.9, 1.7 Hz, 2H), 7.78 – 7.69 
(m, 2H), 7.53 – 7.41 (m, 4H), 7.38 (dd, J = 8.2, 7.0 Hz, 2H), 7.32 (dd, J = 7.0, 1.3 
Hz, 2H), 5.34 (d, J = 2.4 Hz, 2H), 5.22 (d, J = 2.2 Hz, 2H), 3.29 (d, J = 6.0 Hz, 
4H), 2.78 (s, 4H), 1.37 (t, J = 6.1 Hz, 2H); 13C NMR (151 MHz, CDCl3) δ 144.35, 









121.14, 67.65, 44.97, 41.02; HRMS (ESI) calcd for C31H28O4Na m/z [M + Na]+: 






Colourless oil; IR (film): 3372, 2938, 1623, 1440, 1024, 904 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.33 (dd, J = 8.7, 5.3 Hz, 4H), 7.01 (t, J = 8.6 Hz, 4H), 5.24 (d, J 
= 1.7 Hz, 2H), 5.13 – 5.09 (m, 2H), 3.26 (s, 4H), 2.58 (d, J = 0.9 Hz, 4H); 13C 
NMR (151 MHz, CDCl3) δ 162.29 (d, J = 247.6 Hz), 145.08, 139.03 (d, J = 4.5 
Hz), 127.86 (d, J = 7.6 Hz), 117.89, 115.35 (d, J = 21.1 Hz), 67.19, 44.18, 38.80; 
HRMS (ESI) calcd for C21H22O2F2Na m/z [M + H]+: 345.1661; found: 345.1659.  
2,2-bis(2-(4-chlorophenyl)allyl)propane-1,3-diol (3-10g) 
 
Colourless oil; IR (film): 3378, 2927, 1621, 1490, 1025, 907 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.33 – 7.26 (m, 8H), 5.27 (d, J = 1.7 Hz, 2H), 5.18 – 5.06 (m, 
2H), 3.26 (d, J = 5.6 Hz, 4H), 2.58 (s, 4H), 1.61 – 1.55 (m, 2H); 13C NMR (151 










38.55; HRMS (ESI) calcd for C21H22O2Cl2Na m/z [M + Na]+: 399.0889; found: 
399.0901.  
2-(2-benzylallyl)-2-(2-phenylallyl)propane-1,3-diol (3-13a)  
 
Colourless oil; IR (film): 3367, 2924, 1626, 1451, 1028, 900 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.38 – 7.35 (m, 2H), 7.35 – 7.31 (m, 2H), 7.31 – 7.26 (m, 3H), 
7.23 – 7.20 (m, 1H), 7.19 – 7.15 (m, 2H), 5.26 (d, J = 1.8 Hz, 1H), 5.16 – 5.12 (m, 
1H), 4.92 (d, J = 4.0 Hz, 2H), 3.51 (d, J = 11.2 Hz, 2H), 3.46 (d, J = 11.1 Hz, 2H), 
3.38 (s, 2H), 2.68 (d, J = 0.9 Hz, 2H), 2.07 (d, J = 0.9 Hz, 2H); 13C NMR (151 
MHz, CDCl3) δ 146.18, 146.09, 143.10, 139.58, 129.11, 128.60, 128.34, 127.65, 
126.26, 126.17, 117.92, 116.45, 67.54, 44.91, 44.14, 38.91, 38.25 ; HRMS (ESI) 
calcd for C22H26O2Na m/z [M + Na]+: 345.1825; found: 345.1828.  
2-(3,3-dimethyl-2-methylenebutyl)-2-(2-phenylallyl)propane-1,3-diol (3-13b)  
 
Colourless oil; IR (film): 3399, 2956, 1624, 1466, 1029, 901 cm-1; 1H NMR (600 









7.26 (m, 1H), 5.29 (d, J = 1.9 Hz, 1H), 5.19 – 5.16 (m, 1H), 5.07 (s, 1H), 4.92 (d, 
J = 0.9 Hz, 1H), 3.60 (d, J = 11.2 Hz, 2H), 3.52 (d, J = 11.2 Hz, 2H), 2.76 (d, J = 
0.9 Hz, 2H), 2.08 (d, J = 1.3 Hz, 2H), 1.00 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 
154.22, 146.32, 143.20, 128.54, 127.58, 126.29, 117.82, 109.36, 68.35, 43.82, 
38.34, 37.14, 32.45, 29.32; HRMS (ESI) calcd for C19H28O2Na m/z [M + Na]+: 
311.1982; found: 311.1982.  
2-(2-methylallyl)-2-(2-phenylallyl)propane-1,3-diol (3-13c)  
 
Colourless oil; IR (film): 3345, 2935, 1638, 1444, 1028, 896 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.44 – 7.37 (m, 2H), 7.36 – 7.32 (m, 2H), 7.30 – 7.26 (m, 1H), 
5.29 (d, J = 1.8 Hz, 1H), 5.20 – 5.15 (m, 1H), 4.90 (dd, J = 2.5, 1.4 Hz, 1H), 4.75 
(dd, J = 2.3, 1.1 Hz, 1H), 3.50 (d, J = 11.2 Hz, 2H), 3.44 (d, J = 11.2 Hz, 2H), 
2.68 (d, J = 0.9 Hz, 2H), 2.09 (d, J = 0.9 Hz, 2H), 1.80 (m, 5H); 13C NMR (151 
MHz, CDCl3) δ 146.23, 143.17, 143.16, 128.60, 127.64, 126.28, 117.92, 115.17, 
67.75, 43.91, 41.17, 38.81, 25.30; HRMS (ESI) calcd for C16H22O2Na m/z [M + 












2-cinnamyl-2-(2-phenylallyl)propane-1,3-diol (3-13d)  
 
Colourless oil; IR (film): 3338, 2931, 1625, 1439, 1028, 905 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.44 – 7.40 (m, 2H), 7.37 – 7.33 (m, 2H), 7.33 – 7.28 (m, 5H), 
7.22 (d, J = 6.5 Hz, 1H), 6.37 – 6.32 (m, 1H), 6.19 (dt, J = 15.5, 7.6 Hz, 1H), 5.31 
(d, J = 1.8 Hz, 1H), 5.23 – 5.19 (m, 1H), 3.50 (s, 4H), 2.65 (d, J = 0.9 Hz, 2H), 
2.20 (dd, J = 7.6, 1.3 Hz, 2H); 13C NMR (151 MHz, CDCl3) δ 146.03, 143.17, 
137.36, 133.12, 128.59, 128.52, 127.67, 127.16, 126.38, 126.04, 125.74, 117.94, 
68.15, 43.79, 37.43, 35.81; HRMS (ESI) calcd for C21H24O2Na m/z [M + Na]+: 
311.1669; found: 311.1672.  
2-(2-phenylallyl)-2-(prop-2-yn-1-yl)propane-1,3-diol (3-13e)  
 
Colourless oil; IR (film): 3275, 2943, 1625, 1444, 1022, 899 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.44 – 7.39 (m, 2H), 7.34 (ddd, J = 7.7, 6.8, 1.3 Hz, 2H), 7.31 – 
7.27 (m, 1H), 5.32 (d, J = 1.8 Hz, 1H), 5.27 – 5.24 (m, 1H), 3.51 (q, J = 11.1 Hz, 









13C NMR (151 MHz, CDCl3) δ 145.17, 142.63, 128.60, 127.75, 126.25, 118.08, 
81.10, 71.20, 67.27, 43.13, 36.61, 21.86; HRMS (ESI) calcd for C15H18O2Na m/z 
[M + Na]+: 253.1199; found: 253.1207.  
2-benzyl-2-(2-phenylallyl)propane-1,3-diol (3-26)  
 
Colourless oil; IR (film): 3399, 2928, 1622, 1445, 1027, 906 cm-1; 1H NMR (600 
MHz, CDCl3) δ 7.40 – 7.37 (m, 2H), 7.33 (ddd, J = 7.8, 6.9, 0.8 Hz, 2H), 7.29 – 
7.26 (m, 3H), 7.23 – 7.19 (m, 3H), 5.31 (d, J = 1.8 Hz, 1H), 5.19 – 5.17 (m, 1H), 
3.44 – 3.36 (m, 4H), 2.70 (s, 2H), 2.66 (d, J = 0.9 Hz, 2H); 13C NMR (151 MHz, 
CDCl3) δ 146.21, 143.07, 137.70, 130.56, 128.61, 128.11, 127.67, 126.25, 126.24, 
117.86, 66.89, 44.02, 39.40, 38.68; HRMS (ESI) calcd for C19H22O2Na m/z [M + 
Na]+: 305.1512; found: 305.1510.  












To a stirred solution of the diol (0.05 mmol, 1.0 eq) in CHCl3/Hexane (2: 3.5 mL) 
was added catalyst (0.005 mmol, 0.1 eq) and 275mg of 4 Å molecular sieves 
under argon. The mixture was cooled to -60 oC before N-bromophthalimide (0.06 
mmol, 1.2 eq) was added. The reaction was stirred at -60oC for 12 h before it was 
quenched with Na2SO3 (3.0 mL) and extracted with CHCl3 (3 x 5 mL). The 
combined organic extracts was dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified using flash column chromatography 




Colourless oil; [] 26D  +4 (c 1.0, CHCl3, 96:4 er); IR (film): 3462, 2944, 1724, 
1623, 1446, 1303, 1029,  906 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.42 – 7.38 (m, 
2H), 7.36 – 7.33 (m, 4H), 7.31 – 7.28 (m, 3H), 7.23 (m, 1H), 5.30 (d, J = 1.7 Hz, 
1H), 5.24 – 5.20 (m, 1H), 3.81 (d, J = 9.1 Hz, 1H), 3.68 (d, J = 9.1 Hz, 1H), 3.54 
(d, J = 2.1 Hz, 2H), 3.10 (d, J = 10.9 Hz, 1H), 3.03 (d, J = 10.9 Hz, 1H), 2.90 – 
2.86 (m, 1H), 2.81 (d, J = 13.8 Hz, 1H), 2.32 (d, J = 13.4 Hz, 1H), 2.14 (d, J = 
13.4 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 146.51, 143.94, 142.38, 128.58, 









43.12, 39.73 ; HRMS (ESI) calcd for C21H23BrO2Na m/z [M + Na]+: 409.0774; 
found: 409.0770; HPLC (Daicel Chiralpak IA, i-PrOH/hexane = 5/95, 1.0 





Colourless oil; [] 26D  –17 (c 1.0, CHCl3, 96:4 er); IR (film): 3433, 2926, 1627, 










7.22 – 7.16 (m, 2H), 7.18 – 7.12 (m, 4H), 7.10 (d, J = 3.8 Hz, 1H), 5.40 – 5.34 (m, 
1H), 5.07 (d, J = 2.1 Hz, 1H), 3.78 – 3.70 (m, 2H), 3.70 – 3.61 (m, 2H), 3.19 – 
3.07 (m, 2H), 2.85 (dd, J = 13.8, 1.0 Hz, 1H), 2.76 (dd, J = 13.8, 0.9 Hz, 1H), 2.37 
(s, 3H), 2.23 (d, J = 17.1 Hz, 4H), 2.09 (d, J = 13.4 Hz, 1H), 1.06 (t, J = 5.9 Hz, 
1H); 13C NMR (151 MHz, CDCl3) δ 146.93, 142.46, 141.74, 134.63, 133.37, 
132.06, 130.74, 128.34, 127.52, 127.38, 126.29, 125.85, 125.79, 118.93, 85.61, 
74.78, 65.46, 50.09, 44.24, 41.64, 41.52, 21.26, 20.25; HRMS (ESI) calcd for 
C23H28BrO2m/z [M + H]+: 415.1267; found: 415.1266; HPLC (Daicel Chiralpak 
IA, i-PrOH/hexane = 2.5/97.5, 0.6 mL/min, 205 nm) t1 = 19.0 min (minor), t2 = 













Colourless oil; [] 26D  +3 (c 1.0, CHCl3, 82:18); IR (film): 3453, 2922, 1603, 1447, 
1235, 1043,  899 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.23 – 7.16 (m, 5H), 7.13 – 
7.10 (m, 2H), 7.06 – 7.02 (m, 1H), 5.28 (d, J = 1.8 Hz, 1H), 5.22 – 5.19 (m, 1H), 
3.82 (d, J = 9.1 Hz, 1H), 3.68 (d, J = 9.1 Hz, 1H), 3.54 (d, J = 1.4 Hz, 2H), 3.11 
(d, J = 11.0 Hz, 1H), 3.04 (d, J = 11.0 Hz, 1H), 2.87 (dd, J = 13.7, 0.9 Hz, 1H), 
2.82 – 2.78 (m, 1H), 2.36 (s, 3H), 2.34 – 2.31 (m, 4H), 2.13 (d, J = 13.3 Hz, 1H), 
1.21 (t, J = 7.0 Hz, 1H) ; 13C NMR (151 MHz, CDCl3) δ 146.62, 143.90, 142.39, 
138.21, 137.90, 128.53, 128.46, 128.13, 128.12, 127.12, 126.00, 123.42, 122.47, 
117.04, 85.25, 75.09, 65.17, 50.17, 43.88, 43.21, 39.80, 21.58, 21.49; HRMS 
(ESI) calcd for C23H27BrO2Na m/z [M + Na]+: 437.1087; found: 437.1088; HPLC 
(Daicel Chiralpak IA, i-PrOH/hexane = 5/95, 0.6 mL/min, 254 nm) t1 = 13.4 min 















Colourless oil; [] 26D  +8 (c 1.0, CHCl3, 95:5 er); IR (film): 3448, 2922, 1726, 
1619, 1451, 1303, 1038,  901 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.29 (d, J = 8.1 
Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 7.16 – 7.13 (m, 2H), 7.11 (dd, J = 8.2, 0.9 Hz, 
2H), 5.26 (d, J = 1.8 Hz, 1H), 5.19 – 5.15 (m, 1H), 3.80 (d, J = 9.0 Hz, 1H), 3.65 









(dd, J = 11.0, 5.7 Hz, 1H), 2.85 (dd, J = 13.8, 1.0 Hz, 1H), 2.78 (dd, J = 13.8, 0.9 
Hz, 1H), 2.35 (s, 3H), 2.33 – 2.29 (m, 4H), 2.13 (d, J = 13.3 Hz, 1H), 1.08 (t, J = 
6.0 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 146.35, 140.96, 139.44, 137.56, 
137.01, 129.27, 128.97, 126.22, 125.29, 116.57, 85.17, 75.01, 65.14, 50.16, 43.87, 
43.26, 39.78, 21.10, 21.00; HRMS (ESI) calcd for C23H28BrO2Na m/z [M + Na]+: 
437.1087; found: 437.1097; HPLC (Daicel Chiralpak IA, i-PrOH/hexane = 

















Colourless oil; [] 26D  –19 (c 1.0, CHCl3, 93:7 er); IR (film): 3217, 2925, 1725, 
1606, 1448, 1378, 1305, 1053,  908 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.13 – 
8.08 (m, 1H), 7.88 (dd, J = 5.4, 3.1 Hz, 4H), 7.77 (dd, J = 5.5, 3.0 Hz, 3H), 7.50 
(s, 2H), 7.45 – 7.40 (m, 3H), 7.37 (dd, J = 7.0, 1.3 Hz, 1H), 5.65 – 5.60 (m, 1H), 
5.34 (d, J = 2.1 Hz, 1H), 3.91 (d, J = 11.3 Hz, 1H), 3.82 (s, 2H), 3.76 (d, J = 11.1 
Hz, 1H), 3.14 – 3.03 (m, 4H), 2.47 (d, J = 13.3 Hz, 1H), 2.38 (d, J = 14.2 Hz, 1H), 
0.93 (t, J = 5.9 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 167.70, 145.43, 140.94, 
134.58, 134.33, 133.95, 132.61, 130.72, 129.54, 128.76, 128.64, 127.89, 126.22, 
125.94, 125.75, 125.50, 125.23, 125.19, 125.16, 125.05, 123.61, 120.29, 74.66, 
65.36, 44.71, 42.64, 42.41, 29.70; HRMS (ESI) calcd for C29H28BrO2 m/z [M + 
H]+: 487.1267; found: 487.1273; HPLC (Daicel Chiralpak IA, i-PrOH/hexane = 













fluorophenyl)allyl)tetrahydrofuran-3-yl)methanol (3-11f)  
 
Colourless oil; [] 26D  +4 (c 0.5, CHCl3, 82:18 er); IR (film): 2924, 1726, 1602, 
1462, 1299, 1053,  910 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.37 (dd, J = 8.7, 5.3 
Hz, 2H), 7.31 (dd, J = 8.8, 5.3 Hz, 2H), 7.03 (t, J = 8.6 Hz, 2H), 6.99 (t, J = 8.7 










1H), 3.65 (d, J = 9.1 Hz, 1H), 3.54 – 3.45 (m, 2H), 3.12 (d, J = 10.7 Hz, 1H), 3.04 
(d, J = 10.7 Hz, 1H), 2.84 (dd, J = 13.8, 0.9 Hz, 1H), 2.78 (dd, J = 13.7, 0.9 Hz, 
1H), 2.28 (d, J = 13.4 Hz, 1H), 2.11 (d, J = 13.4 Hz, 1H); 13C NMR (151 MHz, 
CDCl3) δ 162.39 (d, J = 247.2 HZ), 162.00 (d, J = 246.3 HZ), 145.33, 139.67 (d, J 
= 3.2 HZ), 138.28 (d, J = 3.3 HZ), 128.02 (d, J = 7.9 HZ), 127.15 (d, J = 8.2 HZ), 
117.42, 115.41 (d, J = 21.4 HZ), 115.11 (d, J = 21.4 HZ), 84.92, 74.92, 64.88, 
50.03, 43.86, 42.96, 39.71; HRMS (ESI) calcd for C21H21BrF2O2Na m/z [M + 
Na]+: 445.0585; found: 445.0575; HPLC (Daicel Chiralpak IA, i-PrOH/hexane = 















Colourless oil; [] 26D  +5 (c 0.5, CHCl3, 82:18 er); IR (film): 3455, 2927, 1625, 
1490, 1378, 1294, 1041,  908 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.34 – 7.30 (m, 
4H), 7.28 (m, 4H), 5.30 (d, J = 1.5 Hz, 1H), 5.22 (d, J = 1.5 Hz, 1H), 3.77 (d, J = 
9.1 Hz, 1H), 3.65 (d, J = 9.1 Hz, 1H), 3.53 – 3.45 (m, 2H), 3.11 (d, J = 10.7 Hz, 
1H), 3.03 (d, J = 10.7 Hz, 1H), 2.84 (dd, J = 13.9, 1.0 Hz, 1H), 2.77 (dd, J = 13.8, 
0.8 Hz, 1H), 2.27 (d, J = 13.4 Hz, 1H), 2.10 (d, J = 13.4 Hz, 1H).; 13C NMR (151 
MHz, CDCl3) δ 145.17, 142.48, 140.67, 133.61, 133.32, 128.68, 128.45, 127.71, 
126.89, 117.96, 84.92, 74.89, 64.81, 50.00, 43.79, 42.69, 39.37; HRMS (ESI) 
calcd for C21H21BrCl2O2Na m/z [M + Na]+: 476.9994; found: 476.9989; HPLC 
(Daicel Chiralpak IA, i-PrOH/hexane = 5/95, 0.6 mL/min, 254 nm) t1 = 23.9 min 












yl)methanol (3-14a)  
 
Colourless oil; [] 26D  –7 (c 0.5, CHCl3, 93:7); IR (film): 3458, 2920, 1638, 1448, 
1234, 1046,  905 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.42 (dd, J = 8.3, 1.3 Hz, 
2H), 7.33 (ddd, J = 21.2, 8.2, 6.7 Hz, 4H), 7.28 (d, J = 7.3 Hz, 1H), 7.25 – 7.19 









3.90 (d, J = 8.9 Hz, 1H), 3.62 – 3.55 (m, 2H), 3.39 (d, J = 3.5 Hz, 2H), 3.29 (d, J 
= 10.9 Hz, 1H), 3.25 (d, J = 10.9 Hz, 1H), 2.40 (d, J = 0.8 Hz, 2H), 2.30 (dd, J = 
2.2, 1.0 Hz, 2H); 13C NMR (151 MHz, CDCl3) δ 146.39, 144.00, 139.11, 129.07, 
128.48, 128.33, 127.45, 126.37, 125.38, 115.78, 85.35, 75.62, 65.15, 49.77, 44.60, 
44.07, 43.17, 39.98; HRMS (ESI) calcd for C22H25BrO2Na m/z [M + Na]+: 
423.0930; found: 423.0940; HPLC (Daicel Chiralpak IC, i-PrOH/hexane = 














phenyltetrahydrofuran-3-yl)methanol (3-14b)  
 
Colourless oil; [] 26D  –3 (c 2.0, CHCl3, 90:10 er); IR (film): 3466, 2957, 1635, 
1448, 1362, 1226, 1054, 895 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.48 – 7.38 (m, 
2H), 7.35 (dd, J = 8.5, 6.9 Hz, 2H), 7.29 – 7.26 (m, 1H), 5.03 (s, 1H), 4.70 (t, J = 
1.5 Hz, 1H), 4.03 (d, J = 8.9 Hz, 1H), 3.97 (d, J = 8.9 Hz, 1H), 3.62 (s, 2H), 3.41 
– 3.30 (m, 2H), 2.48 (q, J = 13.2 Hz, 2H), 2.44 – 2.36 (m, 2H), 1.08 (s, 9H); 13C 
NMR (151 MHz, CDCl3) δ 154.19, 143.96, 128.34, 127.44, 125.40, 108.21, 
85.28, 77.21, 77.00, 76.79, 76.37, 64.87, 49.36, 45.36, 43.01, 36.78, 35.33, 29.19; 
HRMS (ESI) calcd for C19H27BrO2Na m/z [M + Na]+: 389.1087; found: 389.1081; 
HPLC (Daicel Chiralpak IA, i-PrOH/hexane = 2.5/97.5, 0.6 mL/min, 205 nm) t1 = 











yl)methanol (3-14c)  
 
Colourless oil; [] 26D  –3 (c 0.5, CHCl3, 70:30 er); IR (film): 3446, 2974, 2876, 
1623, 1446, 1375, 1033, 907 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.35 (m, 
2H), 7.33 (ddd, J = 7.7, 6.7, 1.3 Hz, 2H), 7.31 – 7.27 (m, 1H), 5.29 (d, J = 1.7 Hz, 
1H), 5.18 – 5.13 (m, 1H), 3.66 – 3.57 (m, 2H), 3.41 – 3.34 (m, 3H), 3.32 (d, J = 










1H), 1.66 (d, J = 13.6 Hz, 1H), 1.37 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
146.45, 142.51, 128.58, 127.75, 126.34, 117.50, 82.00, 73.87, 66.15, 50.10, 43.32, 
41.41, 40.31, 25.46; HRMS (ESI) calcd for C16H21BrO2Na m/z [M + Na]+: 
347.0617; found: 347.0615; HPLC (Daicel Chiralpak IB, i-PrOH/hexane = 














((3R,5R)-5-(bromomethyl)-3-cinnamyl-5-phenyltetrahydrofuran-3-yl)        
methanol (3-14d) 
 
Colourless oil; [] 26D  +7 (c 1.0, CHCl3, 92:8 er); IR (film): 3418, 2930, 1648, 
1494, 1447, 1288, 1224, 1055,  967, 913 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.44 
– 7.41 (m, 2H), 7.38 – 7.27 (m, 7H), 7.24 (d, J = 7.3 Hz, 1H), 6.53 (dt, J = 15.8, 
1.4 Hz, 1H), 6.25 (dt, J = 15.4, 7.6 Hz, 1H), 3.97 (d, J = 9.0 Hz, 1H), 3.88 (d, J = 
9.0 Hz, 1H), 3.65 – 3.58 (m, 2H), 3.30 (d, J = 2.2 Hz, 2H), 2.60 – 2.49 (m, 2H), 
2.44 (d, J = 13.2 Hz, 1H), 2.33 (d, J = 13.2 Hz, 1H); 13C NMR (151 MHz, CDCl3) 
δ 143.75, 137.16, 133.30, 128.57, 128.39, 127.51, 127.34, 126.12, 126.02, 125.46, 
85.65, 74.87, 66.01, 49.91, 43.66, 42.90, 38.42; HRMS (ESI) calcd for 
C21H23BrO2Na m/z [M + Na]+: 409.0774; found: 409.0782; HPLC (Daicel 
Chiralpak IA, i-PrOH/hexane = 2.5/97.5, 0.6 mL/min, 254 nm) t1 = 45.5 min 













yl)methanol (3-14e)  
 
Colourless oil; [] 26D  +21 (c 0.25, CHCl3, 95:5 er); IR (film): 3404, 2936, 1603, 
1447, 1296, 1043,  916 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.41 (dd, J = 8.3, 1.3 
Hz, 2H), 7.35 (dd, J = 8.5, 6.9 Hz, 2H), 7.30 – 7.26 (m, 1H), 3.94 (d, J = 9.2 Hz, 









(m, 2H), 2.46 (d, J = 13.4 Hz, 1H), 2.35 (d, J = 13.4 Hz, 1H), 2.03 (t, J = 2.7 Hz, 
1H); 13C NMR (151 MHz, CDCl3) δ 143.52, 128.41, 127.57, 125.43, 85.73, 81.33, 
74.11, 70.32, 65.74, 49.10, 43.60, 42.49, 24.42; HRMS (ESI) calcd for 
C15H17BrO2Na m/z [M + Na]+: 331.0304; found: 331.0316; HPLC (Daicel 
Chiralpak IA, i-PrOH/hexane = 2.5/97.5, 0.6 mL/min, 205 nm) t1 = 37.3 min 














((3R,5R)-3-benzyl-5-(bromomethyl)-5-phenyltetrahydrofuran-3-yl)           
methanol (cis-3-27)  
 
Colourless oil; [] 26D  +21 (c 0.5, CHCl3, 89:11 er); IR (film): 3441, 2929, 1603, 
1495, 1447, 1291, 1227, 1029,  917 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.41 – 
7.36 (m, 2H), 7.35 – 7.29 (m, 4H), 7.27 – 7.23 (m, 4H), 4.02 (d, J = 8.9 Hz, 1H), 
3.88 (d, J = 8.9 Hz, 1H), 3.58 (q, J = 10.8 Hz, 2H), 3.20 – 3.12 (m, 2H), 2.97 (d, J 
= 13.3 Hz, 1H), 2.87 (d, J = 13.3 Hz, 1H), 2.50 (d, J = 13.3 Hz, 1H), 2.20 (d, J = 
13.3 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 143.95, 138.01, 130.06, 128.37, 
128.32, 127.44, 126.50, 125.39, 85.51, 75.03, 64.64, 50.37, 43.66, 43.10, 39.98; 
HRMS (ESI) calcd for C19H21BrO2Na m/z [M + Na]+: 383.0617; found: 383.0623; 
HPLC (Daicel Chiralpak IB, i-PrOH/hexane = 2.5/97.5, 0.6 mL/min, 205 nm) t1 = 











(D) General procedure for the 2nd Cyclization to Spirocycles 
To a stirred solution of the bromoether (0.05 mmol, 1.0 eq) in CH2Cl2 (2.0 mL) 
was added triphenylphosphine sulfide (0.005 mmol, 0.1 eq). The mixture was 
cooled to -50 oC before N-bromosuccinimide (0.06 mmol, 1.2 eq) was added. The 
reaction was stirred at -50oC for 12 h before it was quenched with Na2SO3 (2.0 
mL) and extracted with CH2Cl2 (3 x 2 mL). The combined organic extracts was 
dried over MgSO4, filtered and concentrated under reduced pressure. The residue 













Colourless oil; [] 26D  -16 (c 2.0, CHCl3, 95:5 er); IR (film): 2967, 2867, 1482, 
1445, 1203, 1044 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.56 (dd, J = 7.4, 1.9 Hz, 
2H), 7.23 – 7.09 (m, 6H), 3.79 (d, J = 11.2 Hz, 2H), 3.70 (d, J = 11.2 Hz, 2H), 
3.65 (d, J = 8.8 Hz, 2H), 3.56 (d, J = 8.8 Hz, 2H), 2.71 (d, J = 13.1 Hz, 2H), 2.63 
(d, J = 13.1 Hz, 2H), 2.38 (s, 6H); 13C NMR (151 MHz, CDCl3) δ 141.07, 133.67, 
132.31, 127.83, 126.15, 126.02, 85.45, 76.16, 52.82, 46.68, 41.09, 21.39; HRMS 
(ESI) calcd for C23H27Br2O2 m/z [M +H]+: 493.0372; found: 493.0358. 
(3S,5S,8R)-3,8-bis(bromomethyl)-3,8-di-o-tolyl-2,7-dioxaspiro[4.4]    nonan-1-
one (3-16) 
 
Colourless oil; [] 26D  -14.2 (c 5.0, CHCl3, 95:5 er); IR (film): 2926, 2865, 1773, 









MHz, CDCl3) δ 7.47 (d, J = 7.7 Hz, 2H), 7.27 (s, 1H), 7.25 – 7.13 (m, 5H), 3.91 
(d, J = 11.6 Hz, 1H), 3.83 (d, J = 11.6 Hz, 1H), 3.73 (d, J = 11.5 Hz, 1H), 3.62 (d, 
J = 11.5 Hz, 1H), 3.55 (dd, J = 8.7, 1.4 Hz, 1H), 3.42 (dd, J = 8.8, 1.3 Hz, 1H), 
3.16 (d, J = 13.7 Hz, 1H), 3.09 – 3.02 (m, 2H), 2.82 (dd, J = 13.5, 1.3 Hz, 1H), 
2.46 (s, 3H), 2.35 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 176.41, 140.31, 138.28, 
134.05, 133.51, 132.98, 132.57, 128.92, 128.18, 126.60, 126.24, 125.55, 125.11, 
86.63, 85.11, 75.73, 53.13, 48.58, 46.14, 40.16, 39.89, 21.49, 21.18; HRMS (ESI) 




Colourless oil; [] 26D  -13.6 (c 1.0, CHCl3, 95:5 er); IR (film): 2968, 1773, 1448, 
1248, 1188, 1079, 1056, 1015, 953, 910 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.44 
(ddd, J = 18.3, 7.9, 1.4 Hz, 2H), 7.31 – 7.13 (m, 7H), 3.85 (d, J = 11.4 Hz, 1H), 
3.77 (d, J = 11.4 Hz, 1H), 3.73 (d, J = 11.5 Hz, 1H), 3.61 (d, J = 11.5 Hz, 1H), 
3.50 (dd, J = 8.7, 1.5 Hz, 1H), 3.36 (dd, J = 8.7, 1.3 Hz, 1H), 3.27 (d, J = 13.6 Hz, 
1H), 3.05 (d, J = 13.4 Hz, 1H), 2.91 (dd, J = 13.8, 1.5 Hz, 1H), 2.81 (dd, J = 13.4, 










140.27, 138.14, 134.04, 133.02, 132.56, 128.80, 128.17, 126.53, 126.23, 125.46, 
125.09, 86.59, 84.50, 75.20, 53.30, 48.46, 47.81, 40.16, 21.47, 21.17, 16.14; 





Colourless oil; [] 26D  +22 (c 2.0, CHCl3, 95:5 er); IR (film): 2997, 1808, 1672, 
1447, 1165, 1124, 1033, 955, 905 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.42 – 7.37 
(m, 4H), 7.35 – 7.31 (m, 1H), 6.05 (t, J = 2.3 Hz, 1H), 4.04 (dd, J = 8.8, 1.1 Hz, 
1H), 3.89 (dd, J = 8.7, 1.1 Hz, 1H), 3.65 (d, J = 11.3 Hz, 1H), 3.58 (d, J = 11.3 
Hz, 1H), 3.35 (dd, J = 17.7, 2.0 Hz, 1H), 3.09 (ddd, J = 17.7, 2.7, 1.0 Hz, 1H), 
3.04 (d, J = 13.4 Hz, 1H), 2.71 (dd, J = 13.4, 1.2 Hz, 1H); 13C NMR (151 MHz, 
CDCl3) δ 175.59, 149.93, 142.29, 128.79, 128.21, 125.40, 87.03, 86.58, 76.51, 
51.89, 47.85, 41.30, 40.07; HRMS (ESI) calcd for C15H14Br2O3Na m/z [M + Na]+: 













Colourless oil; [] 26D  +10 (c 1.0, CHCl3, 90:10 er); IR (film): 2917, 1722, 1597, 
1492, 1447, 1260, 1219, 1126, 1045, 961 cm-1; 1H NMR (600 MHz, CDCl3) δ 
7.43 – 7.37 (m, 2H), 7.33 (dd, J = 8.4, 6.8 Hz, 2H), 7.29 – 7.26 (m, 1H), 4.07 – 
3.98 (m, 2H), 3.72 (d, J = 10.9 Hz, 1H), 3.65 (d, J = 1.1 Hz, 2H), 3.60 (d, J = 10.8 
Hz, 1H), 3.57 (dd, J = 9.1, 1.4 Hz, 1H), 3.48 (d, J = 9.0 Hz, 1H), 2.78 (d, J = 12.8 
Hz, 1H), 2.61 (dd, J = 12.9, 0.9 Hz, 1H), 2.36 (d, J = 14.2 Hz, 1H), 2.21 (d, J = 
14.1 Hz, 1H), 0.96 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 143.28, 128.25, 
127.58, 125.44, 88.55, 85.21, 80.17, 79.95, 52.19, 47.67, 42.70, 40.74, 40.42, 

















1H NMR (600 MHz, CDCl3) δ 7.41 – 7.37 (m, 2H), 7.35 – 7.30 (m, 2H), 7.28 – 
7.26 (m, 1H), 4.24 (dd, J = 8.5, 0.9 Hz, 1H), 4.16 (dd, J = 8.5, 1.1 Hz, 1H), 3.72 
(d, J = 9.0 Hz, 1H), 3.64 (s, 2H), 3.62 (d, J = 10.9 Hz, 1H), 3.55 (d, J = 11.0 Hz, 
1H), 3.21 (dd, J = 9.0, 1.1 Hz, 1H), 2.68 (d, J = 12.6 Hz, 1H), 2.46 (dd, J = 12.7, 
0.9 Hz, 1H), 2.29 (d, J = 1.8 Hz, 2H), 0.98 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 
143.21, 128.30, 127.61, 125.43, 88.56, 85.06, 80.84, 79.38, 52.21, 48.92, 42.57, 
















dioxaspiro[4.5]decane (1:1) (3-20) 
 
Colourless oil; IR (film): 3061, 3030, 2957, 2923, 2853, 1494, 1447, 1301, 1221, 
1176, 1075, 1048, 902 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.46 – 7.39 (m, 4H), 
7.37 – 7.31 (m, 13H), 7.26 (s, 4H), 4.37 (d, J = 8.6 Hz, 1H), 4.21 (t, J = 10.0 Hz, 
2H), 4.14 – 4.07 (m, 2H), 3.95 – 3.86 (m, 2H), 3.71 (d, J = 9.1 Hz, 1H), 3.68 – 
3.58 (m, 4H), 3.55 (dd, J = 11.4, 2.5 Hz, 1H), 3.44 (dd, J = 11.3, 2.5 Hz, 1H), 3.32 
(dd, J = 11.4, 1.8 Hz, 1H), 3.25 (dd, J = 11.5, 1.8 Hz, 1H), 2.97 (d, J = 12.8 Hz, 
1H), 2.67 (s, 2H), 2.48 (dd, J = 12.9, 1.8 Hz, 1H), 2.41 (d, J = 13.2 Hz, 1H), 2.29 
(t, J = 12.7 Hz, 1H), 2.21 – 2.13 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 143.28, 
142.78, 138.58, 138.57, 128.75, 128.69, 128.62, 128.49, 128.32, 128.26, 127.76, 
127.72, 127.43, 127.34, 125.33, 125.29, 86.30, 85.20, 85.06, 84.59, 75.09, 75.00, 
74.38, 74.15, 49.90, 49.65, 48.10, 48.07, 45.65, 45.51, 45.20, 43.76, 42.66, 42.54; 











(3R,5S)-7-benzyl-3-(bromomethyl)-3,9-diphenyl-2-oxa-7-azaspiro[4.5]   dec-8-
ene (3-21) 
 
Colourless oil; [] 26D  +13 (c 0.4, CHCl3, 95:5 er); IR (film): 3060, 3027, 2924, 
2852, 1956, 1722, 1675, 1631, 1595, 1494, 1447, 1364, 1210, 1048, 973, 911 cm-
1; 1H NMR (600 MHz, Chloroform-d) δ 7.37 – 7.32 (m, 2H), 7.32 – 7.26 (m, 5H), 
7.26 – 7.23 (m, 5H), 7.12 – 7.02 (m, 3H), 6.67 (s, 1H), 4.03 (d, J = 14.8 Hz, 1H), 
3.94 – 3.84 (m, 2H), 3.82 (s, 1H), 3.62 (s, 2H), 2.58 – 2.44 (m, 4H), 2.43 – 2.35 
(m, 2H); 13C NMR (151 MHz, CDCl3) δ 144.06, 141.11, 137.80, 133.17, 128.50, 
128.38, 128.29, 127.82, 127.35, 125.40, 123.97, 122.46, 104.66, 99.98, 85.53, 
77.37, 77.21, 77.00, 76.79, 59.35, 53.32, 47.16, 42.89, 42.85, 34.64; HRMS (ESI) 













(E) General two-step procedure for the oxidation of alcohol to acid 
 
To a stirred solution of the alcohol (0.5 mmol, 1.0 eq) in CH 2Cl2 (4.0 mL) was 
added 100mg of 4Å molecular sieves, followed by PCC (0.75 mmol. 1.5 eq). The 
reaction was traced using TLC. After the disappearance of the starting material, 
the reaction was filtered over a plug of silica. The filtrate was concentrated under 
reduced pressure to give the aldehyde.  
The aldehyde was dissolved in t-BuOH (3.0 mL). This was followed by the 
addition of 2-methy-2-butene (9.0 mmol, 18.0 eq), water (3.0 mL), NaH2PO4 (4.0 
mmol, 8.0 eq) and NaClO2 (2.0 mmol, 2.0 eq). The mixture was allowed to stir for 
2 hours before it is quenched with brine and extracted with CHCl3. (3 x 5mL) The 
combined organic extracts was dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified using flash column chromatography 
















Colourless oil; [] 26D  -8.0 (c 10.0, CHCl3, 95:5 er); IR (film): 2926, 1728, 1636, 
1488, 1218, 1063, 910 cm-1; 1H NMR (600 MHz, CDCl3) δ 9.07 (s, 1H), 7.45 (dd, 
J = 7.6, 1.8 Hz, 1H), 7.19 – 7.10 (m, 6H), 7.02 (dd, J = 7.5, 1.4 Hz, 1H), 5.21 (d, J 
= 1.3 Hz, 1H), 5.00 (d, J = 1.5 Hz, 1H), 4.11 (d, J = 9.3 Hz, 1H), 3.89 (d, J = 9.2 
Hz, 1H), 3.73 (d, J = 11.3 Hz, 1H), 3.66 (d, J = 11.3 Hz, 1H), 2.99 (dd, J = 4.4, 
1.2 Hz, 2H), 2.77 (d, J = 13.3 Hz, 1H), 2.46 (d, J = 13.3 Hz, 1H), 2.32 (s, 3H), 
2.29 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 201.97, 145.34, 141.32, 139.88, 
134.87, 133.58, 132.27, 130.52, 128.57, 127.94, 127.64, 126.45, 125.98, 125.78, 
118.68, 86.14, 72.42, 59.27, 42.93, 42.46, 40.88, 21.37, 19.88; HRMS (ESI) calcd 













carboxylic acid (3-11b-COOH) 
 
Colourless oil; [] 26D  +7.1 (c 10.0, CHCl3, 95:5 er); IR (film): 2927, 1704, 1635, 
1454, 1276, 1260, 1054, 918 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.54 – 7.49 (m, 
1H), 7.12 (d, J = 2.9 Hz, 3H), 7.04 – 6.96 (m, 4H), 5.24 (d, J = 1.4 Hz, 1H), 4.98 
(d, J = 1.7 Hz, 1H), 4.01 (d, J = 9.2 Hz, 1H), 3.81 (d, J = 9.2 Hz, 1H), 3.69 – 3.63 
(m, 2H), 3.05 – 2.95 (m, 2H), 2.91 (d, J = 13.5 Hz, 1H), 2.45 (d, J = 13.5 Hz, 1H), 
2.33 (s, 3H), 2.27 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 178.45, 145.65, 141.35, 
140.05, 134.95, 133.92, 132.25, 130.11, 128.90, 127.85, 127.27, 126.30, 125.88, 
125.32, 118.33, 86.14, 73.73, 55.06, 44.62, 43.22, 40.72, 21.35, 19.87; HRMS 

















Colourless oil; [] 26D  +19 (c 3.0, CHCl3, 95:5 er); IR (film): 3289, 3006, 2990, 
1727, 1447, 1275, 1260, 1054 cm-1; 1H NMR (600 MHz, CDCl3) δ 9.32 (s, 1H), 
7.40 – 7.35 (m, 4H), 7.30 (d, J = 7.1 Hz, 1H), 4.21 (d, J = 9.5 Hz, 1H), 4.10 (d, J 
= 9.5 Hz, 1H), 3.67 (s, 2H), 2.80 (d, J = 13.6 Hz, 1H), 2.71 – 2.66 (m, 2H), 2.62 
(dd, J = 16.9, 2.7 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 200.57, 141.93, 128.63, 
128.06, 125.52, 86.45, 79.43, 71.80, 71.16, 58.09, 42.76, 41.46, 22.65; HRMS 
(ESI) calcd for C15H16BrO2 m/z [M + H]+: 307.0328; found: 307.0328. 
(3R,5R)-5-(bromomethyl)-5-phenyl-3-(prop-2-yn-1-yl)tetrahydrofuran-3-
carboxylic acid (3-14e-COOH) 
 
Colourless oil; [] 26D  +22 (c 3.0, CHCl3, 95:5 er); IR (film): 3293, 3006, 2989, 









(dd, J = 8.4, 1.3 Hz, 2H), 7.31 (dd, J = 8.5, 7.0 Hz, 2H), 7.25 – 7.20 (m, 1H), 4.14 
(d, J = 9.3 Hz, 1H), 4.00 (d, J = 9.3 Hz, 1H), 3.65 – 3.56 (m, 2H), 2.95 (d, J = 
13.5 Hz, 1H), 2.77 (dd, J = 2.7, 1.7 Hz, 2H), 2.64 (d, J = 13.6 Hz, 1H), 2.06 (t, J = 
2.6 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 178.47, 142.10, 128.40, 127.83, 
125.57, 86.20, 79.55, 73.36, 71.06, 54.40, 43.54, 41.60, 26.29; HRMS (ESI) calcd 
for C15H15BrO3Na m/z [M + Na]+: 345.0097; found: 345.0090. 
 




Using the general procedure in (E), 3-11a (0.5 mmol, 1.0 eq) was first oxidized to 
the aldehyde 3-11a-CHO. The aldeyde was dissolved in THF/AcOH (1:1) (4.0 










triacetoxyborohydride (1.5 mmol, 3.0 eq). The reaction was allowed to stir 
overnight. The reaction mixture was quenched, made alkaline with aqueous NaOH 
and extracted with CH2Cl2. (3 x 5mL) The combined organic extracts was dried 
over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified using flash column chromatography (hexane/EtOAc 1:1) to give the 
amine 3-11a-NHBn. 
Colourless oil; [] 26D  –6 (c 1.0, CHCl3, 95:5 er); IR (film): 3025, 2925, 1600, 
1493, 1447, 1226, 1109, 1050, 1028, 905  cm-1; 1H NMR (600 MHz, CDCl3) δ 
7.35 – 7.27 (m, 9H), 7.25 – 7.18 (m, 4H), 6.98 – 6.90 (m, 2H), 5.23 (d, J = 1.7 Hz, 
1H), 5.16 (s, 1H), 3.81 (d, J = 8.8 Hz, 1H), 3.58 (d, J = 8.8 Hz, 1H), 3.54 (s, 2H), 
3.16 (s, 2H), 2.81 (s, 2H), 2.36 (d, J = 13.1 Hz, 1H), 2.29 (d, J = 13.1 Hz, 1H), 
2.16 (d, J = 12.2 Hz, 1H), 2.05 (d, J = 12.2 Hz, 1H); 13C NMR (151 MHz, CDCl3) 
δ 146.77, 144.25, 142.67, 128.41, 128.17, 128.16, 127.86, 127.54, 127.22, 126.71, 
126.49, 125.46, 117.11, 85.00, 76.55, 54.11, 52.92, 49.21, 45.09, 43.34, 40.66; 



























To a stirred solution of diol 3-10a (1.0 mmol, 1.0 eq) in THF (5.0 mL) was added 
NaH (1.0 mmol, 1.0 eq) under argon conditions. After stirring for 30 minutes, tert-
butyldimethylsilyl chloride (TBSMSCl) (1.0 mmol, 1.0 eq) was added. The 
reaction was allowed to stir for 16 h before it was quenced with saturated NH4Cl 
and extracted with CH2Cl2. (3 x 5mL) The combined organic extracts was dried 
over MgSO4, filtered and concentrated under reduced pressure. The residue was 
purified using flash column chromatography (hexane/EtOAc 4:1) to give the 3-24. 
Colourless oil; IR (film): 3448, 2953, 2857, 1623, 1471, 1251, 1090, 1032, 902 
cm-1; 1H NMR (600 MHz, CDCl3) δ 7.34 – 7.28 (m, 8H), 7.26 – 7.22 (m, 2H), 
5.24 (d, J = 2.0 Hz, 2H), 5.09 – 5.06 (m, 2H), 3.25 (d, J = 6.6 Hz, 4H), 0.84 (s, 
9H), -0.13 (s, 6H); 13C NMR (151 MHz, CDCl3) δ 146.20, 143.40, 128.31, 
127.32, 126.37, 117.56, 68.01, 67.86, 43.88, 38.24, 25.88, 18.11, -5.86; HRMS 
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Lewis Basic Selenium Catalyzed 
Chloroamidation of Olefins Using 













Haloamidation of an olefin is a practical and useful synthetic transformation 
for synthetic chemists. The resulting product, a vicinal haloamide, is an important 
synthetic intermediate, with the halogen offering a handle for subsequent 
manipulation (Scheme 4.1).1 
 
Scheme 4.1 General scheme for haloamidation of olefins. 
In the literature, there are several methods to install a trans-1,2-
haloamide/amine functionality directly from an olefin.2 A common approach 
involves the use of a nitrogen nucleophile to open a cyclic halonium ion 
intermediate derived from an olefin. In order to achieve the desired products with 
reasonable reaction efficiency, Lewis acids are usually employed to activate the 
stoichiometric halogen source in the olefin halogenation process. For example, 
Corey and co-workers reported the use of strongly Lewis acidic catalysts, such as 
SnCl4 and BF3•OEt2, in the bromoamidation of olefins.3 The transformation was 
an important step towards the synthesis of the anti-fluenza medicine, Oseltamivir 
(Tamiflu®) 4-5, in which NBS was used as the halogen source and acetonitrile as 











Scheme 4.2 Lewis acid catalyzed haloamidation in the synthesis of Tamiflu®). 
Subsequently, the Yadav group reported a similar procedure using InBr3 as 
the catalyst in the haloamidation (Scheme 4.3).4 The substrate scope, however, is 
limited to vinyl arenes only. 
 
Scheme 4.3 InBr3 catalyzed bromoamidation. 
The harsh Lewis acidic conditions, lack of generality and limited substrate 
scope prompted us to initiate a search for new catalysts to achieve this synthetic 
transformation. Since the Lewis acids utilized were for the purpose of activating 
the halogen source, we reckoned that the search for new catalysts may begin from 
halogen activators. In our recent publications, we reported the use of Lewis basic 










processes.5 We rationalized that a similar Lewis basic system may be used to 
catalyze the haloamidation process, which can offer milder reaction conditions.  
Herein, we disclose a facile, mild, and efficient chloroamidation of olefins 
using the commercially available and Lewis basic diphenylselenide as the catalyst 
and N-chlorosuccinimide (NCS) and acetonitrile as the halogen and nitrogen 
source, respectively. This method was found to be applicable to a wide range of 
substrates, which makes it a good complement to the existing strategies, especially 
for the haloamidation of acid-sensitive compounds. 
 
4.2 Results and Discussion 
4.2.1 Catalyst Screening 
Cyclohexene 4-8a was used in our initial study and various Lewis basic 
chalcogen-containing catalysts 4-10 were examined (Scheme 4.4). 
Triphenylphosphine oxide 4-10a was found to be inactive in catalyzing the 
haloamidation reaction. For the catalysts 4-10b–h which contain either a C=X or a 
P=X (X = S, Se) system, very low reaction efficiency was observed. In fact, these 
catalysts were unstable in the reaction system; elemental sulfur or selenium 
evolved gradually during the reaction, which could be attributed to the hydrolytic 
decomposition of the catalysts in the presence of water and a halogen source 











Scheme 4.4 Lewis base catalyst screening for bromoamidation. 
 
 










This result prompted further screening on the diaryl sulfur and selenium 
catalysts, which led to the discovery that diphenyl selenide (4-10j) was 
exceptionally active in catalyzing this type of reaction.  
 
4.2.2 Reaction Conditions Optimization 
After identifying a suitable catalyst, other parameters were optimized. It was 
observed that water is an essential component in the reaction as a controlled 
reaction carried out in moisture-free conditions resulted in almost no product 
formed (Table 4.1, entry 1). The amount of water did not significantly affect the 
reaction and the yield was unchanged upon the addition of up to 10 equivalents of 
water (Table 4.1, entries 2–5).  In addition, no formation of halohydrins was 
observed despite the drastic increase in the concentration of water.  
The concentration of the reaction, howver, did appreciably affect the reaction 












Table 4.1 Reaction conditions optimization. 
 
 
4.2.3 Effect of Halogen Source 
While investigating various halogenating sources, it was found that 
brominating reagents including NBP, N-bromoacetamide (NBA), 2,4,4,6-
tetrabromo-2,5-hexadienone (TABCO), and DBH gave similar yields to that of 
NBS (Table 4.2, entries 1–5). Interestingly, a 52% yield of the chlorinated product 










(NIS) did not result in any desired product (Table 4.2, entry 8). Finally, it was 
found that the yields could be further enhanced by increasing the amount of 
halogenating reagents (Table 4.2, entries 9–10). 












4.2.4 Substrate Scope 
Upon identifying a suitable reaction system, we continued to examine the 
substrate scope and the results are tabulated in Table 4.3. The reactions were 
found to proceed efficiently giving good yields with both alkyl olefins and vinyl 
arenes. For the substituted cyclohexenes 4-8b–e, excellent diastereo- and 
regioselectivity were observed (Table 4.3, entries 1–4). The high 
diastereoselectivity could be explained by the proposed mechanism depicted in 
Scheme 4.6, which shows that the nucleophilic nitrile may be approaching from 
the less sterically hindered face of the halonium intermediate.  
 
Scheme 4.6 Possible transition state of chloroamidation. 
Markovnikov-type products were obtained for aryl olefins 4-8f–h (Table 4.3, 
entries 5–7). However, anti-Markovnikov product 4-11i was achieved (86 % 
yield) when using 4-8i as the substrate (Table 4.3, entry 8). The selectivity can be 
rationalized by the stabilization effect of the carbocation at the terminal carbon by 

































The anti-markovnikov product 4-11i was confirmed by via deuterium exchange 
and proton-proton decoupling experiments (Figures 4.1 and 4.2). The peak at 5.86 
ppm was assigned to be the amide N–H proton via a deuterium exchange 
experiment. Decoupling the N–H proton resulted in a change in the splitting 
pattern of two signals at 3.31 ppm and 4.17 ppm from ddd to dd. This suggested 
that the amide N–H proton has an adjacent methylene group. This led us to 
believe that the nitrogen atom is at the terminal position. To further substantiate 
this claims, we decoupled the proton signal at 4.32 ppm. As predicted, the N–H 
proton signal at 5.86 ppm was not affected while the two other signals that 
corresponded to the methylene protons chnaged from ddd to dd.  
 













Figure 4.2 Proton decoupling experiments for anti-markovnikov product 4-11i. 
  Low yield (7% yield) was observed for cycloheptene 4-8j with most of the 
starting material recovered. No products were observed for both 1,1-
diphenylethylene 4-8k as well as the tri-substituted olefin 4-8l. Similarly, the 
starting materials were observed to be unreacted from the crude 1H NMR. We 
postulate that this is due to the relatively bulkier substituents on the alkenes which 
hindered the nucleophilic attack of the nitrile. Next, (E)-hex-3-ene 4-8m also 
resulted in poor yield (16% yield) when subjected to the same reaction condition. 
This is probably due to the volatile starting materials which caused the 











4.2.5 Haloamidation of Acid Labile Substrates 
Besides the wide substrate scope, it is also important to note that the reaction 
can accommodate acid sensitive functional groups. Thus, this Lewis base 
catalyzed haloamidation can be considered as a complementary method to the 
corresponding Lewis acid protocols.3-4 Some examples are shown in Table 4.4. 
Substrates 4-9j–4-9l gave the desired products smoothly using catalyst 4-10j 
(Table 4.4, entries 1–3), this was in comparison to the deprotected precursors 
(Table 4.4, entries 4 and 6) and the complex mixture obtained (Table 5.4, entry 5) 





















4.2.6 Haloamidation Using Different Nitriles 
To further illustrate the scope of the reaction, we proceeded to examine a 
variety of nitriles. As shown in Table 4.5, both propionitrile and benzonitrile were 
able to produce good yields of the corresponding products 4-13a and 4-13b, 
respectively. 
Table 4.5 Chloroamidation of 4-9a with different nitrile partners. 
 
 
4.2.7 Mechanistic Studies 
During our examination of the crude spectra, especially of the non-aromatic 
products, it was observed that 1H NMR signals in the aromatic region 










prompted us to probe the mechanism more closely through a series of 1H NMR 
experiments carried out in deuterated acetonitrile.  
We initially suspected that the active catalytic species might have been 
diphenyl selenium oxide (4-14), which can be synthesized by treating diphenyl 
selenide (4-10j) with NCS in MeOH/H2O (Scheme 4.7).7 
 
Scheme 4.7 Synthesis of 4-14 using NCS. 
As such, catalyst 4-10j and NCS were dissolved in deuterated chloroform and 
1H NMR spectra were obtained at various time intervals. We observed a gradual, 
as opposed to rapid, consumption of 4-10j to form a new compound over the 
course of 6 hours. The product was isolated and identified to be diphenyl selenium 
oxide, Ph2SeO (4-14). Nonetheless, when 4-14, prepared using the oxidation of 4-
10j using NCS in MeOH, was employed as the catalyst instead of 4-10j as the 
catalyst, the reaction was very sluggish. This leads us to suggest that the reaction 












Scheme 4.8 Examination of 4-14 as the catalyst in the chloroamidation. 
A plausible mechanism for the reaction is described in Scheme 4.8. The first 
step is likely to involve the activation of the chlorine atom on NCS via the Lewis 
basic diphenyl selenide to form intermediate A. The electrophilic Cl might then be 
delivered to olefin 4-8 to form the halonium intermediate B. At this point, 
acetonitrile could attack intermediate B (i.e. B→C) which would subsequently be 
quenched by a molecule of water to form the haloamide product 4-11.  
 












In summary, we have developed a highly efficient Lewis base catalyzed 
chloroamidation which can be applied to a wide range of substrates including 
those that are acid labile. Further application of this methodology to other areas is 
currently being investigated. 
 
4.4 Experimental 
(A) Synthesis of olefins 4-8. 
Cyclohex-2-en-1-yl benzoate (4-8c):  
 
To a solution of 2-cyclohex-2-en-1-ol (0.320 g, 3.26 mmol, 1 eq) in 20 mL of 
methylene chloride was added triethylamine (1.3 mL, 9.32 mmol, 2.85 eq). 
Benzoyl chloride (1.04 mL, 8.95 mmol, 2.75 eq) was then added dropwise via 
syringe and the reaction allowed to stir overnight. The resulting yellow solution 
was quenched with 30 mL of deionized water and extracted with Et2O (4 x 50 
mL) and concentrated in vacuo. The residue was then purified by flash column 
chromatography (9:1 hexane/ethyl acetate) to afford the benzoyl-protected alcohol 
as a colourless liquid. 1H NMR (600 MHz, CDCl3) δ 8.07 – 8.04 (m, 2H), 7.54 










(ddt, J = 10.0, 4.0, 2.2 Hz, 1H), 5.51 (dtd, J = 6.8, 3.6, 1.7 Hz, 1H), 2.18 – 2.11 
(m, 1H), 2.05 (dtdd, J = 11.0, 7.4, 3.5, 1.7 Hz, 1H), 1.98 (dddd, J = 13.3, 9.9, 4.8, 
3.2 Hz, 1H), 1.92 – 1.81 (m, 2H), 1.75 – 1.67 (m, 1H), 1.58 (t, J = 6.3 Hz, 1H); 
13C NMR (151 MHz, CDCl3) δ 166.21, 132.80, 130.71, 129.56, 128.25, 125.66, 
68.54, 31.60, 28.37, 24.92, 18.90; IR (film) 2937, 1710, 1451, 1266, 1110, 916 
cm-1;  HRMS (ESI+) calcd for C13H14O2 [M+Na]+ 225.0886, found 225.0892. 
(The physical data were in full accordance with the literature value in all respects: 
Shi, E. Shao, Y.; Chen, S.; Hu, H.; Liu, Z.; Zhang, J.; Wan, X. Org. Lett., 2012, 
14, 3382–3387.) 
 
4-8d was prepared according to the literature procedure (Ladika, M.; Sunko, D. E. 
J. Org. Chem., 1985, 50, 4544–4548.) 
 




To a solution of 2-cyclohexen-1-ol (2.19 mL, 22.3 mmol, 1 eq) in 10 mL of 
methylene chloride was added Boc2O (6.00 g, 27.5 mmol, 1.2 eq) and Bu4NHSO4 
(20 mg, 0.38 mmol, 0.02 eq) at room temperature. The solution was cooled to 0 oC 
and NaOH (12.0 mL, 30% w/w) was added dropwise. The solution was then 
continuously stirred at room temperature. After 24 hours, the reaction was 










layers were combined and washed with 1M HCl and brine. The solution was then 
dried with anhydrous MgSO4 and concentrated in vacuo. The residue was then 
purified by flash column chromatography (9:1 hexane/ethyl acetate) to yield the 
Boc-protected alcohol as a colourless liquid. 1H NMR (600 MHz, CDCl3) δ 5.98 – 
5.92 (m, 1H), 5.79 – 5.73 (m, 1H), 5.09 – 5.03 (m, 1H), 2.07 (dddd, J = 13.7, 5.7, 
3.8, 2.0 Hz, 1H), 2.01 – 1.94 (m, 1H), 1.92 – 1.86 (m, 1H), 1.84 – 1.73 (m, 2H), 
1.61 (qdd, J = 5.8, 4.8, 2.2 Hz, 1H), 1.49 (s, 9H) ppm; 13C NMR (151 MHz, 
CDCl3) δ 153.27, 132.81, 125.35, 81.68, 70.72, 28.21, 27.79, 24.80, 18.70 ppm; 
IR (film): 2980, 2937, 1731, 1368, 1272, 1248, 1155, 929, 869 cm-1; HRMS 
(ESI+) calcd for C11H18O3 [M+Na]+: 221.1148, found 221.1156. 
 




To a solution of 2-cyclohexen-1-ol (0.50 g, 5.10 mmol, 1 eq) and trityl chloride 
(3.18 g, 11.4 mmol, 2 eq) in 20 mL of methylene chloride was added 1,8-
diazabicyclo[5.4.0]undec-7-ene (2 mL, 13 mmol, 2.5 eq). After 72 hours, the 
solution was diluted with 40 mL of methylene chloride and washed with saturated 
NaHCO3 (50 mL). The aqueous layer was extracted with methylene chloride (2 x 
50 mL). The combined organic layers were dried with MgSO4 and concentrated in 
vacuo. The residue was then purified by flash column chromatography (9:1 










CDCl3) δ 7.53 (ddd, J = 4.4, 3.3, 1.9 Hz, 6H), 7.31 – 7.27 (m, 6H), 7.25 – 7.21 (m, 
3H), 5.62 (dd, J = 10.2, 1.3 Hz, 1H), 5.04 (dd, J = 10.2, 2.8 Hz, 1H), 4.06 (s, 1H), 
1.98 (ddt, J = 10.6, 5.8, 2.8 Hz, 1H), 1.84 – 1.78 (m, 1H), 1.73 (ddd, J = 14.4, 9.3, 
4.4 Hz, 1H), 1.40 – 1.32 (m, 3H) ppm; 13C NMR (151 MHz, CDCl3) δ 145.35, 
129.96, 129.61, 129.01, 127.68, 126.85, 86.87, 67.82, 30.19, 25.03, 19.69 ppm; IR 
(film): 3031, 2931, 1596, 1490, 1448, 1394, 1316, 1275, 1218, 1151, 1048, 1021, 
764, 746, 703 cm-1; HRMS (ESI+) calcd for C25H24O [M+Na]+: 363.1719, found 
363.1725. (The physical data were in full accordance with the literature value in 
all respects: Schwizer, D., Patton, J. T., Cutting, B., Smieško, M., Wagner, B., 
Kato, A., Weckerle, C., Binder, F. P. C., Rabbani, S., Schwardt, O., Magnani, J. L. 
and Ernst, B. Chem. Eur. J., 2012, 18, 1342–1351.) 
 




3-amino-1-cyclohexene (2.16 g, 22.3 mmol, 1 eq) was dissolved in 20 mL of 
methylene chloride was added Boc2O (6.00 g, 27.5 mmol, 1.2 eq) and 
triethylamine (2.78 g, 27.5 mmol, 1.2 eq.) at room temperature. The solution was 
then continuously stirred at room temperature. After 1 hour, the reaction was 
quenched with water and extracted with methylene chloride. The organic layers 
were combined and washed with brine, dried with anhydrous MgSO4 and 










chromatography (19:1 hexane/ethyl acetate) to yield the Boc-protected amine as a 
colourless liquid. 1H NMR (600 MHz, CDCl3) δ 5.80 (ddd, J = 9.5, 5.3, 3.6 Hz, 
1H), 5.60 (dd, J = 10.0, 2.4 Hz, 1H), 4.54 (d, J = 18.8 Hz, 1H), 4.21 – 4.06 (m, 
1H), 2.00 – 1.95 (m, 2H), 1.90 – 1.85 (m, 1H), 1.66 (s, 1H), 1.63 (d, J = 6.4 Hz, 
1H), 1.51 (s, 1H), 1.44 (d, J = 3.2 Hz, 9H) ppm; 13C NMR (151 MHz, CDCl3) δ 
130.43, 128.09, 45.70, 33.52, 29.80, 28.40, 25.51, 24.76, 19.60 ppm; IR (film): 
3332, 2931, 1688, 1498, 1365, 1240, 1166, 1020, 724 cm-1. HRMS (ESI+) calcd 
for C11H19NO2 [M+Na]+: 220.1308, found 220.1342. 
 
(B) General procedure for chloroamidation in acetonitrile. 
 
To a solution of N-chlorosuccinimide (66.7 mg, 0.50 mmol) in dry acetonitrile 
(0.65 mL) at 25 oC in dark was added the olefin (0.25 mmol), diphenyl selenide 
(4-10j) (8.7 µL, 0.05 mmol), and water (5.4 uL, 0.30 mmol). After 18 hours, 
saturated Na2SO3 (0.75 mL) and NaHCO3 (0.75 mL) were added to quench the 
reaction mixture and the aqueous layer was extracted with ethyl acetate (4 x 4 
mL). The combined extracts were dried (MgSO4), filtered, and concentrated in 

















Synthesized according to the general procedure and purified by flash column  
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 56 
%). m.p.: 122-124 oC; 1H NMR (600 MHz, CDCl3) δ 5.53 (s, 1H), 3.99 – 3.90 (m, 
1H), 3.86 (td, J = 10.7, 4.2 Hz, 1H), 2.41 – 2.35 (m, 1H), 2.24 – 2.18 (m, 1H), 
2.00 (d, J = 4.3 Hz, 3H), 1.94 – 1.87 (m, 1H), 1.76 – 1.71 (m, 2H), 1.43 (ddd, J = 
13.3, 9.2, 6.1 Hz, 1H), 1.32 – 1.23 (m, 2H) ppm; 13C NMR (151 MHz, CDCl3) δ 
169.46, 55.29, 55.14, 37.07, 33.33, 26.47, 24.27, 23.49 ppm; IR (film): 3272, 
2936, 2859, 1650, 1558, 1448, 1374, 1317, 1190, 691 cm-1; HRMS (ESI+) calcd 
for C8H14BrNO [M+Na]+: 242.0151, found 242.0157. (The physical data were in 
full accordance with the literature value in all respects: Yeung, Y.; Gao, X.; 
Corey, E. J. Am. Chem. Soc., 2006, 128, 9644–9645) 
 




Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 85 
%). m.p: 122-123 oC; 1H NMR (600 MHz, CDCl3) δ 5.56 (s, 1H), 3.86 (tdd, J = 










2.16 (m, 1H), 2.01 (s, 3H), 1.80 – 1.76 (m, 1H), 1.73 – 1.62 (m, 2H), 1.44 – 1.37 
(m, 1H), 1.26 (dddd, J = 13.1, 11.1, 5.4, 2.9 Hz, 2H) ppm; 13C NMR (151 MHz, 
CDCl3) δ 169.69, 62.48, 55.07, 36.05, 32.77, 25.39, 24.14, 23.48 ppm; IR (film): 
3262, 2935, 2860, 1638, 1562, 117, 736 cm-1; HRMS (ESI+) calcd for C8H14ClNO 
[M+Na]+: 198.0656, found 198.0649. (The physical data were in full accordance 
with the literature value in all respects: Yeung, Y.; Gao, X.; Corey, E. J. Am. 
Chem. Soc., 2006, 128, 9644–9645) 




Synthesized according to the general procedure and purified by flash 
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 65 
%). m.p: 172-173 oC; 1H NMR (600 MHz, CDCl3) δ 5.44 (s, 1H), 4.79 (dd, J = 
10.8, 4.3 Hz, 1H), 2.08 (dddd, J = 9.0, 7.8, 5.5, 0.9 Hz, 3H), 1.95 – 1.94 (m, 3H), 
1.78 – 1.68 (m, 3H), 1.61 – 1.54 (m, 1H), 1.42 (dd, J = 6.0, 2.0 Hz, 1H), 1.35 (s, 
3H) ppm; 13C NMR (151 MHz, CDCl3) δ 169.73, 64.48, 57.98, 35.26, 32.71, 
24.86, 24.61, 21.82, 19.27 ppm; IR (film): 3309, 2939, 2867, 1651, 1549, 1371, 


















Synthesized according to the general procedure and purified by flash 
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 76 
%). m.p: 49–51 oC; 1H NMR (600 MHz, CD3CN) δ 8.06 (dd, J = 8.4, 1.2 Hz, 2H), 
7.65 (d, J = 7.5 Hz, 1H), 7.55 – 7.52 (m, 2H), 6.52 (s, 1H), 5.57 – 5.52 (m, 1H), 
4.23 (dd, J = 9.0, 6.4 Hz, 1H), 4.01 (d, J = 9.2 Hz, 1H), 2.06 – 2.00 (m, 2H), 1.88 
(s, 3H), 1.78 – 1.71 (m, 2H), 1.67 – 1.62 (m, 1H), 1.47 – 1.42 (m, 1H) ppm; 13C 
NMR (151 MHz, CD3CN) δ 170.20, 166.23, 134.28, 131.15, 130.31, 129.65, 
129.60, 76.96, 73.68, 64.15, 51.50, 23.12, 20.06 ppm; IR (film): 3281, 2942, 
1720, 1653, 1271, 1113, 711 cm-1; HRMS (ESI+) calcd for C15H18ClNO3 
[M+Na]+: 318.0867, found: 318.0871. 
 




Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 55 










2H), 8.24 – 8.20 (m, 2H), 5.36 (s, 1H), 5.23 – 5.16 (m, 2H), 2.70 (td, J = 13.4, 4.1 
Hz, 1H), 2.27 – 2.21 (m, 1H), 1.99 (s, 3H), 1.86 (d, J = 13.6 Hz, 1H), 1.78 (d, J = 
13.6 Hz, 1H), 1.69 – 1.61 (m, 2H), 1.56 (dd, J = 13.5, 3.8 Hz, 1H), 1.37 (s, 3H) 
ppm; 13C NMR (151 MHz, CDCl3) δ 170.05, 163.94, 150.63, 135.42, 130.90, 
123.54, 75.13, 65.17, 58.72, 34.40, 31.37, 24.57, 20.58, 19.33 ppm; IR (film): 
3303, 3078, 2947, 1725, 1655, 1528, 1275, 1103, 719 cm-1; HRMS (ESI+) calcd 
for C16H19ClN2O5 [M+Na]+: 377.0875, found: 377.0887. 
 




Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 4:1) to afford a yellow oil (yield: 79 %). 
1H NMR (600 MHz, CDCl3) δ 5.97 (s, 1H), 4.91 – 4.86 (m, 1H), 4.54 (t, J = 7.3 
Hz, 1H), 4.24 – 4.20 (m, 1H), 2.66 (dd, J = 7.5, 4.6 Hz, 1H), 2.55 (d, J = 12.5 Hz, 
1H), 2.37 (ddd, J = 14.7, 6.5, 2.7 Hz, 2H), 2.03 (ddd, J = 14.9, 4.1, 2.2 Hz, 1H), 
1.96 (s, 3H) ppm; 13C NMR (151 MHz, CDCl3) δ 178.37, 169.08, 79.04, 54.95, 
49.69, 35.59, 30.97, 30.01, 23.22 ppm; IR (film): 3287, 2925, 1781, 1657, 1529, 

















Synthesized according to the general procedure and purified by flash column  
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 65 
%). m.p: 99–100 oC; 1H NMR (600 MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 6.19 (s, 
1H), 5.35 (dt, J = 7.8, 5.3 Hz, 1H), 3.91 – 3.82 (m, 2H), 2.08 – 2.04 (m, 3H) ppm; 
13C NMR (151 MHz, CDCl3) δ 169.64, 138.37, 128.77, 128.12, 126.67, 53.55, 
47.53, 23.28 ppm; IR (film): 3276, 3064, 2926, 1647, 1542, 1372, 1296, 725, 698 
cm-1; HRMS (ESI+) calcd for C10H12ClNO [M+Na]+: 220.0500, found: 220.0500. 
 




Synthesized according to the general procedure and purified by flash column  
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 89 
%). m.p: 181–183 oC; 1H NMR (600 MHz, CDCl3) δ 8.21 – 8.15 (m, 2H), 7.66 
(dd, J = 4.6, 3.9 Hz, 1H), 7.55 (t, J = 7.9 Hz, 1H), 6.51 (d, J = 7.3 Hz, 1H), 5.51 – 
5.45 (m, 1H), 3.88 (ddd, J = 28.5, 11.6, 4.9 Hz, 2H), 2.12 – 2.09 (m, 3H) ppm. 13C 










121.51, 52.90, 47.45, 23.18 ppm; IR (film): 3283, 1652, 1529, 1349, 906, 726 cm-
1; HRMS (ESI+) calcd for C10H11ClN2O3 [M+Na]+: 265.0350, found: 265.0361. 
 




Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 50 
%). m.p: 120–121 oC; 1H NMR (600 MHz, CDCl3) δ 7.27 (s, 1H), 7.24 – 7.18 (m, 
3H), 6.01 (s, 1H), 5.51 (d, J = 7.6 Hz, 1H), 3.80 (d, J = 6.1 Hz, 2H), 2.41 (s, 3H), 
2.02 (s, 3H) ppm; 13C NMR (151 MHz, CDCl3) δ 169.46, 136.66, 136.24, 130.98, 
128.09, 126.29, 125.36, 50.29, 46.18, 23.19, 19.31 ppm; IR (film): 3280, 3072, 
1649, 1545, 1373, 1297, 763, 736 cm-1; HRMS (ESI+) calcd for C11H14ClNO 
[M+H]+: 212.0837, found: 212.0844. 
 




Synthesized according to the general procedure and purified by flash column  
chromatography (hexanes/ethyl acetate = 4:1) to afford a white solid (yield: 86 
%). m.p: 152–153 oC; 1H NMR (600 MHz, CDCl3) δ 7.65 (dd, J = 8.1, 1.4 Hz, 










10.5, 2.9 Hz, 1H), 4.17 (ddd, J = 14.7, 6.8, 2.9 Hz, 1H), 3.31 (ddd, J = 14.8, 10.5, 
4.5 Hz, 1H), 1.89 (s, 3H) ppm; 13C NMR (151 MHz, CDCl3) δ 170.15, 136.15, 
131.47, 130.27, 128.15, 47.96, 43.37, 23.12 ppm; IR (film): 3288, 3072, 1650, 
1555, 1428, 1276, 1111, 750, 698 cm-1; HRMS (ESI+) calcd for C22H22ClNOSi 
[M+Na]+: 402.1051, found: 402.1055. 
 




Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 76 
%). m.p: 155–156 oC; 1H NMR (600 MHz, CDCl3) δ 5.47 (s, 1H), 5.14 – 5.05 (m, 
1H), 4.23 – 4.09 (m, 2H), 2.21 – 2.15 (m, 1H), 2.01 (s, 3H), 1.78 (tdd, J = 10.7, 
7.5, 3.9 Hz, 1H), 1.58 (ddd, J = 17.9, 9.5, 6.2 Hz, 3H), 1.52 – 1.47 (m, 9H), 1.45 – 
1.39 (m, 1H) ppm; 13C NMR (151 MHz, CDCl3) δ 169.78, 152.93, 82.42, 74.08, 
61.93, 51.34, 29.69, 28.71, 27.76, 23.54, 19.05 ppm; IR (film): 3284, 2943, 1744, 
1657, 1549, 1371, 1281, 1157, 746 cm-1; HRMS (ESI+) calcd for C13H22ClNO4 


















Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 1:1) to afford a white solid (yield: 70 
%). m.p: 208–210 oC; 1H NMR (600 MHz, CDCl3) δ 7.53 (dd, J = 8.3, 1.1 Hz, 
6H), 7.29 (d, J = 7.8 Hz, 6H), 7.26 – 7.24 (m, 3H), 5.12 (d, J = 7.3 Hz, 1H), 4.16 – 
4.11 (m, 1H), 3.70 – 3.63 (m, 1H), 3.30 (s, 1H), 2.08 – 2.02 (m, 1H), 1.86 (s, 3H), 
1.71 – 1.65 (m, 1H), 1.46 – 1.40 (m, 1H), 1.26 (d, J = 3.2 Hz, 2H), 1.13 (dt, J = 
12.4, 6.2 Hz, 1H) ppm; 13C NMR (151 MHz, CDCl3) δ 168.68, 144.61, 129.00, 
127.75, 127.27, 87.36, 70.27, 62.74, 60.39, 51.13, 27.62, 23.40, 20.00 ppm; IR 
(film): 3303, 2924, 1644, 1538, 1076, 750, 699 cm-1; HRMS (ESI+) calcd for 
C27H28ClNO2 [M+Na]+: 456.1701, found: 456.1708. 
 




Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 1:1) to afford a thin film (yield: 40%). 
1H NMR (600 MHz, CDCl3) δ 5.91 (s, 1H), 4.90 (d, J = 8.5 Hz, 1H), 4.29 (d, J = 










Hz, 4H), 1.44 (s, 9H), 1.28 – 1.24 (m, 1H) ppm; 13C NMR (151 MHz, CDCl3) δ 
169.78, 155.08, 79.92, 62.65, 50.56, 48.36, 28.32, 26.96, 23.41, 19.75, 14.18 ppm; 
IR (film): 3312, 2933, 1692, 1656, 1532, 1366, 1248, 1165, 1049, 912, 732 cm-1; 
HRMS (ESI+) calcd for C13H23ClN2O3 [M+Na]+: 313.1289, found: 313.1298. 
 






To a solution of N-chlorosuccinimide (66.7 mg, 0.50 mmol) and 15 equivalents of 
nitrile (total volume 0.65 mL) at 25 oC in the dark was added cyclohexene (0.25 
mmol), diphenyl selenide (8.7 µL, 0.05 mmol), and water (5.4 µL, 0.30 mmol). 
After 24 hours, saturated Na2SO3 (0.75 mL) and NaHCO3 (0.75 mL) were added. 
The organic layer was separated and the aqueous layer was extracted with ethyl 
acetate (4 x 4 mL). The combined organic extracts were dried (MgSO4), filtered, 
and concentrated in vacuo. The residue was purified by flash column 















N-(2-chlorocyclohexyl)propionamide (4-13a):  
 
Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 4:1) to afford a white solid (yield: 70 
%). m.p: 118–119 oC; 1H NMR (600 MHz, CDCl3) δ 5.59 (s, 1H), 3.90 – 3.81 (m, 
1H), 3.74 (dd, J = 10.6, 4.2 Hz, 1H), 2.23 (s, 4H), 1.79 – 1.67 (m, 3H), 1.40 (dt, J 
= 13.5, 3.4 Hz, 1H), 1.32 – 1.22 (m, 2H), 1.16 (t, J = 7.5 Hz, 3H) ppm; 13C NMR 
(151 MHz, CDCl3) δ 173.44, 62.57, 54.88, 36.05, 32.76, 29.86, 25.40, 24.16, 9.87 
ppm; IR (film): 3289, 3080, 2929, 2858, 1646, 1546, 1449, 1376, 1272, 1214, 
1137, 737 cm-1; HRMS (ESI+) calcd for C9H16ClNO [M+Na]+: 212.0813, found: 
212.0816. 
 
N-(2-chlorocyclohexyl)benzamide (4-13b):  
 
Synthesized according to the general procedure and purified by flash column 
chromatography (hexanes/ethyl acetate = 4:1) to afford a white solid (yield: 83 
%). m.p: 140–141 oC; 1H NMR (600 MHz, CDCl3) δ 7.78 (dd, J = 8.2, 1.1 Hz, 










(d, J = 4.1 Hz, 1H), 2.39 – 2.26 (m, 2H), 1.88 – 1.72 (m, 3H), 1.48 (d, J = 13.2 
Hz, 1H), 1.42 – 1.30 (m, 2H) ppm; 13C NMR (151 MHz, CDCl3) δ 167.24, 
134.73, 131.49, 128.58, 126.92, 62.54, 55.67, 36.13, 32.74, 25.46, 24.19 ppm; IR 
(film): 3309, 2940, 2860, 1637, 1544, 1328, 694 cm-1; HRMS (ESI+) calcd for 
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Towards the Development of a New 













At the onset of this study, our group reported a series of enantioselective 
bromocyclization reactions, catalyzed by cinchona-derived aminothiocarbamate 
catalysts. Generally, all three major types of bromocyclization reactions – 
bromolactonization1, bromoaminocyclization2 (Chapter 2) and 
bromoetherification (Chapter 3), proceeded well, giving products with good yields 
and enantioselectivity. The catalyst acts via a dual activation mechanism whereby 
the bromine atom is activated through interaction with the Lewis basic sulfur atom 
and the nucleophile is activated via the interaction of the acidic proton of the 
substrate with the nitrogen atom on the quinuclidine.  
Despite the good yields and enantioselectivity obtained in these cyclizations, 
there are two limitations of these catalysts. Firstly, catalysts made from the 
pseudo-enantiomeric pair of cinchona alkaloids do not always give the 
corresponding enantiomeric products with equally good enantioselectivity.2b 
Secondly, the efficiency of the catalysts at low temperature conditions was poor. 
In some cases, 3–5 days at -78 oC were required for the reaction to be completed.2 
To resolve these issues, we initiated a project towards the design and 
development of a new class of organocatalyst aimed at performing asymmetric 
halocyclization reactions. We set out two important criteria when searching for an 










commercially available. Next, the catalyst must have readily modifiable handles 
so that its enantioselectivity can be tuned to accommodate different substrates.  
In the design of the new catalyst, we planned to mimick the amino-
thiocarbamate catalyst by having a nitrogen atom acting as a Brønsted base as 
well as a Lewis basic functionality with improved reactivity. In Chapter 4, we 
have shown that selenium-containing compounds are excellent Lewis base 
catalysts for the activation of electrophilic halogen reagents. As such, we aim to 
develop a bifunctional catalyst by incorporating a Lewis basic selenium on a 
chiral amine scaffold. After much consideration, we chose (L)-proline to be our 
starting material as both the proline enantiomers are commercially available and 
inexpensive. 
 
5.2 Results and Discussion 
5.2.1 Synthesis of Catalysts and Preliminary Testing 
Using known procedures, (L)-proline 5-1 was first subjected thionyl chloride 
in methanol to form the proline methyl ester hydrochloride, and subsequently 
treated with triethylamine and trityl chloride to form the tritylated product 5-2 
(Scheme 5.1). Subsequent reduction using lithium aluminium hydride followed by 
Swern oxidation furnished the aldehyde 5-4 in excellent yields. Treating the 










with excellent diastereoselectivity. The complete diastereoselectivity was 
achieved due to the bulkiness of the trityl group which blocks the approach of the 
Grignard reagent from the top face of the aldehyde 5-4, resulting in only one 
product 5-5 being formed.3 Removal of the trityl moiety followed by the 
Eschweiler-Clarke methylation gave the prolinol 5-6 in good yields. 
 
Scheme 5.1 Synthesis of prolinol 5-6. 
When the methylated prolinol 5-6 was treated with phenyl isoselenocyanate, a 
single product was isolated and subsequently identified to be the selenium-type 











Scheme 5.2 Synthesis of amino-selenocarbamate catalyst 5-9. 
We believe that the product was obtained via a Newman-Kwart 
rearrangement whereby the O-type amino-selenocarbamate was first formed; this 
intermediate then underwent the rearrangement to form the Se-type catalyst. 
Conventionally, Newman–Kwart rearrangements are initated under high 
temperature reaction conditions.4 However, the rearrangement of 5-8 to 5-9 
proceeded under room temperature conditions and we believe this was due to the 
adjacent nitrogen atom providing anchimeric assistance (Scheme 5.3).5 
 
Scheme 5.3 Proposed mechanism for the rearrangement of 5-8 to 5-9. 
Unfortunately, we could not test out the catalytic ability of this catalyst as it 










decomposed product was isolated and characterized to be the diselenide 
compound. The decomposition was probably due to the spontaneous hydrolysis of 
the selenocarbamate, and the resulting selenide was oxidized in the air to form the 
diselenide 5-10 (Scheme 5.4). 
 
Scheme 5.4 Decomposition of 5-9 to form 5-10. 
In order to be sure that the instability is not just an isolated case, we 
synthesized five other analogues of the catalyst and investigated their stability 
(Figure 5.1). The bulkier and relatively more hydrophobic 1-naphthyl substituent 
was used to replace the phenyl group in one of the analogue 5-11, while catalysts 
5-12 to 5-14 possessed electron-rich and electron-deficient aryl groups that 
replaced the phenyl group on the selenocarbamate nitrogen. An allyl substituent 
was installed on the proline nitrogen of catalyst 5-15 to mimic the olefin moiety 
on the cinchona-derived thiocarbamate catalyst. Unfortunately, all of them seemed 












Figure 5.1 Other selenocarbamate catalysts synthesized to probe stability. 
Undeterred, we thought that the diselenide products resulting from the 
decomposition of the selenocarbamates could be made useful by utilizing them to 
form other derivatives or even using them as a catalyst. Thus, the diselenide 5-16 
was subsequently reduced and derivatized to the three other amino-selenium 











Scheme 5.5 Derivatization of diselenide 5-16. 
Diselenide 5-16 and its three derivatives 5-17 to 5-19 were tested for their 
catalytic activity using a standard model bromolactonization reaction (Table 5.1). 
It was observed that all the four catalysts were able to catalyze the halocyclization, 
with catalyst 5-17 giving a moderate yield of 57% while the rest gave almost 
quantitative yields. However, only the benzyl derivative 5-19 managed to achieve 










































a Reactions were carried out with 5-20 (0.1 mmol), NBS
(0.12 mmol), catalyst (0.01 mmol) in CHCl3/Toluene (1:2) (3




With these promising results, two other substrates that can undergo 














It was observed that the catalyst was able to catalyze both cyclization 
reactions with good yields. However, the resulting products formed were racemic 
in both cases. Despite this, it was still worthy to note that the 
bromoaminocyclization of 5-24 proceeded at a much faster rate (93% yield 
achieved in 1 day) as compared to the same reaction that was catalyzed using the 




















5.2.2 Reaction Conditions Optimization 
With this, we began a series of screening reactions with the aim of optimizing 
the reaction conditions in the hope of obtaining better enantioselectivity (Table 
5.2).  
Table 5.2 Solvent optimization for the bromolactonization of 5-20. 
 
It was observed that relatively non-polar solvents and non-polar solvent 
mixture such as toluene, chloroform/toluene (1:5) mixture and hexane can cause 
the yield to dramatically plunge (Table 5.2, entries 4, 6 and 9 respectively). The 
yields improved significantly when relatively polar solvent systems were used. As 
for the enantioselectivity of the reaction, the initial chloroform/toluene (1:2) 











5.2.3 Effect of Halogen Source 
Following the solvent screening, the halogen source was also screened to 
determine the best halogen source for the reaction (Table 5.3). 
Table 5.3 Halogen source screening for the bromolactonization of 5-20. 
 
No reaction was observed for NBA and NCS (Table 5.3, entries 4 and 7), 
while 1,3-dibromo-5,5-dimethylhydatoin (DBH), NBP, TABCO and N-
iodosuccinimide (NIS) (Table 5.3, entries 2, 3, 5 and 7) all gave near quantitative 
yields for the halocyclization albeit with diminished enantioselectivities when 
compared with NBS as the halogen source. Thus, NBS was selected to be the 











5.2.4 Catalyst Screening 
After screening the solvent and the halogen source, analogues of this catalyst 
were synthesized and a brief structure-activity relationship study was carried out. 
The substituent on the selenium atom was first varied. 
Both electron-rich and electron-deficient benzyl substituents caused the 
reaction yield to decrease, and the products obtained also have either lower or no 
ee (Table 5.4, entries 2–5). Interestingly, the less sterically hindered methyl 
substituted catalyst 5-19f gave higher ee than benzyl substituted version 5-19a 
(Table 5.4, entry 6) while it was observed that the ethyl substituted catalyst 5-19g 
behaves similar to 5-19a (Table 5.4 entry 7). 
Next, the effect of the aryl substituent on the catalyst was investigated. Both 
the 1-naphthyl and 2-naphthyl substituted catalysts gave products with slightly 
reduced ee (Table 5.4, entry 8–9). Both the electron-deficient 4-fluorophenyl 
(catalyst 5-19j) and electron-rich 4-methylphenyl group (catalyst 5-19k) caused 
the ee also decreased to 18% ee (Table 5.4, entry 10–11). Sterically bulkier phenyl 























Following on, we investigated the importance of the selenium atom in 
catalyst 5-19a by synthesizing the oxygen and sulfur analogues. Remarkably, both 
the oxygen and sulfur variants gave opposite and lower ee as compared to the 
selenium–containing catalyst. This highlights the importance of the selenium atom 
in the mode of action of the catalyst.  




The results obtained from the above study built an excellent platform for a 
new catalyst to be developed. The improved rates of reaction from the use of these 










the improved reactivity of these catalysts. The importance of the Lewis basic 
selenium atom in the catalyst was also emphasized through the use of the oxygen 
and sulfur analogues which gave products with opposite and lower ees. These 
observations serve as good preliminary results for the further development of an 
efficient and highly enantioselective amino-selenoether catalysts. 
 
5.4 Experimental 
(A) Synthesis of prolinol 5-6. 
 
To a stirred solution of aldehyde 5-4 (5 mmol, 1.0 eq), synthesized using (L)-
proline according to the literature procedure (J. Bejjani, F. Chemla, M. Audouin, 
J. Org. Chem. 2003, 68, 9747–9752), in THF (5 mL) was added phenyl 
magnesium bromide (6 mL, 1M, 6 mmol, 1.2 eq) under argon at 0 oC. The 
reaction was allowed to warm up to room temperature and was stirred for an 
additional 12 hours. The reaction was quenched with saturated NH4Cl solution 
and extracted with CH2Cl2 (3 X 10mL). The combined organic extracts were dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by 










To a stirred solution of tritylated prolinol 5-5 (5 mmol, 1.0 eq) in THF (5 mL) was 
added 6M HCl (1mL). The reaction was stirred followed by TLC. After 3 hours of 
stirring, the reaction was diluted with water (5 mL) and washed with ether (3 X 
5mL). The aqueous phase was made alkaline by the addition of NaOH and 
subsequently extracted with CH2Cl2 (3 X 10 mL). The combined organic extracts 
were dried over MgSO4, filtered and concentrated in vacuo to give deprotected 
prolinol which was used without purification for the next step.  
The deprotected prolinol (5mmol, 1.0 eq) was redissolved formic acid (3mL), 
added formaldehyde (1mL, 37% in water) and heated at 80 oC for 16 hours. The 
reaction was quenched with water and made basic using NaOH. The reaction 
mixture was extracted with CH2Cl2 (3 X 10mL). The combined organic extracts 
were dried over MgSO4, filtered and concentrated in vacuo. The residue was 




White solid, 1H NMR (400 MHz, CDCl3) δ 9.85 (d, J = 2.7 Hz, 1H), 7.58 – 7.53 
(m, 6H), 7.30 – 7.23 (m, 7H), 7.21 – 7.15 (m, 3H), 3.81 – 3.72 (m, 1H), 3.28 (dt, J 
= 11.7, 7.2 Hz, 1H), 2.92 (ddd, J = 11.7, 7.6, 5.9 Hz, 1H), 1.59 (ddd, J = 12.5, 6.4, 










NMR (101 MHz, CDCl3) δ 204.34, 144.41, 129.43, 127.74, 126.39, 77.32, 77.00, 
76.92, 76.68, 68.46, 50.58, 27.98, 24.27; HRMS (ESI) calcd for C24H24NO m/z 




White solid, 1H NMR (400 MHz, CDCl3) δ 7.65 – 7.55 (m, 6H), 7.33 – 7.12 (m, 
14H), 7.08 (d, J = 7.5 Hz, 2H), 5.10 (d, J = 3.2 Hz, 1H), 3.73 (td, J = 5.2, 2.6 Hz, 
1H), 3.35 – 3.21 (m, 2H), 3.04 (ddd, J = 11.7, 7.9, 3.5 Hz, 1H), 1.41 (dt, J = 8.0, 
4.2 Hz, 1H), 1.32 (dp, J = 11.7, 4.3 Hz, 1H), 0.80 (dt, J = 8.5, 4.5 Hz, 1H), 0.23 
(dt, J = 11.2, 8.5 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 144.59, 142.19, 129.91, 
127.96, 127.57, 126.49, 126.35, 125.41, 78.15, 77.32, 77.00, 76.68, 75.54, 66.01, 




Colourless oil; 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.30 (m, 4H), 7.25 – 7.21 (m, 
1H), 4.89 (d, J = 2.9 Hz, 1H), 3.22 – 3.13 (m, 1H), 2.55 (td, J = 7.1, 6.4, 3.4 Hz, 










(m, 1H);  13C NMR (151 MHz, CDCl3) δ 141.57, 128.09, 126.78, 125.45, 77.21, 
77.00, 76.79, 71.11, 69.60, 57.52, 39.99, 23.82, 22.91; HRMS (ESI) calcd for 
C12H18NO m/z [M + H]+: 192.1383; found: 192.1385. 
 
(B) Representative example for the synthesis of diselenide. 
 
To a stirred solution of the prolinol 5-6 (5 mmol, 1 eq), phenylselenoisocyanate (5 
mmol, 1 eq) in THF (5 mL) was added NaH (6 mmol, 1.2 eq) at 25 oC. The 
resulting solution was allowed to stir for 16 hours. The reaction was quenched 
with water extracted with CH2Cl2 (3 X 10mL). The combined organic extracts 
were dried over MgSO4, filtered and concentrated in vacuo. The residue was 

















Colourless oil; 1H NMR (600 MHz, CDCl3) δ 7.30 – 7.16 (m, 5H), 4.08 (d, J = 5.6 
Hz, 1H), 3.08 – 3.01 (m, 1H), 2.54 (q, J = 7.3 Hz, 1H), 2.19 (q, J = 9.5 Hz, 1H), 
2.16 (s, 3H), 1.96 (dtt, J = 10.0, 7.3, 5.1 Hz, 1H), 1.86 – 1.79 (m, 1H), 1.69 – 1.55 
(m, 2H); 13C NMR (151 MHz, CDCl3) δ 141.51, 129.40, 127.99, 126.84, 77.21, 
77.00, 76.79, 69.86, 57.63, 53.15, 41.75, 29.75, 22.47; HRMS (ESI) calcd for 
C12H18NO m/z [M + H]+: 509.0969 ; found: 509.0977. 
 
(C) Representative example for the synthesis of amino selenoether catalyst. 
 
To a stirred solution the diselenide 5-16 (5 mmol, 1 eq) in ethanol (5 mL) was 
added sodium borohydride (10 mmol, 2 eq). The reaction mixture was allowed to 










reaction mixture. The reaction was left to stir for 12 hours. The reaction was 
quenched with water extracted with CH2Cl2 (3 X 10mL). The combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo. The residue 




Colourless oil; 1H NMR (600 MHz, Chloroform-d) δ 7.38 (s, 2H), 7.31 (s, 2H), 
7.22 (d, J = 7.6 Hz, 3H), 7.13 (d, J = 1.3 Hz, 3H), 5.83 – 5.73 (m, 1H), 5.06 – 4.99 
(m, 2H), 4.15 (d, J = 5.2 Hz, 1H), 3.54 (s, 1H), 3.47 (s, 1H), 3.21 – 3.12 (m, 1H), 
3.07 (s, 1H), 2.79 – 2.68 (m, 2H), 2.24 (d, J = 8.0 Hz, 1H), 1.97 (d, J = 9.3 Hz, 
1H), 1.81 – 1.54 (m, 4H); 13C NMR (151 MHz, CDCl3) δ 141.28, 139.49, 135.75, 
129.55, 128.98, 128.23, 128.20, 126.84, 126.40, 116.62, 77.21, 77.00, 76.79, 
67.96, 57.32, 53.96, 49.71, 29.48, 26.93, 22.65; HRMS (ESI) calcd for C21H26NSe 
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NMR Spectra of Synthetic Intermediates 
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